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Summary 
When cells experience DNA damage, they halt the cell cycle before sister chromatid separation 
has begun in response to the activation of the DNA damage checkpoint. This surveillance 
mechanism provides time to repair the damage and only when repair has been successful the 
cell cycle is resumed. Therefore, cell cycle arrest and damage repair are important processes to 
ensure the stability of the genome and the faithful transfer of genetic information to daughter 
cells. However, if repair is not possible, cells can override the DNA damage checkpoint and 
terminate the cell cycle arrest by a mechanism called (checkpoint) adaptation. Although many 
proteins have been shown to be involved in the adaptation process, its molecular mechanisms 
still remain elusive. Especially the critical determinants initiating checkpoint adaptation have 
not been fully identified. Understanding this pathway is of particular interest since checkpoint 
adaptation is a driving force of genome instability and has detrimental consequences including 
cell death and various genomic aberrations. Interestingly, the concept of checkpoint adaptation 
is not only found in unicellular eukaryotes like yeast but also in multicellular organisms. 
Especially during cancerogenesis, checkpoint adaptation is thought to contribute to genome 
instability. We could previously show that inhibition of the highly conserved TOR nutrient 
signalling pathway either by genetic or pharmacologic means prevents checkpoint adaptation 
in Saccharomyces cerevisiae. These observations suggests that nutrient signalling pathways 
involving TOR signalling node play an important role in response to DNA damage.  
We set out to further investigate the link between nutrient signalling, checkpoint adaptation and 
genome stability. We show that prevention of adaptation can be achieved by modulating the 
Tap42-PP2A axis downstream of TOR signalling. We found that pharmacological inhibition of 
TOR by rapamycin affects protein levels of Cdc5, a major factor promoting adaptation. Using 
RAD52-deficient yeast cells to mimic the DNA repair defect observed in many human cancers, 
we confirmed previous results showing that preventing adaptation sensitizes these cells to 
genotoxins. However, if adaptation is allowed to occur, repair-deficient cells acquire genotoxin 
resistance and display an aneuploid karyotype. Gene expression profiling revealed that resistant 
repair-defective yeast cells exhibit common aneuploidy-associated phenotypes. Although 
resistant aneuploid cells are still checkpoint-competent, they can proliferate in the presence of 
persistent DNA damage. This underlines the role of checkpoint adaptation in the acquisition of 
genotoxin resistance. Taken together, our results highlight an intriguing relationship between 
the DNA damage response and genome stability, which appears to be associated with 
checkpoint adaptation and nutrient signalling pathways. Furthermore, using an easily tractable 
model organism such as budding yeast, we provide insights into the relationship between 
fundamental and highly conserved cellular processes that could be useful for drug development 
and disease treatment in humans as well.  
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Zusammenfassung 
Wenn die DNA einer Zelle beschädigt wird, stoppt die Zelle im Zellzyklus bevor die Trennung 
der Schwesterchromatiden begonnen hat, als Reaktion auf die Aktivierung des „DNA-Schaden-
Checkpoints“, kurz Checkpoint. Dieser Kontrollmechanismus stellt Zeit zur Reparatur zur 
Verfügung und nur nach erfolgreicher Reparatur kann der Zellzyklus wieder aufgenommen 
werden. Das Anhalten des Zellzyklus und die Reparatur der beschädigten DNA sind daher 
wichtige Prozesse, um die Stabilität des Genoms und den zuverlässigen Transfer der 
genetischen Information an die Tochterzelle zu gewährleisten. Ist eine Reparatur jedoch 
unmöglich, können sich Zellen über den Checkpoint hinwegsetzen und das Anhalten des 
Zellzyklus durch einen Mechanismus beenden, der als Adaptation bezeichnet wird. Obwohl 
nachweislich viele Proteine in den Adaptationsprozess involviert sind, bleibt der molekulare 
Mechanismus immer noch schwer fassbar. Besonders die kritischen Faktoren, welche die 
Adaptation in Gang setzen, wurden noch nicht vollständig identifiziert. Das Verständnis dieses 
Signalwegs ist von besonderem Interesse, da Adaptation eine treibende Kraft für 
Genominstabilität darstellt und schädliche Auswirkungen hat, einschließlich Zelltod und 
verschiedene genetische Abweichungen. Interessanterweise findet man das Konzept der 
Adaptation nicht nur in einzelligen Eukaryoten wie der Hefe, sondern auch in vielzelligen 
Organismen. Besonders während der Karzinogenese trägt Adaptation vermutlich zur 
Instabilität des Genoms bei. Wir konnten bereits nachweisen, dass die Hemmung des hoch 
konservierten TOR-Nährstoff-Signalwegs, entweder durch genetische oder pharmakologische 
Mittel, Adaptation in Saccharomyces cerevisiae verhindert. Diese Beobachtungen lassen 
vermuten, dass Nährstoff-Signalwege einschließlich des Knotenpunkts um den TOR-
Signalweg eine wichtige Rolle bei der Antwort auf DNA-Schäden spielen.  
Das Ziel dieser Dissertation war es, die Verbindung zwischen Nährstoff-Signalwegen, 
Adaptation und Genominstabilität genauer zu untersuchen. Wir weisen nach, dass Adaptation 
verhindert werden kann durch das Anpassen der Tap42-PP2A-Achse, die dem TOR-Signalweg 
nachgeschaltet ist. Wir haben herausgefunden, dass die pharmakologische Hemmung von TOR 
durch Rapamycin den Proteinspiegel von Cdc5 beeinflusst, einem wichtigen Faktor, der 
Adaptation vorantreibt. Indem wir Hefezellen benutzen, denen das Gen RAD52 fehlt um den 
Reparaturdefekt vieler Krebsarten nachzuahmen, konnten wir frühere Ergebnisse bestätigen, 
die zeigen, dass diese Zellen durch das Verhindern von Adaptation anfälliger sind für 
Genotoxine. Wenn Adaptation jedoch stattfinden kann, erwerben diese Reparatur-defekten 
Zellen Resistenzen gegen Genotoxine und weisen einen aneuploiden Karyotyp auf. 
Genexpressionsprofile dieser resistenten und Reparatur-defekten Hefezellen zeigen allgemeine 
Phänotypen, die mit Aneuploidie assoziiert werden. Obwohl resistente aneuploide Zellen 
immer noch kompetent sind bezüglich des Checkpoints, können sie in der Anwesenheit 
anhaltender DNA-Schäden proliferieren. Dies unterstreicht die Rolle von Adaptation beim 
Erwerb von Resistenzen gegenüber Genotoxinen. Zusammenfassend zeigen unsere Ergebnisse 
einen verblüffenden Zusammenhang zwischen der Reaktion auf DNA-Schäden und der 
Genomstabilität, welcher in Verbindung mit Adaptation und Nährstoff-Signalwegen zu stehen 
scheint. Indem wir Bäckerhefe als leicht lenkbaren Modellorganismus benutzen, können wir 
Einblicke in den Zusammenhang grundlegender und hochkonservierter zellulärer Prozesse 
gewinnen, die auch bei der Entwicklung von Medikamenten und der Behandlung von 
Krankheiten des Menschen nützlich sein können 
Zusammenfassung 
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1 Introduction 
Every day, the integrity of the genome is challenged by a variety of agents that could potentially 
cause harm to the genetic material by introducing a wide range of modifications or aberrations. 
In order to ensure that the transfer of genetic information to their progeny can occur as reliably 
as possible, cells are equipped with a variety of mechanisms and pathways to detect and repair 
damage to their DNA.  
Amongst the myriad of DNA lesions, double-stranded breaks (DSBs) are thought to be the most 
lethal due to their ability to induce chromosomal aberrations (Natarajan et al., 1980) including 
deletions, inversions, duplications and translocations. 
  
1.1 The response to genome-wide DNA damage 
At every critical step during the cell cycle, surveillance mechanisms called checkpoints are in 
place to ensure that cell cycle progression will only occur if all necessary requirements are 
fulfilled, e.g. sufficient cell size for the transition from G1 to S phase or complete replication 
of the genome for the transition from S to G2. Accordingly, when cells experience DNA 
damage, an evolutionary conserved response is initiated which leads to the activation of a DNA 
damage checkpoint. Interestingly, cells respond differently depending on the timing of damage 
occurrence with respect to the replication of the genome and the type of lesion. Although the 
set of proteins involved in the checkpoint response remains similar, the checkpoint responses 
seem to differ in terms of outcomes depending on whether or not the cell has already completed 
DNA replication. In the thesis presented here, I will focus on the role and influence of activating 
the DNA damage checkpoint (DDC) in the G2/M phase of the cell cycle. Activation of the DDC 
will ultimately arrest the cell cycle in G2/M at the metaphase to anaphase transition prior to the 
separation of sister chromatids (reviewed in (Melo and Toczyski, 2002)). To prevent the 
transmission of damaged DNA to the daughter cell, a signalling cascade comprising sensors 
and mediators is turned on to ensure signal amplification and transmission to the effectors of 
the DNA damage checkpoint. Activation of the DDC leads to an arrest of the cell cycle to 
provide time to repair the damage. When the damage is repaired, the initial checkpoint trigger 
is abolished which leads to the inactivation of the checkpoint signalling cascade and eventually 
allows cell cycle progression.  
 
1.1.1 Checkpoint sensors and effectors 
After a DSB has occurred, the damage site is processed by nucleases that resect the DNA to 
create single-stranded DNA (ssDNA). This serves as the primary trigger for the activation of 
the DNA damage checkpoint. The MRX complex, consisting of Mre11, Rad50 and Xrs2, 
together with the nuclease Sae2, is responsible for the initial short-range resection occurring 
after a DSB (Mimitou and Symington, 2008; Zhu et al., 2008). In a second step, the MRX 
complex stimulates the recruitment of the Sgs1 helicase as well as Exo1, a nuclease with 5’ to 
3’ processing activity that facilitates long-range resection around the DNA lesion site (Shim et 
al., 2010). The nucleolytic processing of one strand (in 5’ to 3’ direction) in either direction 
from the DSB creates stretches of ssDNA which are then rapidly bound by the heterotrimeric 
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RPA (Replication Protein A) complex (Alani et al., 1992). Binding of RPA serves as a 
signalling platform for the recruitment of a plethora of checkpoint proteins and kinases. One of 
the most upstream factors is Mec1 (Nakada et al., 2005), which is the homolog of human ATR. 
Mec1 is a member of the phosphoinositide (PI)-3-kinase (PI3K)-related kinase (PIKK) 
superfamily (Kato and Ogawa, 1994) and collaborates with Ddc2 (Nakada et al., 2005; Paciotti 
et al., 2000), the yeast homolog of human ATRIP. In addition to Mec1-Ddc2, the PCNA-like 
checkpoint clamp composed of Mec3, Rad17 and Ddc1 is loaded onto the damage site at the 
transition of the single-stranded to the double-stranded DNA (Kondo et al., 1999; Majka and 
Burgers, 2003). Loading of the clamp, which is referred to as the 9-1-1 clamp named after the 
human components Rad9, Hus1 and Rad1, is aided by the clamp loader containing Rad24 and 
four small subunits of the Replication Factor C (RFC) members (Rfc2, 3, 4 and 5) (Green et al., 
2000; Majka and Burgers, 2003; Venclovas and Thelen, 2000). When the 9-1-1 component 
Ddc1 was artificially co-localized with the Mec1-Ddc2 dimer in the absence of damage by 
tethering them to DNA in close proximity, this was sufficient to activate the DNA damage 
checkpoint (Bonilla et al., 2008). This suggests that the 9-1-1 checkpoint clamp is involved in 
Mec1 activation and establishment of the checkpoint signalling cascade. The recruitment of the 
checkpoint adaptor (or mediator) protein Rad9 in response to DNA damage seems to be 
regulated via different pathways. Firstly, Rad9 can localize to damage sites by interacting with 
histones that have been modified in response to damage. However, this mechanism seems more 
critical for checkpoint activation during the G1 phase of the cell cycle (Hammet et al., 2007). 
In a second pathway, Rad9 can interact with a second checkpoint mediator, Dpb11 (human 
TopBP1) (Puddu et al., 2008). Dpb11 gets recruited via Ddc1 (Wang and Elledge, 2002). The 
Rad9 phosphorylation sites that allow Dpb11 interaction were initially found to be cell-cycle 
regulated (Pfander and Diffley, 2011). Later on, also damage-induced Rad9 phosphorylation 
events were observed to facilitate the Dpb11- Rad9 interaction (di Cicco et al., 2017). However, 
the exact order of events as well as the possible involvement of additional factors have not been 
fully elucidated.  
Once Mec1 is activated, it targets the checkpoint mediator Rad9 for phosphorylation at multiple 
sites (Schwartz et al., 2002) allowing the recruitment and subsequent activation of Rad53 
(human CHK2) (Gilbert et al., 2001; Sweeney et al., 2005). Full Rad53 activity requires 
multiple autophosphorylation events as well as trans phosphorylations in a Mec1-dependent 
manner (Ma et al., 2006; Sanchez et al., 1996; Sun et al., 1998). The activation steps of Rad53 
rely on the FHA (forkhead-associated) domains present in Rad53 that serve as phosphopeptide 
binding platforms (Schwartz et al., 2003). In contrast to the high level of conservation regarding 
checkpoint protein orthologues amongst eukaryotes, no single orthologue for Rad9 has been 
identified in humans so far. Rather, a set of proteins has been characterized as checkpoint 
mediators, including MDC1, 53BP1 and BRCA1 (reviewed in (Zhou and Elledge, 2000)).  
In addition to Rad53, a second effector checkpoint kinase named Chk1 (human CHK1) has 
been characterized in yeast (Liu et al., 2000). Rad53 and Chk1 have been shown to achieve a 
DNA damage-induced cell cycle arrest by distinct targets (Sanchez et al., 1999) (See section 
1.1.2). However, Rad53 is considered the central checkpoint kinase to halt the cell cycle by 
phosphorylating multiple downstream targets (See section 1.1.2, see Figure 1 for a schematic 
overview of the initial steps in DDC activation).  
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The human orthologue of Mec1, ATR, seems to play a minor role in the response to DSBs. In 
contrast, the main responder in mammalian cells is ATM which corresponds to Tel1 in budding 
yeast. Tel1 associates with the MRX complex in an Xrs2-dependent fashion (Nakada et al., 
2003) and thereby contributes to the production of ssDNA by enhancing resection (Mantiero et 
al., 2007) which in turn allows the recruitment of Mec1 via RPA binding to ssDNA. Tel1 can 
also activate the DNA damage checkpoint in the absence of Mec1, however, Tel1 activity seems 
to be triggered mostly by several DSBs and is decreased when resection of the lesion is initiated 
(Mantiero et al., 2007) suggesting that Tel1 might be activated in response to blunt or minimally 
resected damage sites. Accordingly, Mec1-regulated resection has been shown to decrease 
Tel1-mediated checkpoint signalling (Clerici et al., 2014). Consequently, resection could serve 
as a tool to switch from Tel1- to Mec1-mediated checkpoint signalling (Mantiero et al., 2007). 
A similar swap from ATM- to ATR-mediated DSB signalling has been proposed to occur in 
human cells in order to coordinate the respective events sparked by both checkpoint kinases 
(Shiotani and Zou, 2009).  
Furthermore, the core histone H2A is phosphorylated at a serine residue at position 129 in 
response to DNA damage in a Mec1- and Tel1-dependent manner (Downs et al., 2000). 
Modification of H2A leads to local chromatin de-compaction enabling the recruitment and 
action of repair proteins (Downs et al., 2000; Redon et al., 2003). Consistently with the high 
conservation of the DNA damage response (DDR) in eukaryotic cells, phosphorylation of 
Figure 1. Schematic overview of the initial steps in DDC activation. Black dots represent critical
phosphorylation events. For simplicity, some proteins (e.g. the clamp loader) are omitted. 
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H2AX, a H2A variant, at serine 139 (dubbed γH2AX) has also been described in mammalian 
cells (Rogakou et al., 1998) where it plays a similarly crucial role in facilitating DNA repair 
(Paull et al., 2000) and is therefore widely used as a read-out for the presence of DNA damage.  
 
1.1.2 Checkpoint targets to halt the cell cycle 
As mentioned above, there are two checkpoint kinases, Chk1 and Rad53, which act as the 
effectors of the DNA damage checkpoint. In order to achieve cell cycle arrest in response to 
DNA damage, both Chk1 and Rad53 elicit downstream signalling pathways to different 
checkpoint targets (Sanchez et al., 1999). Chk1 has been shown to prevent degradation of 
securin, known as Pds1 in budding yeast. In unperturbed conditions, Pds1 is ubiquitinated by a 
central cell cycle regulatory E3 ubiquitin ligase termed anaphase promoting complex (APC) 
(Cohen-Fix et al., 1996; King et al., 1995) in association with its specificity-promoting co-
activator Cdc20 (APCCdc20) (Visintin et al., 1997). The APC plays important roles in cell cycle 
regulation depending on its binding to either Cdc20 or another co-activator, Cdh1. APCCdh1 is 
responsible for mitotic cyclin degradation including Clb2 (Schwab et al., 1997; Shirayama et 
al., 1998; Visintin et al., 1997). Subsequently, Pds1 is targeted for proteasomal degradation 
(Cohen-Fix et al., 1996) leading to the activation of the protease Esp1, also known as separase 
(Uhlmann et al., 1999). Esp1 is responsible for cleaving the Scc1 subunit of cohesin involved 
in sister chromatid cohesion (Uhlmann et al., 1999). During anaphase, Esp1-mediated cohesin 
cleavage allows the segregation of chromatids to the daughter cell and completion of mitosis 
(Ciosk et al., 1998; Michaelis et al., 1997). Upon DNA damage, Pds1 is phosphorylated in a 
Chk1-dependent manner at 9 putative phosphorylation sites (Cohen-Fix and Koshland, 1997; 
Sanchez et al., 1999; Wang et al., 2001), thereby possibly masking or counteracting its 
degradation signal for APCCdc20 and ultimately leading to Pds1 stabilization (Wang et al., 2001). 
Rad53 has been implicated in Pds1 stabilization as well by phosphorylating it and thereby 
disrupting the Pds1-Cdc20 interaction (Agarwal et al., 2003). Therefore, Rad53-mediated 
phosphorylation prevents recognition of Pds1 by the co-activator Cdc20, while Chk1-dependent 
Pds1 phosphorylation has been suggested to render Pds1 a poor APCCdc20 substrate. 
Consequently, Esp1 remains inhibited by Pds1 and sister chromatid separation cannot be 
initiated thereby ensuring mitotic arrest at the metaphase to anaphase transition after DDC 
activation. Importantly, Pds1 does not only function as an Esp1 inhibitor but is also required to 
ensure Esp1’s nuclear localization in order to facilitate Esp1-mediated cohesin cleavage. Hence, 
a two-step model for the roles of Pds1 and Esp1 has been proposed: After phosphorylation by 
the main yeast Cyclin-dependent kinase (Cdk) Cdc28 (reviewed in (Mendenhall and Hodge, 
1998)), Pds1 shuttles previously cytoplasmic Esp1 into the nucleus to allow Esp1-mediated 
proteolysis of cohesin (Agarwal and Cohen-Fix, 2002). After Pds1 degradation via the 
APCCdc20, Esp1 is re-localized from the nucleus to the spindle pole body (SPB), the yeast 
functional equivalent of the centrosome (reviewed in (Kilmartin, 2014)), to participate in sister 
chromatid separation, possibly directed by a remaining pool of Pds1 that had escaped bulk 
proteasomal degradation (Agarwal and Cohen-Fix, 2002; Jensen et al., 2001). Therefore, DDC-
dependent phosphorylation of Pds1 upon damage might prevent the Cdc28-dependent 
phosphorylation observed in unperturbed conditions to ensure that Esp1 remains inhibited and  
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is excluded from the nucleus. Thereby, a cell cycle arrest can be elicited and sister chromatid 
separation is prevented. 
In addition to preventing sister chromatid separation via the Chk1-Pds1 pathway, Rad53 affects 
mitotic progression by regulating Cdc5. Upon DNA damage- induced activation of Rad53, 
Cdc5 is phosphorylated and thereby inhibited in a Rad53-dependent manner (Cheng et al., 
1998; Zhang et al., 2009). In this condition, Cdc5 can no longer inhibit the two-component 
GTPase-activating protein (GAP) Bub2/Bfa1 caused by the Cdc5-dependent phosphorylation 
of Bfa1 (Hu et al., 2001). The Bub2/Bfa1 complex promotes GTP hydrolysis and thereby 
inhibits the small GTPase Tem1 which positively regulates the downstream Cdc15 kinase (Hu 
et al., 2001; Lee et al., 2001a; Shirayama et al., 1994). Being localized at the SPB, the combined 
activation of the protein kinases Cdc15, Dbf2 and Mob1 are thought to drive mitotic exit 
(Visintin and Amon, 2001). This is achieved by a complex regulatory pathway termed the 
Mitotic Exit Network (MEN) which ultimately releases the Cdc14 phosphatase from the 
nucleolus to the cytoplasm where it can remove Cdc28-mediated phosphorylations on multiple 
proteins thereby driving cells from mitosis into the subsequent G1 phase of the cell cycle 
(Jaspersen et al., 1999; Shou et al., 1999; Visintin et al., 1999). In summary, DDC activation 
leads to the inhibition of Cdc5 and thereby prevents activation of MEN resulting in a damage-
induced cell cycle arrest. In addition to the Cdc5-mediated inhibition of Bfa1, Rad53 has been 
proposed to positively modulate Bub2/Bfa1 interaction with Tem1 thereby keeping Tem1 
inactivated and preventing the onset of MEN (Liang and Wang, 2007). 
Taken together, at least two Rad53-mediated pathways have been proposed to ensure a cell 
cycle arrest induced by DNA damage both independent and dependent on Cdc5.  
Figure 2. Simplified scheme of DDC effectors and targets leading to cell cycle arrest in response to
DNA damage. RNR: ribonucleotide reductase complex. 
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1.1.3 Transcriptional response to DNA damage 
In addition to halting the cell cycle, DNA damage also elicits a transcriptional response. The 
protein kinase Dun1 has been identified as one of the central transcriptional regulators after 
DNA damage. Rad53 activation leads to the phosphorylation and subsequent activation of Dun1 
accompanied by Dun1 autophosphorylation events (Bashkirov et al., 2003; Zhou and Elledge, 
1993). Subsequently, Dun1 phosphorylates the DNA binding protein Crt1 preventing its 
binding to consensus DNA binding motifs. Consequently, gene expression from these loci is 
allowed to occur, and this has been shown to include the redundant RNR genes (Huang et al., 
1998). These genes encode the subunits of the ribonucleotide reductase (RNR) complex 
responsible for converting ribonucleotides (NTPs) into deoxyribonucleotides (dNTPs) and 
thereby maintaining dNTP pools within the cell (Lammers and Follmann, 1984). To facilitate 
dNTP pool homeostasis and to account for the increased demand due to DNA repair 
mechanisms, the RNR inhibitor Sml1 (Zhao et al., 1998) has been shown to be targeted and 
degraded after DNA damage in a DDC-dependent manner also involving Dun1 (Zhao et al., 
2001; Zhao and Rothstein, 2002). Appropriate activity of the RNR complex seems 
indispensable for cell viability in response to damage since deletion of the RNR inhibitor SML1 
or overexpression of RNR components can rescue lethality of both RAD53 and MEC1 deletions 
(Desany et al., 1998; Zhao et al., 1998) which is probably due to the higher demand for dNTPs 
required for DNA repair processes following DNA damage. 
In a second pathway parallel to the Dun1-mediated transcriptional response, DDC activation 
has been shown to downregulate the CLB2 transcription cluster including CLB2 itself, as well 
as CDC5, CDC20 and many other genes required for the execution of mitosis (Gasch et al., 
2001). Transcription of the CLB2 cluster is mediated by the transcription factors Mcm1 and the 
forkhead transcription factors, Fkh1 and Fkh2 (Kumar et al., 2000; Zhu et al., 2000). Fkh2 
recruits the positive regulator Ndd1 to promoters of the CLB2 cluster (Koranda et al., 2000) via 
an interaction of Fkh2’s forkhead-associated domain (FHA) and a phosphorylation in Ndd1 
(Reynolds et al., 2003). Clb2-Cdc28 and Cdc5 kinase activity have been shown to facilitate the 
Fkh2-Ndd1 interaction (Darieva et al., 2006; Reynolds et al., 2003) thereby promoting a 
positive feedback-loop that leads to high transcription of the CLB2 cluster. In response to DNA 
damage, Ndd1 is phosphorylated directly by Rad53. This prevents Ndd1 association with 
promoters of the CLB2 transcriptional cluster via the Rad53-Dun1 axis (Edenberg et al., 2014).  
In addition, gene expression profiling performed after exposure of yeast to different 
environmental stresses has revealed a common environmental stress response (ESR) (Gasch et 
al., 2000). Interestingly, the checkpoint kinase Mec1 was shown to regulate the ESR in response 
to the DNA alkylating agent methylmethanosulfate (MMS) and ionizing radiation (Gasch et al., 
2001) showing that DNA damage influences the transcriptome in a DDC-dependent manner.  
In summary, checkpoint activation in response to DNA damage (i) halts the cell cycle by 
targeting proteins involved in mitotic progression such as Pds1, Cdc5 and Bfa1, (ii) ensures 
DNA repair capacity by upregulating the RNR complex, and (iii) elicits a transcriptional 
response involving the CLB2 transcriptional cluster to reinforce the checkpoint arrest and to 
facilitate a more general stress response (summarized in Figure 2). 
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1.2 Types of DNA damage 
Single-stranded (SSB) and double-stranded breaks (DSB) are thought to be the most common 
types of DNA damage with an estimated frequency of 55,000 or 25 lesions, respectively, per 
cell every day (reviewed in (Tubbs and Nussenzweig, 2017)). However, SSBs have a propensity 
to be converted into DSBs which, in turn, are considered the most deleterious type of damage 
since no complementary strand is left to enable template-based repair processes. This suggests 
DSBs are potentially lethal damage. Consequently, cells have developed multiple pathways to 
ensure appropriate and timely repair of the different types of DNA damage.  
 
1.2.1 Endogenous sources of DNA damage  
Spontaneous DNA damage occurring from endogenous sources can contribute to evolution to 
a certain extent. However, it also imposes a major threat to genome stability by introducing 
unwanted or harmful mutations. It has been recognized a long time ago that due to its chemical 
properties, DNA can engage in multiple chemical reactions affecting its stability and 
characteristics. Since then, these chemical reactions have been identified as sources of 
endogenous DNA damage and there are different pathways dedicated to deal with the distinct 
outcomes and consequences. 
One source of endogenous damage is given by the spontaneous hydrolysis of DNA. Direct 
conversion of the four bases into another base is a common type of hydrolytic damage occurring 
in the aqueous cellular environment. For example, cytosine can undergo deamination and is 
thereby converted to uracil. Consequently, this will lead to a base pairing mismatch since uracil 
is now base-paired to guanine. In the subsequent round of DNA replication, the base 
incorporated opposite of the uracil will be adenine while the uracil itself will be replaced by 
thymidine thereby introducing a point mutation (reviewed in (Marnett and Plastaras, 2001)). 
This has been estimated to occur approximately 190 times a day per cell (reviewed in (Tubbs 
and Nussenzweig, 2017)). 
Spontaneous depurination or depyrimidination is another type of hydrolytic DNA damage 
causing the occurrence of abasic sides thereby leaving a gap in one of the two DNA strands. 
This type of damage seems to affect purine bases much more often than pyrimidines and both 
types of lesions are thought to occur approximately 12,000 or 600 times a day in every cell 
(reviewed in (Tubbs and Nussenzweig, 2017)). 
One of the most potent endogenous DNA damage sources is given by oxidative damage which 
is caused by radicals arising from mitochondrial metabolism. This crucial biological process 
produces reactive oxygen species (ROS) that can potentially cause multiple forms of oxidative 
damage to DNA. Therefore, ROS are considered especially harmful due to the various and 
heterogeneous types of lesions that can be induced including the modification of bases, inter- 
and intrastrand crosslinking events, crosslinking of proteins to the DNA and DNA strand breaks 
(reviewed in (Jena, 2012)). One of the best characterized oxidative damage lesion is 7,8-
dihydro-8-oxoguanine (8-oxo-G) which has been implied to play a role in cancer and aging 
(reviewed in (Loft et al., 2008)). 
Not only hydrolytic and oxidative damage but also methylation in non-enzymatic reactions can 
pose a threat to the integrity of DNA molecules. Non-enzymatically catalysed spontaneous 
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methylation events can modify bases, especially 3`-methyladenine has been suggested as a 
harmful modification due to its ability to block replication. The intracellular methyl group donor 
S-adenosylmethionine (SAM) that functions as a co-substrate can act as a weak alkylating agent 
under physiological conditions (reviewed in (Lindahl, 1993)). 
The above mentioned lesions and aberrations can be caused by endogenously occurring 
damage, however, they can also be inflicted by exogenous damage sources. 
 
1.2.2 Exogenous DNA damage sources  
In addition to endogenous damage occurring under physiological conditions as the 
consequences of biological processes or due to the chemical properties of individual molecules, 
cells also have to deal with exogenously induced DNA damage. This comprises both naturally 
occurring DNA lesions caused for example by UV light or irradiation as well as non-natural 
damage induced by drug treatment, for example bleomycin and CPT, as used in this study. 
 
1.2.2.1 Radiation and radiomimetic agents 
Exposure to ultra-violet (UV) radiation also contained in sunlight induces the formation of 
bulky adducts in the DNA double strands caused mainly by the creation of cyclic photoproducts 
and dimers between bases. These lesions lead to an altered symmetry of the DNA double helix 
thereby hampering transcription and replication and their removal is a major task for NER 
(reviewed in (Costa et al., 2003; Rastogi et al., 2010)). 
X-rays constitute a type of electromagnetic radiation which also includes UV radiation and 
γ- rays. Like the latter, X-rays possess enough energy to ionize molecules and thereby they have 
been classified as ionizing radiation. It has been commonly accepted that ionizing radiation 
induced different types of DNA lesions including damage to bases, single and double strand 
breaks and intra-strand crosslinks between the two DNA strands. The fact that X-rays cause 
DNA damage has been exploited for a long time and, amongst other observations, led to the 
identification of crucial repair factors such as Rad52 (Game and Mortimer, 1974). 
Interestingly, the types of lesions caused by ionizing radiation seem to be very similar in their 
chemical properties to ROS-induced DNA damage. However, it has been estimated that the 
damage inflicted by endogenous ROS action exceeds the damage load usually delivered to 
human cells using conventional radiotherapy during cancer treatment (reviewed in (Lindahl, 
1993; Markkanen et al., 2012)). One explanation why radiation-induced DNA damage still 
shows higher cytotoxicity could be the complexity of lesions. Upon irradiation, DNA damage 
occurs in a bundled or grouped fashion accumulating within one or more DNA helical turns. 
This is referred to as clustered damage and it is thought to be more difficult to repair and have 
the potential to be converted into additional DSBs thereby causing cell death ((Costa et al., 
2003; Game and Mortimer, 1974) and reviewed in (Loft et al., 2008)). In fact, already soon 
after the discovery of X-rays in the late 19th century and, shortly after, γ-rays as a natural source 
of radiation, they were used in radiotherapy for cancer treatment (reviewed in (Connell and 
Hellman, 2009)). Although for some cancer types, radiotherapy is used as the standard 
treatment since it allows targeted delivery of the damaging agent and thereby helps to preserve 
integrity of the surrounding healthy tissue, tumour cells can be resistant to radiation 
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(radioresistance). This has been mainly attributed to intrinsic properties of individual cell types 
and the surrounding tumour microenvironment and remains an obstacle especially in the 
treatment of cancers affecting the central nervous system (reviewed in (Kelley et al., 2016)).  
As an alternative to ionizing radiation, genotoxic compounds mimicking radiation-induced 
DNA damage can be used. These agents are referred to as radiomimetic drugs, although, in 
contrast to ionizing radiation, they seem to induce damage in a highly specific manner by 
creating mostly DSBs (reviewed in (Rastogi et al., 2010)). Together with its derivatives 
phleomycin and zeocin, bleomycin belongs to the class of radiomimetic agents used in 
chemotherapy and its mode of action leading to the cleavage of the DNA backbone has been 
revealed several years ago (reviewed in (Burger, 1998)). 
 
1.2.2.2 Camptothecin (CPT) 
Although the compound camptothecin (CPT) was isolated in the 1950s, the cellular targets, 
DNA topoisomerases, were discovered and characterized only several years later, first in 
bacteria in 1971 (Wang, 1971) and afterwards in mouse cells (Champoux and Dulbecco, 1972). 
Topoisomerases counteract topological stress in the DNA double helix arising from the 
requirement to massively compact DNA. Supercoiled DNA is an obstacle to transcription as 
well as replication and needs to be resolved transiently to facilitate the segregation of replicated 
DNA strands to the daughter cells before cell division can occur (reviewed in (Pommier et al., 
2010)). Eukaryotic topoisomerases have been grouped into two classes, with type I enzymes 
relieving topological tension by transiently incising one strand of the DNA duplex thereby 
creating a SSB, and type II enzymes acting by cleavage of both DNA strands thereby forming 
a DSB. Type I topoisomerases can be further subdivided into type IA and type IB enzymes. 
Saccharomyces cerevisiae contains three genes encoding for the different but highly conserved 
topoisomerase classes: TOP3 coding for the type IA enzyme (Kim and Wang, 1992), TOP1 for 
the type IB enzyme (Thrash et al., 1985), and the type II topoisomerase encoded by the TOP2 
gene (Goto and Wang, 1984). Yeast Top1 and type IB class members in other species can 
resolve both positive and negative supercoiling (reviewed in (Wang, 1996)). Mechanistically, 
type IB enzymes like Top1 utilize several transesterification steps involving their catalytically 
active tyrosine residue to attack the DNA phosphodiester backbone and transiently form a 
Top1-DNA complex. This complex has been termed the Top1- cleavable complex (Top1cc) 
and leads to the formation of a SSB. Subsequently, Top1 can lead to a strand rotation thereby 
relieving the topological stress. As a last step, the SSB created by Top1 action is re-ligated 
thereby resolving the Top1-DNA intermediate (Top1cc). The two subclasses type IA and IB 
are discriminated by the kind of enzyme-DNA linkage that is formed during the reaction and 
the mechanism by which they lead to DNA relaxation. CPT treatment causes the stabilization 
of the transient Top1cc by intercalating into the cleavage site between Top1 and the DNA 
strand. Thereby, CPT prevents the final step of DNA re-ligation and consequently causes a 
persistent SSB (reviewed in (Pommier et al., 2010)). Since CPT does not directly interfere with 
Top1’s catalytic activity to inhibit its function, the term Top1 poison has been established. As 
a result of the stabilized Top1-DNA intermediate, RNA and DNA polymerases encounter an 
obstacle during transcription and replication, respectively. Collision of the polymerases with 
the Top1cc ultimately leads to a DSB and an irreversible crosslink between Top1 and the DNA. 
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Although not fully understood, the repair of CPT-induced lesions requires both the removal of 
the enzyme Top1 and the religation of the free DNA ends (reviewed in (Pommier et al., 2010)).  
So far, at least three pathways to repair CPT-induced DNA damage have been proposed. The 
best studied mechanism involves the tyrosyl-DNA phosphodiesterase 1 (Tdp1) (Yang et al., 
1996). In order to enable repair of the DNA, Top1 protein has to be removed from the stabilized 
Top1cc by degradation via the proteasome (Desai et al., 2001; Lin et al., 2009). Subsequently, 
Tdp1 can process the Top1 tyrosyl remnant left behind (Debethune et al., 2002; Pouliot et al., 
1999) . Eventually, polynucleotide kinase/ phosphatase (PNKP in humans and Tpp1 in budding 
yeast) removes the 3`phosphate left on the DNA strand by Tdp1 to allow subsequent repair.  
Alternative pathways have implicated endonucleases in the removal of the CPT-mediated 
stabilized Top1cc or the reversal of the replication machinery concerted with the action of a 
helicase (reviewed in (Pommier et al., 2006)).  
Analogous to topoisomerase I poisoning by CPT, also the type II topoisomerases can be 
poisoned using etoposide and its derivatives. As for the topoisomerase I-CPT interplay, 
etoposide stabilizes the reaction intermediate between enzyme and DNA (reviewed in (Cuya et 
al., 2017)). Due to their mode of action, CPT and its derivatives require DNA replication to 
cause cytotoxicity and are therefore considered S-phase specific.  
An increasing number of CPT derivatives and analogues has been developed and tested for their 
suitability in cancer treatment. However, the poor chemical stability of CPT under physiological 
conditions renders drug development difficult. Moreover, the cellular concentration of CPT is 
decreased due to the activity of pumps such as breast cancer resistant protein (BRCP) or the 
efflux transporter p-glycoprotein thereby drastically decreasing CPT efficacy as an anti-tumour 
drug. Nevertheless, CPT compounds are used in chemotherapy targeting a range of cancer types 
including lung, cervical and breast cancer (reviewed in (Beretta et al., 2006)).  
Combinational therapies including CPT derivatives or analogues appear to be especially 
promising. For example, concomitant inhibition of Tdp1, which is involved in repair of CPT-
induced damage, should enhance CPT efficacy as a chemotherapeutic (reviewed in (Cuya et al., 
2017)). Although Tdp1-independent CPT damage repair has been reported and this pathway 
relies on the DNA damage checkpoint, co-administration of CPT and Tdp1 inhibitor can be 
beneficial based on the fact that most cancers are (at least partially) checkpoint-deficient 
(reviewed in (Broustas and Lieberman, 2014)). 
 
1.3 DNA damage arising from dysfunctional telomeres 
Not only intrachromosomal lesions but also DNA damage arising from chromosome ends can 
lead to the activation of the DDC. This is because telomeres, the ends of linear chromosomes, 
structurally resemble one half of a DSB. However, telomeres are protected from being 
recognized as damage since inappropriate repair events would lead to lethal repair outcomes 
such as fusions between chromosomes. How telomeres escape from being recognized as DNA 
damage to ensure genome stability is outlined below. 
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1.3.1 Overview of yeast telomeres  
1.3.1.1 Structure and maintenance of telomeres  
Telomeres in the budding yeast Saccharomyces cerevisiae consist of simple but heterogeneous 
repeats with the sequence abbreviated as C1-3A/TG1-3 (Shampay et al., 1984) extending over a 
total length of approximately 300 bp (+/- 75 bp). Wild type yeast cells express telomerase to 
maintain telomere length, which functions as a reverse transcriptase adding telomeric repeat 
sequences by using a bound RNA as a template. Budding yeast telomerase consists of three 
proteinaceous components called Est1, Est2 and Est3, named after their deletion phenotype ever 
shorter telomeres, and the telomeric repeat templating RNA moiety, Tlc1 (reviewed in 
(Wellinger and Zakian, 2012)). Since DNA sequences at the very ends of linear chromosomes 
would be lost during DNA replication due to the end-replication problem or by the action of 
nucleases and therefore, telomeres would shorten in every round of cell division eventually 
leading to the loss of genetic information. The majority of eukaryotic cells, including 
Saccharomyces cerevisiae, employs telomerase to maintain telomere length (reviewed in 
(Wellinger and Zakian, 2012)). Importantly, human somatic cells do not express telomerase at 
detectable levels and therefore only divide a limited number of times, which is referred to as 
the Hayflick limit (Hayflick, 1965). This difference in telomerase expression amongst 
eukaryotes could reflect distinct requirements in short-lived versus long-lived organisms. 
Chromosome ends are not blunt-ended but possess a 3`single-stranded overhang extending 
from the G-rich strand, referred to as the G-tail. While the G-tail only comprises roughly 15 
nucleotides during most of the cell cycle (Larrivee et al., 2004), its length is increased (to 
approximately 30 to 100 nucleotides) during late S and early G2 (Wellinger et al., 1993). This 
increase in G-tail length is not only due to telomerase action but also caused by a cell-cycle 
dependent degradation of the opposing C-rich strand and is linked to the semiconservative 
nature of DNA replication (reviewed in (Bonetti et al., 2013)). Telomeric repeats constitute the 
terminal part of telomeres and lack nucleosomes (Ichikawa et al., 2014; Wright et al., 1992). In 
contrast, the sequences oriented towards the centromere are termed subtelomeric regions and 
are considered very dynamic and prone to undergo recombination events (reviewed in 
(Wellinger and Zakian, 2012)). Subtelomeric DNA is mostly packaged into nucleosomes 
(Wright et al., 1992) and interestingly, H2A phosphorylated at serine 129 has been found 
enriched at subtelomeres. This seems curious since H2A phosphorylation is created in a 
Mec1/Tel1-dependent manner in response to DNA damage indicating that telomeres are at least 
transiently recognized as damage ((Kim et al., 2007), reviewed in (Longhese, 2008)).  
 
1.3.1.2 Telomeric binding proteins and their function 
Although telomeres are considered histone-free, they are bound by specialized telomeric-
binding proteins such as Rap1, which binds the dsDNA part of the telomeric repeats. The Rap1 
C-terminus is crucial for its function at telomeres and serves as a binding platform for the 
silencing proteins Sir3 and Sir4 which establish the heterochromatic status of telomeres by 
recruiting the histone deacetylase Sir2. Additionally, Rap1 recruits the Rap1-interacting factors, 
Rif1 and Rif2 functioning in telomere length maintenance by negatively regulating telomerase 
(reviewed in (Wellinger and Zakian, 2012)).  
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Another protein complex binding to telomeric dsDNA consists of the Yku70 and Yku80 
heterodimer referred to as the Ku complex. The Ku proteins play a key role in telomere structure 
and maintenance (Gravel et al., 1998) and are important regulators of the non-homologous end  
joining (NHEJ) pathway to repair DNA damage (Boulton and Jackson, 1996; Milne et al., 
1996). They have been proposed to localize at the dsDNA-ssDNA border of the telomere 
(Martin et al., 1999) but also to the subtelomeric region via an interaction between Yku80 and 
the Sir4 silencing protein (Roy et al., 2004). 
The ssDNA portion of the yeast telomere is bound by the essential protein Cdc13 (Lin and 
Zakian, 1996), identified as a temperature-sensitive mutant affecting cell cycle progression, 
hence the akronym Cdc for cell division cycle (Hartwell et al., 1973). Cdc13’s localization to 
the telomere and its DNA binding ability is conferred by a C-terminal OB (oligonucleotide/ 
oligosaccharide binding) domain exhibiting high affinity and specificity for telomeric ssDNA 
sequences (Mitton-Fry et al., 2002; Mitton-Fry et al., 2004). In addition, Cdc13 harbours more 
OB folds of which the OB1 domain in the N-terminus is involved in dimerization and has been 
suggested to bind telomeric ssDNA sequences as well (Mitchell et al., 2010). Cdc13 has a 
capping function at telomeres preventing them from being recognized as DNA damage by 
concealing the telomeric ssDNA (Garvik et al., 1995). To accomplish its capping function, 
Cdc13 cooperates with Stn1 and Ten1 to form the CST (Cdc13-Stn1-Ten1) complex (Grandin 
et al., 2001b; Grandin et al., 1997). Cdc13 has been reported to prevent homologous 
recombination at the telomere thereby preserving genome stability (Grandin et al., 2001a). In 
addition to CST-mediated telomere capping and protection, Cdc13 is also involved in telomere 
length maintenance. The OB1 fold serves as a binding platform for DNA polymerase α involved 
in C-strand synthesis (Sun et al., 2011). Within the Cdc13 protein, the OB1 fold is followed by 
a telomerase recruitment domain (RD) facilitating the interaction with the telomerase subunit, 
Est1 (Chandra et al., 2001), which leads to the recruitment of the holoenzyme to the telomere 
to allow elongation. Stn1 has been reported to bind to a similar or adjacent stretch in the Cdc13 
protein sequence thereby competing with Est1 and suggesting that Stn1 acts as a negative 
regulator of telomerase (Grandin et al., 2001b; Grandin et al., 1997). Therefore, a dual role for 
Cdc13 in telomere length regulation, both positive and negative, has been proposed (see Figure 
3 for an overview on telomere binding proteins and their function).  
Figure 3. Overview on telomeric binding proteins in S. cerevisiae and their functions in telomere
biology. 
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In the temperature-sensitive cdc13-1 mutant, a proline residue at position 371 is mutated to 
serine (Nugent et al., 1996). Due to its location within the OB2 domain, this amino acid 
substitution has been reported to impair Cdc13 dimerization. As a consequence, the interaction 
between Cdc13 and Stn1 is abolished (Mason et al., 2013) leading to a capping defect which is 
dramatically exacerbated at elevated temperatures in combination with over-elongated 
telomeres due to the lack of the negative telomerase regulator, Stn1 (Grandin et al., 1997). 
Importantly, the CST complex has been shown to be dispensable for telomere capping in non-
dividing cells. Rather, the Ku complex in association with Rap1 are responsible for telomere 
protection in this instance (Vodenicharov et al., 2010). Another protein implicated in telomere 
length maintenance is Tel1 which also functions in the DDC (Lustig and Petes, 1986). As in the 
DNA damage response pathway, Tel1 associates with the MRX complex (Ritchie and Petes, 
2000) and facilitates the recruitment of telomerase (Goudsouzian et al., 2006).  
In addition but not surprisingly given its binding specificity, also the ssDNA binding complex 
RPA has been proposed to associate with telomeres and positively regulate telomerase action 
(Luciano et al., 2012). 
 
1.3.2 The DNA damage response at telomeres 
Telomeres can be recognized as DNA damage via two different pathways. Firstly, telomere 
dysfunction can occur immediately, for example by removal of telomere binding proteins. 
Secondly, in the absence of telomerase as a telomere-lengthening mechanism, chromosome 
ends shorten continuously which eventually leads to DDC activation resulting in permanent cell 
cycle arrest termed replicative senescence (AS and Greider, 2003; Lundblad and Szostak, 
1989). The senescent state can be overcome by homology-mediated recombination dependent 
on Rad52 in order to elongate telomeres in the absence of telomerase and re-establish cell 
division potential (Lundblad and Blackburn, 1993). Telomerase-deficient yeast cells that have 
escaped senescence employing this pathway were termed survivors and the mechanism of 
recombination-mediated telomere elongation in telomerase-negative cells was found to be 
conserved in human cells (Bryan et al., 1997; Bryan et al., 1995). This recombination-mediated 
and telomerase-independent alternative lengthening of telomeres (ALT) has been studied 
extensively since the unlimited proliferative capacity characteristic of cancer cells is either 
based on the ALT pathway (approximately 10% of cancers) or the re-activation of telomerase 
(reviewed in (Apte and Cooper, 2017)).  
Telomere capping mediated by the CST complex prevents DNA damage signalling and 
consequently protects from undesired repair events such as homologous recombination and 
non-homologous end joining.  
Acute telomere dysfunction elicited for example by using the cdc13-1 allele causes the 
uncapping of telomeres. Consequently, this leads to the loading of the 9-1-1 checkpoint clamp 
onto telomeres aided by the clamp loader to activate Exo1 which leads to the degradation of the 
C-rich strand (Jia et al., 2004; Zubko et al., 2004). The newly created ssDNA serves as a 
recruitment platform for DNA damage sensors such as Ddc1 (Melo et al., 2001) and causes 
DDC activation followed by cell cycle arrest. It has been suggested that Mec1 activates Rad9 
to prevent further ssDNA generation via Rad53-dependent and -independent mechanisms (Jia 
et al., 2004). In addition, a role for additional nuclease(s) upon telomere uncapping has been 
Introduction 
14 
 
proposed which are thought to be regulated by the clamp loader component, Rad24 (Jia et al., 
2004). In order to obtain full DDC activation in response to telomere uncapping, the Rad9 
checkpoint adaptor is required to couple Mec1 recruitment and activation to the downstream 
signalling cascade involving Rad53 (Garvik et al., 1995). On the other hand, telomere 
dysfunction caused by successive telomere shortening in the absence of telomerase requires a 
second checkpoint adaptor, Mrc1 (Grandin and Charbonneau, 2007). Mrc1 is also required for 
checkpoint activation in response S-phase specific damage leading to replication stress 
(Alcasabas et al., 2001). This suggests that telomere dysfunction is also detected via the cellular 
response to replication stress. In addition, Mrc1 has also been attributed to play a role in 
telomere end protection in cdc13-1 mutants, where Mrc1 prevents Exo1 access and checkpoint 
activation (Tsolou and Lydall, 2007)  
Cdc13 prevents Mec1 association with telomeres to prevent Exo1-mediated ssDNA generation 
and thereby attenuate DDC activation. However, Tel1-MRX recruitment is allowed to occur 
even at Cdc13-capped telomeres underlining the positive function of Tel1 in telomere length 
regulation (Hirano and Sugimoto, 2007). This highlights the dual functions of many proteins 
that play an important role in both response to telomere damage and intrachromosomal damage 
such as a DSB. Since these two scenarios require differential treatment, a recent publication has 
proposed the establishment of a threshold by the helicase Pif1 (Strecker et al., 2017). The 
authors suggest that Pif1, which also acts as a telomerase inhibitor, can bind to break sites that 
harbour short telomeric sequences representative for an intrachromosomal DSB and prevent 
telomerase-dependent telomere sequence addition. On the contrary, it is dispensable at break 
sites flanked by long telomeric sequences resembling a telomere (Strecker et al., 2017). 
Consequently, the presence of Pif1 at break sites can prevent that these damage sites are treated 
as telomeres and thereby allow repair events to take place. The same publication showed that 
the decreased association of Pif1 with breaks sites resembling telomeres was due to the presence 
of Cdc13 in its function as a telomere binding protein (Strecker et al., 2017). Conversely, 
recruitment and activation of Mec1 at intrachromosomal break sites prevents Cdc13 binding to 
these sites via a Mec1-dependent phosphorylation thereby blocking the recognition of 
intrachromosomal damage as a telomere (Zhang and Durocher, 2010). 
Why is it crucial to promote repair at intrachromosomal DSBs but prevent it at telomeres? 
Accidental DSBs in intrachromosomal regions need to be repaired in order to facilitate 
unobstructed DNA replication and transcription. On the other hand, unscheduled repair events 
at telomeres can have detrimental outcomes for cell survival. There are two main pathways in 
place to repair DSBs: homologous recombination (HR) and non-homologous end joining 
(NHEJ). While the occurrence of HR at telomeres is required to some extent for telomere length 
maintenance in the absence of telomerase, full activation of HR is considered harmful due to 
increased rates of sister-chromatid exchanges and the appearance of telomeric circles (reviewed 
in (Claussin and Chang, 2015)). Telomeric sister-chromatid exchanges have been linked to 
accelerated rates of replicative senescence (Blagoev et al., 2010) and the formation of 
extrachromosomal circles containing telomeric DNA can lead to loss of genetic material (Wang 
et al., 2004). NHEJ of telomeres lead to telomere fusion events that can eventually cause 
circular or dicentric chromosomes. These structurally aberrant chromosomes are unable to 
segregate properly to daughter cells during mitosis and therefore precede copy number 
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alterations. Rap1 has been reported to play a major role in preventing NHEJ at telomeres 
(reviewed in (Marcand, 2014)). 
 
1.4 DNA damage repair pathways 
In order to facilitate optimal repair for the many different kinds of lesions that can affect DNA 
integrity and function, cells have evolved distinct pathways involving specialized repair 
proteins. Outlined below are the two major pathways to ensure repair of DSBs: NHEJ and HR, 
as well as a short summary of pathways involved in repair of base damages. 
Interestingly, in addition to other factors like cell cycle stage and the type of lesion, also the 
localization of the damage site with respect to the nuclear space influences repair pathway 
choice and efficiency (Lee et al., 2016; Lemaitre et al., 2014). Moreover, inefficiently repaired 
or even irreparable damage sites were shown to localize to the nuclear periphery. This process 
is mediated by repair factors associated with the lesion and the nuclear envelop protein, Mps3 
or nuclear pore components suggesting that the nuclear periphery is a specialized repair 
environment (reviewed in (Freudenreich and Su, 2016)). Likewise, eroded telomeres eliciting 
a DDR have been reported to re-localize to nuclear pore complexes (Khadaroo et al., 2009).  
 
1.4.1 Non-homologous end joining (NHEJ) 
Non-homologous end joining (NHEJ) describes the direct ligation of two DSB ends regardless 
of sequence homology and is therefore considered an error-prone repair pathway. 
Consequently, homology-based repair pathways are favoured if homologous sequences are 
present. The homologous sequences suitable as repair templates are available either after DNA 
replication in S and G2 phase or throughout the cell cycle in diploid yeast cells. As a result, 
NHEJ is only occurs in G1 phase of the cell cycle and in haploid yeast cells. This is in contrast 
to mammalian cells, where NHEJ is enabled throughout the cell cycle except for mid-S phase 
(Karanam et al., 2012; Mao et al., 2008). Ploidy-dependent repression of NHEJ is accomplished 
by the presence of the a1-α2 heterodimer expressed from the heterozygous mating locus in 
diploids. The a1-α2 heterodimer represses the transcription of NEJ1, encoding a crucial NHEJ 
factor (Frank-Vaillant and Marcand, 2001; Kegel et al., 2001; Valencia et al., 2001).  
The core proteins facilitating NHEJ comprise the Ku complex, DNA Ligase IV (Dnl4), Lif1, 
Nej1 and the MRX complex (reviewed in (Emerson and Bertuch, 2016)). The process 
underlying NHEJ can be roughly divided into 3 steps consisting of tethering the DSB ends 
together and protecting them, assembling the protein complex and finally, ligating the ends. 
The Ku70/80 heterodimer together with the MRX complex have been described to localize 
rapidly in a first response to the DSB (Wu et al., 2008). The Ku complex prevents nucleolytic 
processing of the DSB (Clerici et al., 2008; Mimitou and Symington, 2010) thereby funnelling 
the repair pathway towards NHEJ. MRX has been proposed to function as a linker between the 
DBS ends (Chen et al., 2001) thereby tethering the ends together in cooperation with Tel1 and 
Rif2 (Cassani et al., 2016). In the next step, DSB ends are stabilized by strand annealing (if 
there is homology) and the formation of the NHEJ repair complex. This is facilitated by a 
scaffolding function of Ku, which recruits the Dnl4-Lif1 complex and Nej1 to the break site 
(Chen and Tomkinson, 2011; Zhang et al., 2007). Dnl4 is stabilized by Lif1 (Herrmann et al., 
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1998) and while it is recruited via the Ku80 C-terminus it can conversely also stabilize the Ku 
proteins at the DSB (Chen and Tomkinson, 2011; Zhang et al., 2007). The accessory protein 
Lif1 interacts with Nej1 (Ooi et al., 2001), which is the subject of mating locus-mediated NHEJ 
repression in yeast diploids. Nej1 has been proposed to reinforce Ku`s function in preventing 
nucleolytic processing (Zhang et al., 2007) and assist in the recruitment and stimulation of other 
downstream NHEJ factors including Pol4 (Yang et al., 2015). The Pol4 polymerase functions 
in gap filling subsequent to the Dnl4-mediated ligation of the two DSB ends (Bebenek et al., 
2005; Tseng and Tomkinson, 2002; Wilson and Lieber, 1999). Pol4 has a high propensity to 
induce errors and exhibits low processivity making it suitable for filling in small gaps and 
tolerating the limited sequence homology found during NHEJ (Bebenek et al., 2005). The 
involvement of the MRX complex which functions in resection seems counterintuitive given 
the fact that nucleolytic processing of DSB ends channels the break site into recombination-
based repair pathways (reviewed in (Emerson and Bertuch, 2016)). Clb-mediated Cdc28 
activity is required to initiate resection which serves as the initiation step for homology-based 
repair pathways (Aylon et al., 2004; Ira et al., 2004). This is facilitated by a Cdc28-mediated 
phosphorylation of the nuclease Dna2 to enable long-range resection at DSBs (Chen et al., 
2011b). However, how cell-cycle mediated regulation of short-range resection is achieved is 
not fully understood. Since activity of the Clb-Cdc28 complex is low during G1 phase resection 
is inhibited thereby establishing NHEJ as the favoured repair pathway. These findings seem to 
contradict a role for the MRX complex in resection at DSB in G1 phase, yet the involvement 
of MRX during NHEJ is crucial. Rather, MRX has been suggested as a bridging factor thereby 
helping to hold the two broken DNA ends together. This seems consistent with the structure of 
the MRX complex or, more precisely, its Rad50 subunit (reviewed in (Emerson and Bertuch, 
2016)). Moreover, MRX recruitment to intrachromosomal DSBs has been proposed to act as a 
switch for repair pathway choice dependent on the cell cycle stage (reviewed in (Mathiasen and 
Lisby, 2014)). 
 
1.4.2 Homology-directed repair (HDR)  
As outlined above, ploidy and cell cycle stage regulate repair pathway choice. The latter is 
achieved by regulation of resection on a post-translational level by Cdc28-mediated 
phosphorylation of Sae2 and Dna2 in S and G2 phase. In addition, association of Cdc28 with 
the G1-specific Cln3 regulates resection factors on a transcriptional level (reviewed in 
(Mathiasen and Lisby, 2014)). 
The resection step necessary for HDR can be subdivided into two steps: a short-range 
nucleolytic processing carried out by MRX and Sae2, followed by an extensive long-range 
processing mediated by Exo1 and Dna2 (reviewed in (Mathiasen and Lisby, 2014)).  
After the initial critical resection step during homologous recombination, the newly created 
ssDNA will be bound efficiently by RPA. Coating of the ssDNA is necessary for protection 
from further nucleolytic processing and prevents the formation of secondary structures that 
could be an obstacle for the downstream events (Alani et al., 1992; Sugiyama et al., 1997). 
However, RPA has to be removed by the crucial HR mediator protein, Rad52 (Game and 
Mortimer, 1974; Sugiyama et al., 1997; Sung, 1997a), in order to allow the loading of Rad51, 
a central factor during HR (Game and Mortimer, 1974; Shinohara and Ogawa, 1998; Sugiyama 
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and Kowalczykowski, 2002; Sung, 1997a). The Rad51-loading function carried out by Rad52 
is assisted by Rad55 and Rad57 (Sung, 1997b), which are paralogs of Rad51 (Lovett, 1994). A 
direct interaction of Rad52 and Rad51 has been documented, although this has been found to 
be dispensable for Rad52`s HR mediator function (Krejci et al., 2002). Subsequently, Rad51 
binds to the ssDNA to form a stable nucleoprotein filament which is actively protected by the 
Shu complex from disassembly by the helicase and anti-recombinase Srs2 (Bernstein et al., 
2011; Godin et al., 2013). The Rad51-containing nucleoprotein filament then scans the genome 
searching for an intact homologous sequence that can be used for repair. The movement of the 
broken ends caused by a DSB searching for a homologous repair template has been tracked in 
live cells (reviewed in (Mine-Hattab and Rothstein, 2013)) and seems dependent on DDC 
factors as well as proteins involved in HR (Dion et al., 2012). Once a homologous stretch has 
been found, Rad51 catalyses the displacement of one strand of the intact homologous duplex to 
create a displacement loop (D-loop) which allows the invasion of the ssDNA portion of the 
broken end (reviewed in (Symington et al., 2014)). After invasion, the structure is stabilized by 
Rad52-mediated base-pairing with one strand of the intact homologous duplex (Mortensen et 
al., 1996) and by RPA coating the displaced strand of the intact duplex (Eggler et al., 2002; 
Sugiyama et al., 1997). Following strand invasion, two possible mechanisms have been 
proposed. On one hand, during the pathway described as classical DSB repair (DSBR), Rad54-
mediated removal of Rad51 is necessary to make the invading strand accessible for the 
replication machinery (Li and Heyer, 2009). The DNA polymerase responsible for DNA 
synthesis in a D-loop during HR is DNA polymerase δ ((Maloisel et al., 2008), reviewed in 
(Symington et al., 2014)). Subsequently, HR intermediate structures called Holliday junctions 
Figure 4. DNA repair by non-homologous end joining (NHEJ) and homologous recombination (HR). 
The two different scenarios, DSBR and SDSA, following strand invasion during HR are also outlined
in panel A and B, respectively. DSBR: Double-strand break repair; SDSA: synthesis-dependent strand 
annealing. Figure taken from (Do et al., 2014). 
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(HJ) need to be resolved in order to allow subsequent undisturbed chromosome segregation. 
Removal of interlinked DNA molecules arising during the HR process is achieved mainly by 
two different mechanisms. First, the Sgs1-Top3-Rmi1 helicase complex together with the 
helicase Mph1 can function in HJ dissolution and secondly, nucleases including Mms4 and 
Mus81 can resolve repair intermediates that remain after helicase-mediated processing 
(reviewed in (Bizard and Hickson, 2014; Talhaoui et al., 2016)). 
In a second alternative scenario that can follow strand invasion and which has been termed 
synthesis-dependent strand annealing (SDSA), no HJ are formed since the D-loop migrates with 
DNA synthesis and therefore, no HR intermediates have to be resolved afterwards (reviewed in 
(Symington et al., 2014), see Figure 4 for an overview). 
As information encoded in the damaged DNA sequence is copied from an intact homologous 
repair template, the HR repair pathway is considered largely error-free.  
 
1.4.2.1 The role of Rad52 in budding yeast and mammalian cells 
It has been suggested that yeast Rad52 has two distinct roles at different steps during HR: it can 
act as a mediator protein to enable Rad51-mediated nucleoprotein filament formation and later 
on, assist in strand annealing after a homologous repair template has been invaded. Therefore, 
Rad52 is a core factor for seemingly all types of HR processes (reviewed in (Mortensen et al., 
2009)). Rad52 has been identified in a genetic screen for X-ray sensitive mutants and is the 
founding member of the RAD52 epistasis group including also the HR protein, Rad51, and the 
central checkpoint kinase, Rad53 (Game and Mortimer, 1974).  
In light of the high conservation amongst eukaryotes in HR, it was surprising that mammalian 
Rad52 was shown to be dispensable for resistance to genotoxins including irradiation (Rijkers 
et al., 1998). It has been proposed that human Rad52 might serve as a back-up protein since 
loss of Rad52 in cells lacking other HR factors was found to be synthetically lethal (Feng et al., 
2011; Lok et al., 2013). Human Rad52 has been implicated in facilitating strand annealing 
during HR, while the mediator function of yeast Rad52 has been attributed to human BRCA2 
(reviewed in (Liu and Heyer, 2011)). Together with BRCA1, BRCA2 has been identified as a 
hereditary breast cancer susceptibility gene and mutations in these genes predispose to a variety 
of cancers including breast but also ovarian, prostate and pancreatic cancers (reviewed in 
(Prakash et al., 2015)). 
 
1.4.2.2 Mammalian BRCA2 and its involvement in cancer treatment resistance 
BRCA1 is a central player in the mammalian HR pathway and engages in multiple protein 
complexes to fulfil numerous critical steps during the repair process. For example, BRCA1 
associates with BRCA2 and others to facilitate strand invasion (reviewed in (Lee et al., 2017)). 
This encourages the idea that human BRCA2 acts solely as a mediator and is supported by the 
fact that BRCA2 seems to lack a strand annealing function ((Jensen et al., 2010), reviewed in 
(Liu and Heyer, 2011)). In summary, cells lacking the BRCA gene products are highly impaired 
in their DNA repair proficiency thereby providing a target pathway to eradicate these cells.  
Especially platinum-based chemotherapeutics such as carboplatin have proven as valuable 
agents against BRCA- deficient cancer cells. These agents introduce DNA damage by forming 
 Introduction  
19 
 
adducts with DNA bases and causing intrastrand crosslinks (reviewed in (Siddik, 2003)). 
Additionally, treatment with inhibitors of the PARP enzymes were found to be very effective 
in these settings. PARP1 (poly-(ADP-ribose)-polymerase 1) localizes to DNA damage sites and 
adds poly-ADP-ribose (PAR) molecules to various DDR proteins, a posttranslational 
modification referred to as PARylation. Eventually, PARP1 will PARylate itself as well and 
therefore mediate its release from the damage site. There are two PARP enzymes present in 
mammalian cells which are activated by DNA damage and all inhibitors developed to date 
target both PARP1 and PARP2. Inhibitors of PARP enzymes have been tested for their efficacy 
as a single-agent therapy ((Bryant et al., 2005), reviewed in (Ohmoto and Yachida, 2017)) but 
they are also used as sensitizing agents for other cancer treatments like radiation but mostly 
with chemotherapeutics such as carboplatin (reviewed in (Drean et al., 2016)). Since loss of 
one or both BRCA genes renders cells unable to use HR-mediated repair pathways upon DNA 
damage, concomitant inhibition of PARP directs towards error-prone repair mechanisms. 
Thereby, cells are driven into cell cycle arrest or apoptosis ((Farmer et al., 2005), reviewed in 
(Ohmoto and Yachida, 2017)). However, BRCA- deficient and therefore HR- impaired cancers 
often acquire resistance to chemotherapeutic treatment (reviewed in (Lord et al., 2015)). 
Mainly, cells are BRCA-deficient due to deletions in the coding region(s) leading to the 
expression of non-functional truncation mutants of BRCA1 and/or BRCA2. Therefore, a major 
pathway towards resistance is the acquisition of secondary mutations that are able to restore 
BRCA function and thereby re-establish the HR repair pathway (Edwards et al., 2008; Sakai et 
al., 2008). Such a process causing the re-gain of BRCA protein function is exacerbated in a 
treatment scheme that favours error-prone repair pathways and is applied over a longer period 
of time thereby allowing for the selection of resistant cancer cells that are able to avoid the 
treatment.  
 
1.4.2.3 Rad52- independent repair  
As described above, BRCA deficiency in human cancers is often reverted by secondary 
mutations that lead to the expression of a mutant but at least partially functional BRCA protein. 
Furthermore, human Rad52 is not strictly required for HR. Also yeast cells lacking the central 
HR gene RAD52 have been described to utilize alternative Rad52-independent repair pathways 
instead. Especially when extensive homologous sequences flank the DSB site, for example at 
the rDNA locus, Rad52 has been shown to be dispensable for strand annealing (Ozenberger and 
Roeder, 1991). Moreover, telomerase-negative yeast survivors that use a HR-based telomere 
maintenance pathway can form in the absence of Rad52. In this case, telomerase- and HR-
deficient cells were shown to maintain their chromosome ends using palindromic sequences 
that protected from loss of essential genetic material (Maringele and Lydall, 2004). A second 
report studying telomere length maintenance in the absence of both telomerase and Rad52 
proposed an end-joining mechanisms and termed the novel pathway ILT for inherited long 
telomere (Grandin and Charbonneau, 2009). In rad52 mutants, recombination events were still 
found to occur but their outcomes were changed indicating the occurrence of an alternative HR 
pathway (Haber and Hearn, 1985). Moreover, upon UV-induced damage, rad52 mutants 
showed similar recombination products as wild type yeast cells. The same study showed a 
requirement for the MRX member Rad50 in both spontaneous and UV-induced recombination 
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and for the Rad52 paralog, Rad59, for spontaneous recombination in the absence of Rad52 
(Coic et al., 2008).  
Taken together, these results highlight the existence of Rad52-independent HR events that seem 
to be influenced by the environment of the damage site in terms of DNA sequence as well as 
the type of damage which requires recombination-mediated repair. 
 
1.4.3 Other pathways involved in DNA damage repair 
1.4.3.1 Break-induced replication (BIR) 
Break-induced replication (BIR) constitutes a sub-pathway of homologous recombination. As 
other HR-mediated repair events, BIR usually requires Rad51-mediated strand invasion to form 
a D-loop. BIR occurs after replication fork collapse or at dysfunctional telomeres (reviewed in 
(Malkova and Ira, 2013)). It is thought to take place when only one end of a DSB can 
successfully invade a duplex with homologous sequence or if there is only one free end such as 
in the case of a SSB. Subsequently, a replication fork is assembled containing similar protein 
components as canonical replication forks initiated from origins of replications. For example, 
the MCM helicase and DNA Polα-primase complex as well as DNA polymerase δ have been 
reported to be involved in BIR (Lydeard et al., 2007; Lydeard et al., 2010). In addition, the Pif1 
helicase was reported to promote DNA Pol δ-mediated replication and deal with topological 
stress during the BIR process (Wilson et al., 2013). Importantly, two different models regarding 
the BIR mechanism and progression have been proposed depending on whether the initial D-
loop resulting from strand invasion is resolved or maintained during replication (reviewed in 
(Malkova and Ira, 2013)). Although based on presumably error-free homologous 
recombination, BIR is a highly mutagenic process (Deem et al., 2011). Furthermore, BIR has 
been linked to genome rearrangements since the replication fork mediating BIR can dissociate 
and restart during the process thereby leading to template switching (Smith et al., 2007). Finally, 
BIR events can lead to translocations and cause loss of heterozygosity (reviewed in (Malkova 
and Ira, 2013)).  
 
1.4.3.2 Mismatch repair (MMR) 
Mismatch repair (MMR) contributes to DNA replication fidelity by dealing with mismatched 
bases or mispairing due to insertions or deletions up to 12 mispaired bases (reviewed in 
(Kolodner and Marsischky, 1999)). MMR proteins are also involved in other DNA repair 
pathways such as BER, DSBR and interstrand crosslink repair. A critical step during MMR is 
the discrimination between the parental DNA strand containing the correct base and the nascent 
DNA strand in which the mispairing has occurred. In prokaryotes, DNA methylation that is yet 
missing on the nascent daughter strand can serve as a discrimination signal. Contrastingly, in 
eukaryotes several replication characteristics have been proposed as such signals including 
nicks occurring during lagging strand synthesis, incorporated ribonucleotides or 
asymmetrically loaded PCNA (reviewed in (Liu et al., 2017a)). In brief, mismatches are 
recognized by the Msh2-Msh6 heterodimer and the Msh2-Msh3 heterodimer, which seem to 
have overlapping functions in the recognition process. Subsequently, the Mlh1-Pms1 
heterodimer is recruited and introduces a nick in the newly replicated daughter strand 
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containing the mismatch. The newly created nick then serve as the access point for an 
exonuclease such as Exo1. The resected strand is subsequently filled in by DNA polymerase δ 
and the remaining nick is ligated to finish the reaction (reviewed in (Reyes et al., 2015)). In 
order to allow immediate repair of mismatches, the Msh heterodimeric complexes travel along 
with the replication fork mediated by an interaction with PCNA (Clark et al., 2000).  
Loss of or mutations in MMR genes lead to a drastic increase in mutation frequency and are 
therefore associated with cancer development. In fact, especially colon cancer has been linked 
to MMR deficiencies. Furthermore, increased mutational rates leading to genome instability 
and possibly increased DNA damage loads are associated with pre-mature aging, however, the 
exact role and impact of MMR has not been fully understood yet (reviewed in (Hsieh and 
Yamane, 2008)). 
 
1.4.3.3 Nucleotide excision repair (NER) 
Nucleotide excision repair (NER) deals with bulky DNA lesions including ultraviolet (UV) 
light‐induced pyrimidine dimers but also other helix-distorting aberrations that are obstacles to 
transcription and replication. In addition, NER is implicated in the removal of lesions caused 
by oxidative stress (reviewed in (Boiteux and Jinks-Robertson, 2013)). NER comes in two 
flavours: one is transcription-coupled (TC-NER) while the other sub-pathway acts globally and 
genome-wide (GG-NER). Both sub-branches share common players involved in later repair 
steps but seem to differ in proteins responsible for damage recognition.  
GG-NER is initiated when the Rad4-Rad23-Rad33 heterotrimer (equal to XPC, HRAD23B and 
CEN2 in mammalians) recognizes a lesion (den Dulk et al., 2006; Jansen et al., 1998). The 
recognition step could be mediated by interactions of Rad4, a critical player in both NER 
pathways, with chromatin remodelling factors (Gong et al., 2006). In addition, a heterodimeric 
complex consisting of Rad7 and Rad16 (DDB1 and 2 in mammalians), both unique for GG-
NER, is recruited (Verhage et al., 1994). This complex exhibits high affinity for UV-damaged 
DNA, a Rad16-mediated histone acetylase activity and has been linked to different interacting 
partners (Guzder et al., 1997; Teng et al., 2008). One interaction involves Afb1 allowing DNA 
translocation and conformational changes. Moreover, Rad7-Rad16 can interact with an E3 
ubiquitin ligase forming a functional complex mediating the ubiquitination of Rad4 and other 
proteins in response to UV (reviewed in (Boiteux and Jinks-Robertson, 2013)). The essential 
initiation factor TFIIH, a multi-subunit complex required for RNA polymerase II-mediated 
transcription, is an important player of NER, both due to its helicase function and because of 
its interactions with other NER proteins (reviewed in (Egly and Coin, 2011)). Furthermore, also 
the ssDNA binding protein RPA is a crucial player in the NER pathway due to its ability to bind 
the undamaged DNA strand (de Laat et al., 1998). The aforementioned steps are often 
summarized as pre-incision complex formation and are followed by the actual incision of the 
lesion-containing DNA strand. This has been proposed to occur in a dual incision step flanking 
the lesion and is exerted by Rad2 (mammalian XPG) and Rad1-Rad10 (mammalian XPF and 
ERCC1) which are structure-specific endonucleases (Habraken et al., 1993; Tomkinson et al., 
1993). Rad1-Rad10 interacts directly with Rad14 (XPA in mammals), a zinc finger domain 
protein with high affinity to UV-damaged DNA (Guzder et al., 1993, 1996). DNA polymerase 
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δ or ε are thought to accomplish re-synthesis of the excised DNA and finally, the nick is sealed 
by Cdc9, yeast DNA ligase I, to finish NER (reviewed in (Boiteux and Jinks-Robertson, 2013)). 
In contrast to GG-NER, TC-NER is specifically activated upon RNA polymerase II stalling. 
After the initial damage recognition, TC-NER utilizes the same factors as GG-NER. Then, TC-
NER is divided into two sub-branches with one being dependent on Rad26 and the second 
dependent on the RNA polymerase II subunit, Rpd9 (reviewed in (Boiteux and Jinks-Robertson, 
2013)). Interestingly, Rad26 is phosphorylated by Mec1 upon polymerase stalling to increase 
the efficiency of TC-NER (Taschner et al., 2010). Upon transient stalling of the transcription 
machinery, Rad26 has been suggested to promote damage bypass. On the other hand, at difficult 
obstacles or upon permanent stalling of the RNA polymerase complex, Rad26 leads to 
chromatin remodelling and recruitment of additional TC-NER components. Similarly, Rpb9 
has been proposed to have comparable functions in the absence of Rad26 (reviewed in (Boiteux 
and Jinks-Robertson, 2013)). 
In human cells, defects in TC-NER lead to a neurodegenerative disease condition termed 
Cockayne syndrome and deficiencies in GG-NER proteins are causative for xeroderma 
pigmentosum which is characterized by extreme sensitivity to sunlight and cancer 
predisposition (reviewed in (Garfinkel and Bailis, 2002)).  
 
1.4.3.4 Base-excision repair (BER) 
In order to deal with lesions caused by endogenous damage such as base deaminations or 
oxidative base damage, base-excision repair (BER) utilizes the sequential activity of repair 
complexes. The basic procedure of BER is initiated by cleavage of the N-glycosidic bond and 
therefore release of the damaged base from the DNA backbone by a DNA N-glycosylases. In 
yeast, two types of DNA N-glycosylases have been identified: one functions solely as a 
glycosylase, for example Ung1, while the second type can also act as an endonuclease to 
introduce a nick. Ogg1 belongs to the latter type (Sandigursky et al., 1997) and is involved in 
the removal of 8-oxo-G, a well-studied oxidative damage lesion. In the next step, a nick is 
introduced at the newly created abasic site by an endonuclease/lyase. APN1 and APN2 encode 
the two yeast endonucleases required for nick introduction. Before gap filling can take place, 
the SSB ends have to be processed by different enzymes including Rad27 and Tpp1 in order to 
produce a 3`hydroxyl group or 5`phosphate. Finally, DNA polymerase ε fills in the gap that is 
sealed in a last step by Cdc9, DNA ligase I (reviewed in (Boiteux and Jinks-Robertson, 2013)).  
Interestingly, PARP1 has often been implicated in mammalian BER due to its ability to bind a 
SSB and the observation that cells lacking PARP1 could not complete BER in in vitro assays. 
However, instead of being a member of the canonical BER pathway, PARP1 has been suggested 
to play a more general role in response to SSB promoting their repair (Strom et al., 2011). 
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1.5 Termination of the checkpoint: recovery and adaptation 
After DNA damage has been encountered, a cell cycle arrest is elicited in order to allow time 
for repair. To do so, a plethora of repair pathways has evolved to deal with the different kinds 
of lesions introduced by endogenous or exogenous damages.  
If repair succeeds, the DDC has to be shut off for the cell to resume the cell cycle and continue 
proliferation. This process is referred to as checkpoint recovery.  
Conceptually different from the recovery process is checkpoint adaptation. The term describes 
checkpoint termination followed by cell cycle progression despite the continuous presence of 
damage. This scenario can occur in a repair-defective or -impaired setting and has been 
described in many organisms.  
 
1.5.1 Checkpoint recovery 
The necessity to terminate the DDC and to abrogate the associated cell cycle arrest has obvious 
physiological relevance for a cell. Only after the DDC has been inactivated, cell cycle 
progression is possible and cell growth and division can be resumed. In the following section, 
I will outline factors involved in terminating the checkpoint after successful repair of the lesion.  
In order to study effectors of DNA damage recovery, mostly the HO cut system has been used. 
In this case, the HO (homothallic switching) endonuclease has been employed which naturally 
introduces a DSB within the mating locus to facilitate mating type switching. Repair can take 
place using the silenced HML or HMR loci thereby leading to a switch from one mating type to 
the other (reviewed in (Haber, 1998)).  
In such an experimental set-up, cells lacking the helicase Srs2 were recovery-defective (Vaze 
et al., 2002). The srs2 recovery defect as evidenced by the inability to form colonies was 
restored when DDC function was abolished after successful repair using caffeine, a general 
inhibitor for PIKK kinases including Mec1 and Tel1. This suggested that Srs2 is indeed required 
for recovery and it was hypothesized that Srs2 function was required for removal of checkpoint 
proteins such as the Mec1-Ddc2 dimer or the 9-1-1 checkpoint clamp from the break site or for 
restoring normal chromatin structure thereby terminating the DDC (Vaze et al., 2002).  
Since the DDC is mainly signalling via phosphorylation events, a series of phosphatases has 
been implied in recovery that could terminate the checkpoint after repair by reverting the 
activating phosphorylation signal. Consistently, the PP2C phosphatase family member Ptc2 has 
been implicated in acting at the level of Rad53 phosphorylation (Marsolier et al., 2000). Further 
investigations confirmed that Ptc2 as well as Ptc3, another PP2C family member, bind to and 
dephosphorylate Rad53 and thereby facilitate checkpoint recovery (Leroy et al., 2003). How 
exactly the phosphatases are regulated in order to switch off the DDC at the appropriate time 
or if an equilibrium of Rad53 phosphorylation and dephosphorlyation is shifted by Ptc2/Ptc3 
activity remains elusive.  
Another candidate for DDC inactivation is Pph3, which is part of the PP4 phosphatase complex 
(Keogh et al., 2006). Pph3 was shown to dephosphorylate histone H2A at serine 129 and 
thereby remove of one the most upstream signals for checkpoint activation. However, Pph3 
targeting of phosphorylated H2A seems to occur after its removal from the damage site (Keogh 
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et al., 2006) suggesting that the mechanism provided by Pph3 is not the initial trigger for 
checkpoint recovery. 
Since the creation of ssDNA is a very early and critical event in DDC signalling, proteins 
affecting resection could be also involved in DDC termination. Such an example is given by 
the endonuclease Sae2, which is phosphorylated in a checkpoint-dependent manner to restrict 
MRX action in a negative feed-back loop (Baroni et al., 2004; Clerici et al., 2006). 
1.5.2 Checkpoint adaptation 
The term adaptation in its basic meaning describes the adjustment to a specific environment or 
stimulus and thereby often implies a desensitization.  
In the case of DNA damage, repair can be impossible for example due to mutations in or lack 
of crucial repair factors such as RAD52 in yeast or BRCA1 in human cells. Furthermore, also 
the location of the damage within a heterochromatic region can influence repair (reviewed in 
(Feng et al., 2016)). In such a scenario, cells can adapt to prolonged checkpoint activation and 
cell cycle arrest without prospective repair. As for checkpoint recovery, the DDC gets 
terminated in order to allow cell cycle resumption. Adaptation has been first observed in yeast 
(Sandell and Zakian, 1993) but was also found to occur in higher eukaryotes such as Xenopus 
laevis and human cancer cells. Adaptation might present a reasonable attempt for repair in a 
different cell cycle stage. For multicellular organisms, adaptation might also provide a 
possibility to remove cell progeny that harbours damaged DNA via apoptosis.   
 
1.5.2.1 Major regulators 
1.5.2.1.1 Casein Kinase II (CKII) 
A genetic screen for regulators of adaptation in yeast identified CKB1 and CKB2 (Toczyski et 
al., 1997), which encode for the two non-essential regulatory subunits of casein kinase 2 (CK2) 
(Reed et al., 1994). In addition to Ckb1 and Ckb2, CK2 comprises the catalytic subunits Cka1 
and Cka2 (reviewed in (Glover et al., 1994)). CK2 plays an important role in the regulation of 
cell morphology and size in yeast and mammalian cells (reviewed in (Canton and Litchfield, 
2006)). Moreover, CK2 plays a critical role in cell cycle progression. First, it is required for 
G1/S transition and later again for the progression of G2/M (Hanna et al., 1995). Consistently, 
CK2 phosphorylates Cdc28 at an N-terminal residue (serine 46) (Russo et al., 2000) and it was 
suggested that CK2-mediated phosphorylation might attenuate Cdc28`s binding to G1 cyclins 
in an unfavourable environment or until a critical cell size has been reached (Russo et al., 2001). 
However, it has been demonstrated that ATP and substrate binding by CK2 seems unaffected 
by the nutritional status (Tripodi et al., 2011). In addition to a direct modulation of Cdc28, CK2 
also phosphorylates Sic1, an inhibitor of Cdc28 in G1 (Coccetti et al., 2006). Furthermore, CK2 
has also been reported to facilitate entry into S phase at a transcriptional level (Tripodi et al., 
2013). Another layer of cell cycle regulation by CK2 is given by its activating phosphorylation 
of Cdc34 (Coccetti et al., 2008), an ubiquitin-conjugating enzyme required for the G1 to S 
transition (Willems et al., 1996). 
After the initial finding that repair-defective cells lacking CKB1 or CKB2 fail to adapt to 
damage (Toczyski et al., 1997), further analysis of the mutants revealed more insights into their 
possible role during adaptation. CK2 has been found to phosphorylate Ptc2 at a critical site 
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(T376) which facilitates Ptc2’s interaction with the Rad53 FHA1 domain (Guillemain et al., 
2007) and thereby promote checkpoint termination. However, ckb1 and ckb2 mutants showed 
a more severe adaptation defect than the Ptc phosphatase mutants indicating that CK2 has other 
functions during checkpoint adaptation (Guillemain et al., 2007), a notion supported by 
increasing numbers of CK2 targets.  
 
1.5.2.1.2 Cdc5 
Together with CK2, a second adaptation defective allele was characterized and identified as a 
variant of Cdc5 (Toczyski et al., 1997). Originally discovered in a screen for cell cycle mutants 
(Hartwell et al., 1973), Cdc5 is now known as one of the master regulators of mitosis and 
belongs to the highly conserved Polo kinase family found in all eukaryotes except plants 
(reviewed in (Archambault and Glover, 2009)).  
 
1.5.2.1.2.1 Cdc5 key functions during an unperturbed cell cycle 
Cdc5 protein levels start to accumulate during S and G2 phases and remain high until cells 
divide. Cdc5 activity, however, was reported to be highest during mitosis suggesting a 
posttranslational regulation of its kinase activity (Cheng et al., 1998; Hardy and Pautz, 1996; 
Kitada et al., 1993). Indeed, kinase activity of Cdc5 depends on phosphorylation by Cdc28 at 
multiple sites including a highly conserved threonine residue (Thr242) residing in the Cdc5 
kinase domain (Mortensen et al., 2005). Upon its activation, Cdc5 participates in every critical 
step throughout mitosis: mitotic entry, chromosome segregation, mitotic exit and cytokinesis. 
To initiate entry into mitosis, Cdc5 localizes to the bud neck and phosphorylates Swe1 (Asano 
et al., 2005), a negative regulator of the Clb2-Cdk1 interaction necessary to initiate mitosis 
(Booher et al., 1993). Importantly, Cdc5 substrate recognition via its Polo-binding domain has 
been shown to require priming phosphorylations by other kinases, including Cdc28 (Elia et al., 
2003). Cdc5 activity is also required in the nucleus to facilitate the onset of mitosis. By 
phosphorylating the Mcm2-Fkh2-Ndd1 transcription factor complex, transcription of the CLB2 
cluster is facilitated (Darieva et al., 2006). The correct attachment of sister chromatids to the 
mitotic spindle (spindle assembly checkpoint, SAC) serves as a trigger for APCCdc20 activation 
and subsequent targeting of Pds1 (securin) for proteasomal degradation (Cohen-Fix et al., 
1996). During metaphase, Cdc5 binds to chromatin and targets the cohesion subunit Scc1 
(Alexandru et al., 2001), however, this phosphorylation is counteracted by PP2ACdc55 (Yaakov 
et al., 2012) to prevent premature sister chromatid separation. After Pds1 destruction, Esp1 
(separase) can cleave the Cdc5-phosphorylated Scc1 (Ciosk et al., 1998) and simultaneously 
downregulate PP2ACdc55 to eventually allow separation of sister chromatids. Cdc5 is involved 
in two regulatory networks, termed FEAR (Cdc Fourteen early anaphase release) and MEN 
(mitotic exit network) to complete and exit mitosis. In brief, the main purpose of these two 
signalling cascades is the release of the Cdc14 phosphatase from the nucleolus into the 
cytoplasm to inactivate Cdc28 and revert Cdc28 phosphorylation events (reviewed in (Weiss, 
2012)). At anaphase onset, both Cdc28-Clb2 and Cdc5 phosphorylate the Cdc14 nucleolar 
anchoring protein, Net1, (Liang et al., 2009; Visintin et al., 2003; Yoshida and Toh-e, 2002) to 
trigger a first short wave of Cdc14 phosphatase activity during FEAR. Further on in late 
anaphase, Cdc5 acts at the spindle pole body (SPB) to trigger MEN by phosphorylating the 
Bfa1/Bub1 GTPase-activating protein (Geymonat et al., 2003; Hu et al., 2001) which leads to 
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Tem1 and subsequently Cdc15 activation to ultimately exit from mitosis (Jaspersen et al., 1998; 
Visintin and Amon, 2001). It has been demonstrated recently, that another Cdc28-mediated 
phosphorylation in the Cdc5 N-terminus is required for its functions during mitotic exit 
(Rodriguez-Rodriguez et al., 2016). Finally, Cdc5 also participates in cytokinesis by promoting 
the assembly of the contractile actin ring (Yoshida et al., 2006) and inactivating Cdc42, a 
requirement for cytokinesis (Atkins et al., 2013).  
Control over Cdc5 localization is a key factor in regulating kinase activity and specificity 
towards its targets. As outlined above, Cdc5 is localized at the SPB after S phase and is shuttled 
to the nucleus in order to promote mitotic entry. Afterwards, a re-localization form the 
nucleoplasm to the cytoplasm is required to ensure proper mitotic exit and cytokinesis 
(reviewed in (Botchkarev and Haber, 2017)).  
 
1.5.2.1.2.2 The role of Cdc5 after DNA damage and during adaptation 
When cells encounter DNA damage, for example induced by telomere dysfunction, Cdc5 is 
phosphorylated by the checkpoint proteins Mec1 and Rad53 mediated by Rad9 (Cheng et al., 
1998). At the same time, Cdc5 activity was found to be downregulated after damage (Zhang et 
al., 2009). Moreover, nuclear localization of Cdc5 is maintained upon damage to prevent the 
activation of MEN (Valerio-Santiago et al., 2013). Consistently, a recent study found Cdc5 
spatially separated from its MEN target, Bfa1, after damage (Botchkarev et al., 2017).  
The decision to undergo checkpoint adaptation appears to be tightly regulated. Especially the 
damage load has been suggested as a critical factor since cells experiencing a single DSB will 
adapt after 8 to 12 hours of checkpoint arrest, while already two DSB will lead to a permanent 
cell cycle arrest (Lee et al., 1998; Sandell and Zakian, 1993). Interestingly, also cdc13-1 cells 
grown at the non-permissive temperature will eventually undergo adaptation (Toczyski et al., 
1997) suggesting that DNA damage elicited by telomere dysfunction could be sensed or 
evaluated slightly differently. In line with this, it has been hypothesized that the amount of 
ssDNA that is generated serves as a measure for damage and determines the decision to undergo 
adaptation. Consistently, many mutants altering the initial processing of DSBs were found to 
be adaptation-defective, for example yku70 mutants exhibiting excessive amounts of ssDNA 
(Lee et al., 1998).  
Many insights into the regulation of checkpoint adaptation in yeast could be obtained by either 
overexpression of Cdc5 while cells were experiencing damage or by using a CDC5 allele 
termed cdc5-ad that was found to be specifically adaptation-defective in response to DNA 
damage (Toczyski et al., 1997). The cdc5-ad allele harbours a leucine to tryptophan substitution 
at position 251 which is located within the kinase domain but outside of the well-characterized 
T-loop required for Cdc5 activity (Toczyski et al., 1997). Consistently, the cdc5-ad mutant has 
been found to be kinase-proficient in assays using a heterologous substrate (Charles et al., 1998; 
Rawal et al., 2016). However, while high Cdc5 levels lead to the complete loss of Rad53 
phosphorylation despite of persistent damage in a manner dependent on Cdc5 kinase activity, 
overproduction of cdc5-ad fails to completely abolish Rad53 phosphorylation (Vidanes et al., 
2010). Nevertheless, cdc5-ad is not simply a defective allele of CDC5, which is an essential 
gene in budding yeast. Levels of Cdc5 (and presumably activity) are dose dependent for 
adaptation (Vidanes et al., 2010), however, cdc5-ad seems expressed and degraded during the 
cell cycle comparable to the wild type protein (Rawal et al., 2016). As mentioned before, 
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overproduction of Cdc5 affects the ability of Rad9 to promote Rad53 autophosphorylation and 
thereby interferes with checkpoint maintenance (Vidanes et al., 2010) but Cdc5 also plays a 
role at several steps upstream, such as DSB processing (Donnianni et al., 2010). In agreement 
with the idea that the decision to undergo adaptation is dependent on the amount of damage 
present in the cell and since ssDNA serves as a measure for this, CDC5 overexpression was 
shown to delay resection after a nuclease-induced DSB (Donnianni et al., 2010). Since a defect 
in overall kinase activity does not seem to account for the cdc5-ad phenotype, it has been 
hypothesized that these mutants fail to recognize a subset of targets or activate the APC to 
initiate proteasomal degradation (Cheng et al., 1998; Toczyski et al., 1997).  
Taken together, basic insights into the regulation of Cdc5-driven adaptation could be obtained 
but the specific functions hampered in the cdc5-ad allele remain elusive. 
 
Given the high conservation of both the DNA damage response and Cdc5/PLK1, it is not 
surprising that also in mammalian cells several parallel pathways have been identified that 
facilitate crosstalk between damage and PLK1. An early observation stated that PLK1 is 
inactivated by the DNA damage checkpoint (Smits et al., 2000) and subsequently degraded via 
the proteasome (Bassermann et al., 2008) and this was shown to depend on ATM and ATR (van 
Vugt et al., 2001). Key PLK1 phosphorylation events including the activating modification at 
Thr210 (corresponding to Thr242 in budding yeast) were found to be abolished upon DNA 
damage (Tsvetkov and Stern, 2005). It was shown later that loss of the activating 
phosphorylation carried out by the Aurora A kinase in association with its cofactor Bora is due 
to a CHK1-dependent inhibition of Aurora A activity (Krystyniak et al., 2006) as well as ATR-
mediated degradation of Bora (Qin et al., 2013). In summary, multiple proteins involved in 
PLK1 regulation are targeted in response to damage in order to allow cell cycle arrest and repair.  
 
1.5.2.2 Other factors involved in adaptation 
As mentioned above, ssDNA generation has been suggested as a mechanism influencing the 
decision to undergo adaptation. Therefore, loss of the Ku70/80 complex, a negative regulator 
of resection, leads to extensive ssDNA creation accompanied by an adaptation defect which can 
be restored by loss of resection factors such as MRX components (Lee et al., 1998). Moreover, 
mutations affecting subunits of the ssDNA binding protein RPA, such as rfa1-t11 or 
phosphomimetic mutations in the Rfa1 N-terminus, can re-establish adaptation in yku70 
mutants (Ghospurkar et al., 2015; Lee et al., 1998). These findings indicate that measurement 
of ssDNA levels plays an important role in the regulation of adaptation. However, the 
adaptation defect observed in cdc5-ad mutants is not abolished in a rfa1-t11 background 
suggesting that Cdc5 promotes adaptation by a mechanism different from assessment of ssDNA 
levels (Pellicioli et al., 2001). Therefore, also the nuclease Sae2 which is involved in resection 
displays both a recovery- and an adaptation defect (Clerici et al., 2006). A similar function in 
the assessment of ssDNA levels has been suggested for Tid1 (also called Rdh54), a helicase 
previously proposed to participate in HR (Lee et al., 2001b) and its homolog, the chromatin 
remodelling factor Fun30 (Eapen et al., 2012). Also the Ino80 chromatin remodeller was shown  
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to be required for adaptation, presumably because the loss of Ino80 leads to lower levels of 
phosphorylated H2A and increased incorporation of a histone variant in the vicinity of lesions 
(Papamichos-Chronakis et al., 2006).  
In addition to being recovery-defective when damage is repairable, cells lacking the helicase 
Srs2 are also unable to adapt to an irreparable lesion (Vaze et al., 2002). The same holds true 
for the phosphatases Ptc2 and Ptc3 (Leroy et al., 2003). 
In summary, factors involved in early steps of damage processing and the assessment of ssDNA 
levels as well as proteins influencing the chromatin environment have been shown to influence 
checkpoint adaptation (see Figure 5 for a summary of proteins that influence adaptation).  
Interestingly, not only nuclear factors play a role during adaptation. Also cytoplasmic processes 
such as autophagy are regulated during DNA damage. It has become clear that autophagy is 
induced in response to DNA damage leading to vacuolar degradation of Pds1 resulting in 
mislocalized Esp1 (Dotiwala et al., 2013; Eapen and Haber, 2013). Importantly, Pds1 has a dual 
function in regulating Esp1: first, Pds1 is required to shuttle Esp1 into the nucleus where its 
proteolytic activity is desired and in a second step, Pds1 destruction is necessary to liberate and 
activate Esp1 (Agarwal and Cohen-Fix, 2002). It was found that DNA damage triggers a 
specific sub-pathway of autophagy, termed genotoxin-induced targeted autophagy (GTA), and 
this response is dependent on checkpoint factors such as Mec1 and Rad53 and requires proteins 
involved in selective autophagy (Eapen et al., 2017). It has been proposed that DNA damage 
leads to a transient induction of autophagy causing Pds1 degradation and nuclear exclusion of 
Esp1in order to arrest cells prior to anaphase. However, if autophagy is hyperactivated, cell 
cycle arrest becomes permanent and cells display an adaptation defect even when the damage-
induced phosphorylation of Rad53 is lost. Adaptation can be re-established when autophagy is 
blocked, especially when affecting factors required for selective autophagy, or when Esp1 is 
artificially driven into the nucleus (Dotiwala et al., 2013; Eapen and Haber, 2013; Eapen et al., 
2017). 
Figure 5. Summary of proteins involved in checkpoint termination either during recovery or adaptation 
as mentioned in the main text. The step or process that is likely affected during checkpoint termination 
is indicated.   
 
 
 Introduction  
29 
 
1.6 When repair fails: genome instability, chromosome instability and aneuploidy 
When cells fail to repair and attempt cell division, chromosome missegregation can be the 
consequence. Losses or gains of whole chromosomes resulting in an aberrant and unbalanced 
chromosomes number is referred to as aneuploidy. However, aneuploidy cannot only affect 
whole chromosomes but it can also comprise translocations, deletions, amplifications or other 
chromosomal rearrangements, described as segmental aneuploidy (reviewed in (Geigl et al., 
2008)). It has been proposed that imbalances in chromosome segregation or genome 
maintenance factors resulting from aneuploidy as well as DNA damage created by aneuploidy 
are causative for overall genome instability which is defined as an increased mutation rate and 
considered a hallmark of cancer (reviewed in (Giam and Rancati, 2015; Hanahan and Weinberg, 
2011)). The term genome instability includes different instability phenotypes including 
chromosomal instability (CIN). CIN describes the cell-to-cell variability in chromosome gains 
or losses or parts of chromosomes (reviewed in (Geigl et al., 2008)).  
 
1.6.1 Aneuploidy-associated phenotype 
Transcriptome analysis of aneuploid yeast cells revealed that the majority (approximately 90%) 
of genes are expressed according to their copy number (Torres et al., 2007). At the proteome 
level, protein abundance was mostly positively correlated with gene and mRNA dosage 
suggesting that there is no general dosage compensation occurring in aneuploid yeast cells 
(Torres et al., 2007; Torres et al., 2016). In contrast, another study had revealed that up to 40% 
of the genes found amplified due to aneuploidy showed expression levels that were lower than 
expected from their gene dosage implying that, to a certain extent, dosage compensation takes 
place (Hose et al., 2015). However, both studies reported that proteins that are possibly 
subjected to dosage compensation are components of multi-protein complexes (Hose et al., 
2015; Torres et al., 2007; Torres et al., 2016). In order to preserve stoichiometry, 
supernumerous components of multi-protein complexes have to be degraded and thereby 
challenge the cellular protein quality control system (Oromendia et al., 2012; Torres et al., 
2007). This leads to proteotoxic stress and renders aneuploid cells sensitive to compounds that 
further impair protein degradation or protein folding (Oromendia et al., 2012; Tang et al., 2011; 
Torres et al., 2007). In line with these findings, loss of a deubiquitinating enzyme, Ubp6, 
alleviates the higher proteasomal work load observed in aneuploid yeast cells and thereby 
improves their fitness (Torres et al., 2010). Moreover, a general transcriptional pattern in 
response to aneuploidy has been identified in a number of organisms including yeast, plants, 
mice and humans (Sheltzer et al., 2012). In yeast, the aneuploidy-induced gene expression 
pattern overlaps greatly with a previously identified transcriptional profile defined as the 
general environmental stress response (ESR) (Gasch et al., 2000). In addition to impaired 
overall fitness, aneuploid yeast cells display a prominent cell cycle delay due to an inability to 
activate the Cln3-Cdc28 complex (Thorburn et al., 2013) and a more subtle delay during S and 
G2/M phases (Beach et al., 2017). Consistently, also human aneuploid cell lines display a G1 
and S phase delay (Stingele et al., 2012). The delay in later phases of the cell cycle has been 
explained by increased and persistent DNA damage both in yeast and human aneuploid cells 
(Blank et al., 2015; Passerini et al., 2016) suggesting a link between aneuploidy and checkpoint 
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adaptation. Importantly, adaptation has been shown to cause genome instability (Galgoczy and 
Toczyski, 2001) and vice versa, aneuploid cells show increased genome instability (Sheltzer et 
al., 2011). In agreement with these observations, also aneuploid human cells suffer from 
increased genome instability and show elevated levels of autophagy (Ariyoshi et al., 2016; 
Passerini et al., 2016). The involvement of autophagy as a mechanism to counteract aneuploidy 
is supported by the finding that aneuploid human cells are very sensitive to autophagy inhibitors 
(Tang et al., 2011). At the same time, aneuploid cells are hypersensitive to compounds 
increasing metabolic stress, including the starvation-mimetic drug rapamycin (Tang et al., 
2011; Torres et al., 2007). Another striking hallmark of aneuploidy is a high level of non-genetic 
heterogeneity, both in response to intracellular and extracellular stimuli ((Beach et al., 2017), 
see Figure 6 for a summary of the aneuploidy-associated phenotype).  
 
1.6.2 The relationship of aneuploidy and genome instability 
Although it has become clear that an intimate relationship between aneuploidy and genome 
instability exists, it has not been well established yet which is the cause or consequence. On one 
hand, aneuploidy can lead to genome instability phenotypes but on the other hand, pre-existing 
genome instability can facilitate aneuploidy (reviewed in (Giam and Rancati, 2015)). 
Strikingly, most solid tumours and about 50% of cancers affecting the hematopoietic system 
have been shown to be aneuploid (reviewed in (Pariente, 2012)). A recent report proposed 
aneuploidy as a cause of genomic instability in tetraploid mouse cells (Thomas et al., 2017).  
It has been noted though that aneuploidy is not equal to chromosomal instability as seen in 
individuals with Down syndrome (trisomy 21). Although these patients carry an extra copy of 
chromosome 21 in every cell rendering the cells aneuploid, there is no cell-to-cell variability in 
chromosome composition and therefore no chromosomal instability (reviewed in (Geigl et al., 
2008)). Although linked to additional phenotypes and malignancies of varying degrees, a few 
aneuploid karyotypes are viable in humans including the trisomy of chromosome 13, 18, 21 or 
the sex chromosomes or monosomy for the X chromosome (reviewed in (Hassold and Hunt, 
2001)). 
 
Figure 6. Aneuploidy-associated phenotypes identified in yeast and mammalian cells. ESR:
environmental stress response 
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1.7 TOR nutrient signalling pathway 
Cellular growth is a tightly regulated mechanism in all organisms in order to utilize nutrients 
present in the environment in the most optimal way. In yeast, a critical cell size has to be reached 
in order for the cell to commit to cell division. A central and highly conserved regulatory 
network for growth in eukaryotes is organized by the TOR kinase. TOR (target of rapamycin) 
belongs to the PI3K-related kinase family including also ATM/ATR and Mec1/Tel1.   
In yeast, TORC1 is considered as the main sensor for the availability of nitrogen including 
amino acids, while a second nutrient sensory pathway involving Protein Kinase A (PKA) is the 
major glucose sensor (reviewed in (Zaman et al., 2008)). 
 
1.7.1 TOR in yeast 
Unlike all other eukaryotes, the budding yeast genome encodes for 2 TOR kinases, TOR1 and 
TOR2. Loss of TOR1 can be tolerated, while loss or mutation of TOR2 is lethal suggesting 
partially overlapping but also unique functions of the two kinases. Indeed, Tor1 or Tor 2 can 
form the TOR complex 1 (TORC1) which also comprises the accessory proteins Kog1, Lst8 
and Tco89. On the other hand, Tor2 builds up the TOR complex 2 (TORC2) together with Lst8, 
Bit61 and the Avo proteins 1, 2 and 3. Both TORC1 and TORC2 are huge protein complexes 
of about 2 MDa and most likely exist as homodimers (reviewed in (Wullschleger et al., 2006)). 
TORC1 regulates temporal aspects of cell growth, while TORC2 is also involved in the spatial 
regulation of growth and plays a role in actin skeleton polarization (Loewith et al., 2002; 
Schmidt et al., 1996). Importantly, only TORC1 is sensitive to rapamycin (Loewith et al., 2002), 
a fungal metabolite with antibiotic and immunosuppressive activity (reviewed in (Schreiber, 
1991)). In fact, the search for the cellular targets conferring rapamycin sensitivity has led to the 
identification of the Tor proteins (reviewed in (Loewith and Hall, 2011)). To inhibit TORC1, 
rapamycin binds to an intracellular cofactor, FKBP12 (FK506-binding protein of 12 kDa) 
(Heitman et al., 1991a). FKBP12 is a highly conserved peptidyl-prolyl cis/trans isomerase 
encoded by the FPR1 gene in yeast (Heitman et al., 1991b). The rapamycin-FKBP12 complex 
binds to the FRB domain including a highly conserved serine residue (S1972 in Tor1 and S1975 
in Tor2) which is adjacent to the Tor kinase domain (Stan et al., 1994). Although the FRB 
domain is also part of Tor2 and therefore present in the TORC2 complex, rapamycin is 
specifically inhibiting TORC1 which has been explained by a masking of the respective binding 
site in Tor2 by the additional proteins present in TORC2 (Loewith et al., 2002). TORC2 has 
been mainly found at the plasma membrane (Wedaman et al., 2003), while TORC1 localizes 
constitutively to the vacuolar membrane where it is catalytically active (Binda et al., 2009; 
Urban et al., 2007). Active TORC1 promotes anabolic processes including translation initiation 
and ribosome biogenesis but counteracts catabolic processes such as autophagy and the 
expression of genes required for metabolizing less favourable carbon sources (reviewed in 
(Loewith and Hall, 2011), see Figure 7 for an overview on TOR complexes).  
Since rapamycin acts specifically on TORC1, I will further focus on this branch of the Tor 
signalling network.  
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1.7.1.1 Upstream factors regulating TORC1 activity 
TORC1 can sense nutrient availability in response to different environmental cues, including 
carbon, nitrogen, phosphate and amino acids. TORC1 seems to integrate both the abundance 
but also the quality of available nutrients, however, the exact molecular mechanisms have not 
been fully elucidated (reviewed in (Loewith and Hall, 2011)). In addition to nutrients, TORC1 
activity is also regulated by extracellular stimuli such as high temperature or redox stress (Urban 
et al., 2007). In adverse conditions or in the presence of stresses including DNA damage, 
TORC1 activity is downregulated. However, in favourable, nutrient-rich conditions, active 
TORC1 signalling promotes cell mass accumulation thereby facilitating cell division. 
Importantly, treatment with rapamycin induces the same cellular response as TORC1 inhibition 
upon starvation (Barbet et al., 1996). Nutrient-deprived cells including yeast cells enter 
stationary phase or quiescence (termed G0) characterized by a metabolically active but non-
dividing state. A screen to identify mutants unable to recover from rapamycin-induced growth 
arrest revealed the EGO (escape from rapamycin-induced growth arrest) complex as an 
upstream regulator of TORC1 (Dubouloz et al., 2005). Like TORC1 itself, the EGO complex 
consisting of Ego1, Ego3, Gtr1 and Gtr2 is localized to the cytoplasmic face of the vacuolar 
membrane (Binda et al., 2009). Gtr1 and 2 are Ras-like GTPase (Kim et al., 2008) and the 
nucleotide-binding status of Gtr1 seems determinant of TORC1 activity in response to amino 
acids, especially leucine (Binda et al., 2009) and glutamine (Crespo et al., 2002). Gtr1 GTPase 
activity seems regulated by the guanine-nucleotide exchange factor (GEF) Vam6 residing at the 
vacuolar membrane (Binda et al., 2009). However, a corresponding GTPase activating enzyme 
(GAP) remains to be identified. It is also unclear how exactly Gtr1 activity is triggered in 
response to nutrients, however, the vacuolar localization suggests that intravacuolar amino acid 
levels could be the link between TORC1 and the EGO complex. The TORC1 component Tco89 
seems to be the interaction interface coupling the two protein complexes (Binda et al., 2009). 
In addition to responding to extracellular nutrient levels, TORC1 activity is also increased in 
response to treatment with the translation inhibitor cycloheximide suggesting that TORC1 can 
Figure 7. Protein composition and cellular functions of the two TOR signalling complexes in S. 
cerevisiae and mammalian cells. Of note, only the TORC1 complex is sensitive to rapamycin. Figure
taken from (Inoki et al., 2005). 
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also sense free amino acids in the cytoplasm (Beugnet et al., 2003; Binda et al., 2009; Urban et 
al., 2007).    
 
1.7.1.2 Downstream effectors and consequences of TORC1 activity 
1.7.1.2.1 Sch9 
The kinase Sch9 is one of the best characterized downstream effectors of active TORC1. Sch9 
belongs to the AGC kinase family which also comprises the mammalian Sch9 ortholog and 
TORC1 target, S6K1 kinase. Phosphorylation of Sch9 in its C-terminus by TORC1 is required 
for Sch9 activity in order to regulate translation initiation, ribosome biogenesis and prevent 
entry into stationary phase (Urban et al., 2007). In addition to TORC1, activation of Sch9 also 
depends on multiple phosphorylations by Pkh1 and 2, the yeast homologs of mammalian PDK1 
(3-phosphoinositide-dependent kinase 1) (Roelants et al., 2004).  
 
1.7.1.2.2 PP2A 
In parallel to the Sch9 branch, TORC1 signalling involves type 2A phosphatases including 
PP2A as well as 2A-related phosphatases such as Sit4 (reviewed in (Loewith and Hall, 2011)). 
The phosphatase complex PP2A comprises one of three redundant catalytic subunits Pph21, 
Pph22 or Pph3 associated with a scaffolding protein Tpd3 and a regulatory subunit encoded 
either by CDC55 or RTS1. Likewise, the related 2A-like phosphatase contains catalytically 
active Sit4 bound by a regulatory subunit which is either Sap155, Sap190 or Sap185 (reviewed 
in (Zaman et al., 2008)). 
PP2A regulation by TORC1 involves Tap42 which binds to and inactivates the phosphatase 
complex under nutrient-rich conditions facilitated by TORC1 phosphorylation (Di Como and 
Arndt, 1996; Jiang and Broach, 1999). Upon nutrient starvation or rapamycin treatment leading 
to TORC1 inactivation, Tap42 becomes dephosphorylated causing the liberation and activation 
of PP2A (Di Como and Jiang, 2006; Jiang and Broach, 1999; Yan et al., 2006). Similar to 
TORC1, also the Tap42-PP2A complex resides at the vacuolar membrane (Yan et al., 2006). 
Taken together, these findings suggested Tap42 as a negative regulator of PP2A activity, 
however, also a phosphatase-activating role for Tap42 has been proposed (Duvel et al., 2003) 
highlighting the complexity of TORC1 downstream signalling. How exactly Tap42 is regulated 
by TORC1 is currently not fully understood, both direct and indirect mechanisms have been 
proposed. On one hand, Tap42 has been shown to be directly phosphorylated by TORC1 (Jiang 
and Broach, 1999). However, a genetic screen identified Tip41 as a Tap42-interacting protein 
and found that Tip41 can both positively and negatively regulate TORC1 signalling (Jacinto et 
al., 2001). Together with the Sch9 kinase, PP2A has been suggested as the major downstream 
effector to coordinate TORC1 signalling.  
 
1.7.1.2.3 Ribosome biogenesis and protein synthesis 
TORC1 activity is a positive regulator of ribosome biogenesis and 5`cap dependent translation 
initiation. Protein synthesis and translation initiation are influenced by TORC1 via two different 
downstream effectors, the Tap42-PP2A complex and Sch9.  
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For efficient ternary complex formation during translation, GDP-bound translation initiation 
factor eIF2 has to be exchanged with GTP-bound eIF2. However, nutrient starvation or 
rapamycin treatment lead to the phosphorylation of a conserved serine residue (serine 51 in 
yeast) in the α subunit of eIF2 which is encoded by SUI2. Phosphorylation of eIF2α hampers 
the interaction with its GEF and thereby decreases the efficiency of translation initiation and 
consequently general protein synthesis (reviewed in (Aitken and Lorsch, 2012)). GCN2 encodes 
the sole yeast eIF2α kinase and its phosphorylation at serine 577 for decreases Gcn2 kinase 
activity (reviewed in (Loewith and Hall, 2011)). In response to TORC1 inhibition, Gcn2 is 
dephosphorylated at serine 577 in a Tap42-PP2A-dependent manner (Cherkasova and 
Hinnebusch, 2003). Consequently, Gcn2 becomes activated and phosphorylates Sui2 (eIF2α) 
at serine 51 which ultimately leads to decreased 5`cap dependent translation under nutrient-
poor conditions or upon rapamycin treatment. Which kinase is responsible for Gcn2 
phosphorylation and therefore inactivation to promote protein synthesis under nutrient-rich 
conditions remains unclear, however, a role for Sch9 as a TORC1 effector has been excluded 
(reviewed in (Loewith and Hall, 2011)). In addition to its role in regulating translation initiation 
via eIF2α, TORC1 has also been implicated in phosphorylating other translation factors such 
as the eIF4G scaffolding protein thereby regulating its stability (Berset et al., 1998) or the 
eIF4E-associated protein, Eap1 (Cosentino et al., 2000).  
TORC1 is the major regulator of ribosome biogenesis and this regulation is mostly brought 
about at the transcriptional level involving the Sch9 branch of TOR signalling (Huber et al., 
2009). Ribosome biogenesis includes the transcription and maturation of rRNA, tRNA, 
ribosomal proteins and other ribosome biogenesis (RiBi) factors involving all RNA 
polymerases and is considered the rate-limiting step for cell growth. Moreover, a large fraction 
of the cell’s energy is devoted to the production of ribosomes and therefore, tight regulatory 
mechanisms of this costly process exist (reviewed in (Warner, 1999)). TORC1 inhibition 
impairs ribosome biogenesis in multiple pathways. Short-term effects of TORC1 inactivity 
affects the translation of ribosomal proteins by decreasing protein synthesis rates in general (see 
above), but in the long range, inactive TORC1 also impacts on RNA polymerase I-mediated 
transcription of rDNA by degrading the essential transcription factor Rrn3 (Claypool et al., 
2004; Reiter et al., 2011). Furthermore, the TORC1 effector kinase Sch9 phosphorylates the 
RNA polymerase III repressor protein Maf1 leading to the stimulation of RNA polymerase III-
dependent transcription of rDNA under nutrient-rich conditions (Lee et al., 2009; Upadhya et 
al., 2002; Vannini et al., 2010). In addition to influencing rDNA transcription, TORC1 also 
impinges on the transcription of ribosomal proteins and RiBi factors. For example, TORC1 
activity leads to the phosphorylation of the transcription factors Stb3, Dot6 and Tod6 via the 
Sch9 signalling branch (Liko et al., 2010; Lippman and Broach, 2009). Loss of phosphorylation 
due to TORC1 inhibition allows the recruitment of the three transcription factors to their 
respective target promoter elements and leads to the recruitment of the RPD3L histone acetylase 
complex to repress transcription of RiBi factors. Likewise, TORC1 also regulates the 
transcription of ribosomal proteins by influencing the association of the transcription factor 
Fhl1 with either Ifh1 to allow transcription or Crf1 to repress it (reviewed in (Loewith and Hall, 
2011)). An additional layer of control over ribosome biogenesis is given by post-transcriptional 
regulations via TORC1. Catalytical steps of ribosome assembly are controlled by TORC1 as 
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well as some aspects of mRNA stability and pre-mRNA splicing (reviewed in (Loewith and 
Hall, 2011)).  
 
1.7.1.2.4 Autophagy 
Autophagy is a major catabolic pathway devoted to the degradation of cytoplasmic and nuclear 
components as well as organelles within the vacuole in yeast or lysosomes in higher eukaryotes.  
Non-selective autophagy is referred to as macroautophagy, however, also selective 
microautophagy involving receptors and targeting organelles or nuclear compartments exist as 
well as non-canonical but selective autophagy pathways such as the cytosol-to-vacuole (Cvt) 
pathway (reviewed in (Reggiori and Klionsky, 2013)). Autophagy constitutes the second option 
of protein degradation in addition to the proteasome. The latter mainly deals with short-lived 
or misfolded proteins by marking them for degradation via the attachment of ubiquitin. While 
the proteasome is constitutively active, autophagy is mostly an inducible process and responds 
to starvation but also other stimuli (reviewed in (Lilienbaum, 2013)).  
In nutrient-rich conditions triggering TORC1 activity, Atg13 is hyperphosphorylated by 
TORC1 which prevents its binding to Atg1 kinase, whose catalytic activity is required for 
autophagy and depends on Atg13 (Kamada et al., 2000; Matsuura et al., 1997). When TORC1 
is inhibited by starvation or rapamycin treatment, phosphorylation of Atg13 is lost (Scott et al., 
2000) by active dephosphorylation by the PP2A phosphatase complex (Yeasmin et al., 2016). 
However, a more recent study implied that the binding of Atg1 and Atg13 is constitutive (Kraft 
et al., 2012). Atg17, Atg29 and Atg31 form a stable ternary complex that is required for the 
maximal activation of the Atg1 kinase (Kabeya et al., 2009; Kamada et al., 2000; Kawamata et 
al., 2008). These steps are required for autophagy induction and formation of the 
autophagosome, the vesicular structure that engulfs the substrate for degradation. Atg9 is a 
transmembrane protein which is strictly required for autophagosome formation (Noda et al., 
2000). Atg9 is translocated to the endoplasmic reticulum and passed on to the Golgi apparatus 
after synthesis to be sorted into vesicles (Geng et al., 2010) and it likely acts as a scaffold and 
provider of initial membrane surface required to initiate autophagosome formation (Mari et al., 
2010; Yamamoto et al., 2012). Atg12, a small, ubiquitin-like protein, is conjugated to Atg5 and 
subsequently interacts with Atg16. This complex has been proposed to act as an interaction 
platform and E3-like enzyme that facilitates the lipidation of Atg8 to form the Atg8-PE 
conjugate in an ubiquitin conjugation-like enzymatic reaction (Hanada et al., 2007; Noda et al., 
2013). The lipidated Atg8 protein marks both the growing and complete autophagosome 
membrane (reviewed in (Reggiori and Klionsky, 2013)). Conjugation of LC3 (or LC3-I), the 
mammalian homolog of Atg8, to the membrane lipid PE, which is then referred to as LC3-II, 
is a commonly used read-out for autophagy induction (reviewed in (Tanida et al., 2008)). 
Studies of Atg8 or its mammalian counterpart LC3 have provided first insights into the 
mechanism of selective autophagy.  
One pathway of selective cargo recognition and degradation by autophagy is the cytosol-to-
vacuole (Cvt) pathway. In brief, the protein machinery used for non-selective macroautophagy 
appears to be largely the same as in selective autophagy. The scaffold protein Atg11 as well as 
the cargo receptors Atg19 and Atg34 are Cvt-specific components (reviewed in (Reggiori and 
Klionsky, 2013)). The Cvt pathway is required for the delivery of several hydrolases to the 
vacuole thereby employing the core autophagy proteins. However, the Cvt pathway also 
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requires additional proteins such as Vps53 and Vps51 (for vacuolar protein sorting) which are 
involved in vesicle formation and tethering during Cvt. The four proteins Vps51, 52, 53 and 54 
assemble a complex that is referred to either as VFT after its eponym Vps Fifty Three or GARP 
for Golgi-associated retrograde protein transport (reviewed in (Lynch-Day and Klionsky, 
2010)). 
In our experiments, we employed deletions of ATG5 to abolish non-selective macroautophagy 
or VPS51 to negatively interfere with the Cvt pathway.  
 
As outlined previously, autophagy is emerging as an important player in the DNA damage 
response causing the nuclear exclusion and degradation of cell cycle regulators like Esp1 and 
Pds1. In addition, an autophagy pathway engulfing small parts of the nucleus has been identified 
first in yeast (Roberts et al., 2003) and was then found to be conserved in higher eukaryotes. 
This selective autophagy pathway has been termed piecemeal autophagy of the nucleus (PMN) 
and requires an interaction between the vacuolar membrane protein Vac8 and the nuclear 
envelop component Nvj1 in addition to core macroautophagy proteins (reviewed in (Luo et al., 
2016)). Although PMN could serve as an important interface between the nuclear and 
cytoplasmic response after several stimuli including DNA damage, its regulation and 
consequences have not been fully understood yet. 
In addition, autophagy induction has been shown to occur in response to histone deacetylases 
(HDAC) inhibitors (Shao et al., 2004). This has been attributed to an Atg19-dependent 
degradation of the resection and recombination protein Sae2, implicating the Cvt pathway in 
the DNA damage response and repair pathway (Robert et al., 2011). 
 
1.7.1.2.5 Cell cycle progression 
TORC1 signalling via Sch9 appears to be a major determinant of cell size which is mediated 
by the stimulation of ribosome biogenesis ((Jorgensen et al., 2002), reviewed in (Loewith and 
Hall, 2011)). In yeast, cell size is seen as a threshold for cell division and therefore, TORC1 
has been proposed as a coordinator of cell size and division. Indeed, treatment with high doses 
of rapamycin causing TORC1 inhibition leads to a cell cycle arrest in G1 due to insufficient 
translation of Cln3 (Barbet et al., 1996). Surprisingly, rapamycin-induced G1 arrest was found 
to be accompanied by cell size increase which has been explained by the swelling of the vacuole 
due to the induction of autophagy (Granot and Snyder, 1991; Heitman et al., 1991a). TORC1 
also promotes transition through S phase by regulating deoxyribonucleotide homeostasis, 
especially in response to DNA damage (Shen et al., 2007). Finally, TORC1 regulates transition 
through G2/M by influencing the localization of Cdc5 via Tap42-PP2A (Nakashima et al., 
2008). Mislocalized Cdc5 fails to degrade Swe1, an inhibitor of Clb2-Cdc28, and consequently 
delays entry into mitosis (reviewed in (Botchkarev and Haber, 2017)). In the presence of DNA 
damage, TORC1 inhibition by rapamycin prevents checkpoint adaptation (Klermund et al., 
2014). Although the induction of autophagy is sufficient for preventing adaptation, 
macroautophagy is not required in this process (Dotiwala et al., 2013; Klermund et al., 2014).  
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1.7.2 TOR in mammalian cells (mTOR) 
1.7.2.1 Functions and regulation of mTOR 
In contrast to yeast, mammalian cells contain only one gene encoding the TOR kinase but still 
harbour two different TOR complexes depending on the accessory proteins. The mammalian 
equivalent of the rapamycin-sensitive yeast TORC1 contains mTOR itself as well as raptor 
(yeast Kog1), mLST8 (yeast Lst8), PRAS40 and DEPTOR and is called mTORC1. The 
mammalian counterpart of yeast TORC2, termed mTORC2, is composed of mTOR, rictor 
(yeast Avo3), mLST8 and the putative homolog of yeast Avo1, hSIN1. In multicellular 
organisms, mTOR is a coordinator of development and cell growth (reviewed in (Loewith and 
Hall, 2011)). 
Like yeast TORC1, mTORC1 responds to nutrients including glucose and amino acids and 
stress stimuli such as hypoxia. Another layer of mTORC1 upstream regulators in multicellular 
organisms is given by the presence of growth-promoting factors. In brief, insulin and insulin-
like growth factors serve as activating signals for mTORC1 which in turn recruits PI3K 
(phosphoinositide 3-kinase). The PI3K pathway is triggered by many different classes of 
receptors responding to extracellular cues and has been proposed to be the most commonly 
activated signal transduction pathway in cancers (reviewed in (Liu et al., 2009)). PI3K 
phosphorylates the membrane lipid PIP2 to create PIP3 and this step is counteracted by the lipid 
phosphatase PTEN. PIP3 can recruit the kinase PDK1 and its substrate, the kinase PKB (also 
known as Akt) thereby leading to PKB activation (Alessi et al., 1997). Active PKB/Akt signals 
to mTORC1 via the negative TOR regulators, TSC1 and TSC2. The TSC heterodimer functions 
as a GAP for the small GTPase Rheb which activates mTORC1 when Rheb is bound to GTP. 
Therefore, promotion of Rheb GTPase activity by the TSC heterodimer keeps mTORC1 
inactive (reviewed in (Wullschleger et al., 2006)).  
Comparable to yeast, mTORC1 positively regulates 5`cap dependent translation via S6K1, the 
mammalian homolog of yeast Sch9 (Urban et al., 2007), and 4E-BP1, a translation repressor 
that is inactivated by mTORC1 signalling (Gingras et al., 1998). In addition, mTORC1 
promotes ribosome biogenesis via multiple pathways and represses autophagy. Like yeast 
TORC2, mTORC2 is involved in actin cytoskeleton organization (reviewed in (Wullschleger 
et al., 2006)).  
 
1.7.2.2 mTOR in disease and cancer  
Rapamycin has been first described to possess immunosuppressive functions and is therefore 
used after organ transplantations as well as in the treatment of autoimmune diseases. In addition, 
rapamycin or pharmacologically optimized derivatives thereof have been proposed in the 
treatment of cardiovascular diseases as well as metabolic disorders including diabetes 
(reviewed in (Wullschleger et al., 2006)).  
The majority of research devoted to mTOR signalling is fuelled by the observation that up to 
70% of cancers exhibit hyperactive mTORC1 (reviewed in (Xie et al., 2016)). In line with this, 
a recent report suggested that the failure of cancer cells to down-regulate mTOR activity in the 
presence of DNA damage promotes cancer cell survival. In this study, aberrantly active mTOR 
suppressed spontaneous DNA damage and replication stress by controlling the levels of CHK1 
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(Zhou et al., 2017). Consequently, inhibition of mTOR activity in cancer cells could serve as a 
potent anti-tumour strategy. Indeed, initial studies showed that rapamycin and its derivatives 
such as everolimus or sirolimus (first generation rapamycin orthologues) decrease tumour 
growth in several animal models, however, they failed to show significant effects when used as 
a single anti-tumour drug (reviewed in (Xie et al., 2016)). Rather, TORC1 inhibitors have been 
suggested as sensitizing agents to be used in combination with damage-inducing agents. The 
rationale for this was given by the finding that rapamycin was shown to suppress repair of DSBs 
in human cancer cells, both via NHEJ and HR, and in addition increase the frequency of 
chromosome breakage even in the absence of exogenous damage (Chen et al., 2011a). Recent 
reports have shown that the combination of mTOR and PARP1 inhibition is very effective in 
targeting cancer cells, especially BRCA-deficient breast cancers that are prone to acquire 
resistance resulting in relapse of the tumour. The combinational treatment with mTOR and 
PARP1 inhibitors renders cells unable to repair DNA damage due to the simultaneous inhibition 
of DSB and SSB repair (Osoegawa et al., 2017). Rapamycin treatment hampers HR by 
impairing the recruitment of RAD51 and BRCA1 (Chen et al., 2011a) but also by decreasing 
the levels of SUV39H1, a histone methyltransferase implicated in HR (Mo et al., 2016).  
 
1.7.2.3 The role of TOR signalling in longevity and ageing 
Strikingly, reduced TORC1 activity increases lifespan in all model organism tested so far. This 
can be achieved even in nutrient-rich conditions by mutations or pharmacologic inhibition of 
TORC1 signalling. In addition, also dietary restriction decreases TORC1 activity leading to 
lifespan extension (reviewed in (Evans et al., 2011)). However, the combination of dietary 
restriction and mutations in the TORC1 pathway did not lead to a synergistic effect on lifespan 
extension. Dietary restriction is known to slow down aging and delay aging-related diseases 
and it has been proposed that also mTORC1 inhibition could have these positive effects 
(reviewed in (Johnson et al., 2013)).  
In yeast, extension of chronological lifespan by rapamycin-mediated TORC1 inhibition 
requires a functional DDC. Taken together with the finding that rapamycin prevents checkpoint 
adaptation these observations suggest that decreasing TORC1 activity promotes lifespan 
extension by increasing genome stability (Klermund et al., 2014).  
 Introduction  
39 
 
1.8 Rationale and scope of the thesis 
An early link between DNA damage (in this case elicited by dysfunctional telomeres) and 
nutrient signalling was reported in 2008 (Qi et al., 2008). Further investigation in our lab has 
revealed that decreased TORC1 signalling, a highly conserved nutrient sensor, prevents 
adaptation to the DNA damage checkpoint (Klermund et al., 2014). As adaptation describes the 
termination of the DNA damage checkpoint despite unrepaired DNA damage, adaptation is 
considered as an attempt to preserve cell viability although it is associated with genome 
instability. Additional studies by many research groups have strengthened the intriguing 
connection between nutrient signalling and the damage response. For example, Cdc5, a main 
regulator of checkpoint adaptation, is mislocalized when TORC1 activity is compromised 
(Nakashima et al., 2008). Moreover, quantitative mass spectrometry has identified mTOR as a 
regulator of the DDR (Bandhakavi et al., 2010) and, vice versa, many studies, especially in 
mammalian cells, have revealed a downregulation of TOR signalling in response to DNA 
damage. Intriguingly, mTOR inhibition also involves functional p53 (Cam et al., 2014), the 
most commonly mutated tumour suppressor in human cancers (Kandoth et al., 2013). A second 
pathway to inhibit mTOR after DNA damage relies on the PKB/Akt network which itself is 
heavily involved in cancerogenesis (reviewed in (Carnero, 2010)). Deregulated energy 
metabolism is an emerging hallmark of cancers as well as genome instability. The latter is 
accompanied by chromosomal instability and aneuploidy which can themselves fuel further 
genomic instability in a vicious cycle. Furthermore, cancers often harbour mutations and 
alterations in DNA repair pathways and therefore readily undergo adaptation as the only route 
to escape permanent cell cycle arrest. This suggests adaptation as a major threat to genome 
stability and loops back to TOR signalling as a regulator of adaptation. 
 
Building on these observations, we could show previously that TOR inhibition prevents 
checkpoint adaptation in yeast (Klermund et al., 2014). However, this study used telomere 
dysfunction to elicit DNA damage. We therefore wanted to explore the role of adaptation in the 
case of irreparable damage and chose yeast strains lacking the central HR protein Rad52 as a 
model. Yeast Rad52 is the equivalent of human BRCA2, providing us with a powerful model 
system to study the interplay between adaptation in response to genotoxins and genome 
instability. An earlier study had already revealed that adaptation causes genome instability in 
yeast (Galgoczy and Toczyski, 2001) but how exactly adaptation is regulated with respect to 
external cues including the nutritional status remains poorly understood.  
We could show that adaptation in response to telomere-elicited DNA damage can be modulated 
via the Tap42-PP2A axis downstream of TORC1 signalling. Although the exact molecular 
mechanism of Cdc5 regulation in response to damage is unclear, we could show that rapamycin 
treatment appears to regulate Cdc5 protein levels. Using repair-deficient (rad52) yeast cells, we 
were able to show that the prevention of adaptation both genetically and pharmacologically 
using rapamycin sensitizes these cells to genotoxic treatment. Importantly, repair-proficient 
cells did not experience any disadvantages when adaptation was inhibited. Furthermore, if 
adaption is allowed to occur, repair-deficient rad52 mutants acquire multidrug resistance which 
could be directly translated to chemoresistance observed in BRCA-deficient human cancers. In 
addition, our analysis of rad52 cells that had adapted and acquired genotoxin resistance 
revealed that these cells had become aneuploid. Consistently, they display a variety of 
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aneuploidy-associated phenotypes including chronic DNA damage. Therefore, we could 
provide a link between adaptation, drug resistance and aneuploidy, however, the order of events 
establishing cause and consequence in this set-up is not yet fully understood. Nevertheless, the 
observation that repair-defective cells acquire an aneuploid karyotype provides useful insights 
in how to target these cells after their emergence. Notably, inhibition of TORC1 signalling 
could play two important functions: rapamycin treatment can prevent adaptation but it can also 
sensitize adapted and aneuploid repair-defective cells. 
Taken together, the results presented here provide basic insights into the involvement of nutrient 
signalling in adaptation. Moreover, we could strengthen the link between acquisition of 
genotoxin resistance and aneuploidy, which we suggest as results of adaptation.      
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2 Results  
2.1 Preventing adaptation in repair-proficient cells improves cell viability 
In order to investigate the regulatory pathways influencing checkpoint adaptation, we used the 
budding yeast Saccharomyces cerevisiae as a model organism. Occurrence of DNA damage 
leads to a highly orchestrated and conserved order of events termed the DNA damage response 
in order to arrest the cell cycle and allow appropriate damage repair. 
Yeast cells harbouring the temperature-sensitive cdc13-1 allele of the telomere binding protein 
Cdc13 activate the DNA damage response when shifted to the restrictive temperature 
accompanied by telomeric ssDNA accumulation and G2/M cell cycle arrest (Garvik et al., 1995; 
Hartwell et al., 1973; Lin and Zakian, 1996). Interestingly, after a prolonged period of telomere 
dysfunction, cdc13-1 mutants downregulate the DNA damage checkpoint as evident from the 
dephosphorylation of the checkpoint kinase Rad53 (Figure 8 A, (Klermund et al., 2014; Ratsima 
et al., 2016)). Shifting cdc13-1 cells to the restrictive temperature for a short period of time (6 
hours) did not result in loss of cell viability when cells were returned to the permissive 
temperature to restore Cdc13 protein function and hence allow cellular recovery (Figure 8 B). 
However, prolonged incubation at the restrictive temperature (24 hours) eventually caused a 
loss of viability in cdc13-1 cells (Figure 8 B, (Toczyski et al., 1997)). These findings suggest 
that downregulation of checkpoint activity in the presence of persistent DNA damage may lead 
to lethality. The yeast polo-like kinase Cdc5 has been shown to override the DDC at the level 
of Rad53 phosphorylation (Vidanes et al., 2010) and by acting on the upstream signalling 
cascade (Donnianni et al., 2010). The observation that the DDC can be “overridden” despite 
persistent DNA damage is referred to as (checkpoint) adaptation and Cdc5 has been identified 
as a main driver of adaptation (Toczyski et al., 1997). To test the idea that cdc13-1 cells undergo 
checkpoint adaptation and therefore lose viability, we made use of the checkpoint adaptation-
defective cdc5-ad allele harbouring a single point mutation (L251W). While cell cycle 
progression in unperturbed conditions is unaffected, cdc5-ad mutants are unable to undergo 
checkpoint adaptation (Toczyski et al., 1997). We found that in cdc13-1cdc5-ad double 
mutants, cell viability was preserved even after long-term incubation at the restrictive 
temperature (Figure 8 B). This is consistent with previous findings (Toczyski et al., 1997) and 
implicates checkpoint adaptation as the major cause for the loss of cell viability in cdc13-1 cells 
exposed to prolonged DNA damage.  
The onset of adaptation has been linked to the loss of Rad53 phosphorylation which correlates 
with the inactivation of Rad53 kinase activity (Pellicioli et al., 2001). Analysing the 
phosphorylation status of Rad53 in adaptation-proficient cdc13-1 cells by Western Blot 
revealed that although the checkpoint had been fully activated at the 6 h time point, it was 
downregulated after prolonged DNA damage (Figure 8 C). This was consistent with the 
expression of cell cycle markers: the G2/M cyclin Clb2 was present at the early 6 h time point 
supporting the accumulation of cells in the G2/M phase of the cell cycle due to checkpoint 
activation. Accordingly, expression of Sic1, a G1-specific CDK inhibitor, was absent at the 6 h 
time point. However, after prolonged damage at the 24 hour time point, the majority of the 
Rad53 pool was found dephosphorylated which coincided with lower levels of the G2/M 
marker Clb2. At the same time, Sic1 accumulated suggesting that at least a subpopulation of 
cdc13-1 cells had dephosphorylated and therefore inactivated Rad53 to override the DNA 
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damage checkpoint and progressed through the cell cycle. In the presence of the adaptation-
defective cdc5-ad allele, Rad53 remained phosphorylated and therefore maintained its 
checkpoint kinase activity even after a long period of DNA damaging conditions (Figure 8 C). 
Taken together, these results are consistent with previously published data using an irreparable 
DSB induced by expression of the HO endonuclease (Pellicioli et al., 2001). 
A previous report had already linked nutrient signalling via the highly conserved TORC1 
signalling pathway and cell viability after prolonged DNA damage in cdc13-1 cells (Qi et al., 
2008). We therefore set out to confirm the finding that TORC1 inhibition rescues cell viability 
in cdc13-1 cells by incubating them at the restrictive temperature in the presence of the TORC1 
inhibitor rapamycin. As shown in Figure 8 D, cdc13-1 viability was not compromised after 
short-term telomere dysfunction (6 h) when cells were returned to the permissive temperature 
to allow colony formation. However, as seen previously, only very few cdc13-1 cells were 
viable and able to proliferate after a 24 h incubation at the restrictive temperature. Importantly, 
Figure legend: see next page 
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the presence of rapamycin drastically improved cell viability in cdc13-1 cells (Figure 8 D). We 
then analysed the phosphorylation status of Rad53 by Western blot in cdc13-1 cells at the 
restrictive temperature in the presence and absence of rapamycin. In the absence of rapamycin, 
cdc13-1 cells activate the DNA damage checkpoint after 6 h at the restrictive temperature, 
however, after prolonged DNA damage, the checkpoint was turned off as evidenced by the loss 
of Rad53 phosphorylation (Figure 8 E). In contrast, the presence of rapamycin prevented 
checkpoint inactivation even after long-term DNA damage (24 h). As shown in Figure 8 C, the 
maintenance of Rad53 phosphorylation correlated well with the expression of Clb2 indicating 
that the cells remained arrested in the G2/M phase of the cell cycle and with an active 
checkpoint. This result was further confirmed by DNA content analysis using flow cytometry. 
As seen in Figure 8 F, cdc13-1 cells arrested with a 2C DNA content after 6 h incubation at the 
restrictive temperature both in the absence and presence of rapamycin. However, without 
rapamycin, cells progressed further through the cell cycle after long-term DNA damage as seen 
by the appearance of a 1C DNA peak and a large fraction with even lower DNA content (sub-
G1 DNA content) indicative of cell death. In the presence of rapamycin, cells remained arrested 
with a 2C DNA content even at the 24 h time point. Of note, the slight distortion of the 2C DNA 
content peak towards the right might be explained by the enlarged cell size due to a prolonged 
cell cycle arrest (Johnston et al., 1977). This suggests that TORC1 inhibition using rapamycin 
can improve viability in cdc13-1 mutants by preventing checkpoint adaptation thereby 
maintaining checkpoint activity and checkpoint-mediated cell cycle arrest. In agreement with 
this hypothesis and consistent with Figure 8 B and C, cdc13-1 cells harbouring the adaptation-
deficient cdc5-ad allele also remained arrested with a 2C DNA content (24 h, Figure 8 F). 
Figure 8. Checkpoint adaptation occurs after prolonged telomere dysfunction and is prevented by 
the cdc5-ad allele and rapamycin treatment. (A) cdc13-1 cells were arrested in G1 by treatment with
1 nM αFactor at 23°C for 2.5 h. Cells were then released at the restrictive temperature of 37°C and
protein samples were harvested at the indicated time points. Total protein lysates were subjected to
Western Blot analysis to detect Rad53. (B) Strains of the indicated genotypes were grown overnight in
YPD at the permissive temperature of 23°C. Cultures were then diluted and shifted to the restrictive
temperature of 37°C. At the indicated intervals, cells were spotted in serial dilutions on YPD agar plates
and incubated at the permissive temperature (23°C) to allow colony formation and the assessment of
recovery capacity. (C) Yeast strains were treated as described in (B), but at the indicated time points,
protein samples were harvested and processed for Western Blot. For Rad53 detection, samples were run
on 7.5 % polyacrylamide gels while for Clb2 and Sic1 detection, proteins were separated on gradient
4- 15 % polyacrylamide gels. Subsequently, membranes were probed with antibodies specific for
Rad53, Clb2 and Sic1 and proteins were visualized using chemiluminescence. (D) Wild type and 
cdc13- 1 cells were treated as described in (B), but the incubation at the restrictive temperature (37°C)
was performed in the presence of either 5 nM rapamycin or DMSO as a vehicle control. (E) Cells 
described in (D) were subjected to Western Blot analysis as described for (C). (F) DNA content of the 
yeast strains described in (D) was analysed by flow cytometry after staining with Sytox® Green. (G) 
cdc13-1 cells were grown overnight in SC medium lacking tryptophan (SC-Trp) at the permissive 
temperature (23°C) and subsequently diluted in SC-Trp and shifted to the restrictive temperature of
37°C for 6 h to arrest them in G2/M. Afterwards, the culture was split and treated with either 5 nM 
rapamycin or DMSO and cells were imaged at the restrictive temperature. Re-budding events were 
counted manually using Fiji Software. Numbers in brackets denote the number of re-budded cells with 
respect to the total number of cells analysed. Panels (B) and (F) have been published in (Klermund et 
al., 2014) and my master thesis (Bender, K., 2013). The observation in panel (C) has been published in 
(Klermund et al., 2014). Experiments shown in panels (D) and (E) have been performed by Julia
Klermund and have been published in (Klermund et al., 2014).  
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Interestingly, the presence of rapamycin could further reduce the small fraction of sub-G1 DNA 
content (compare cdc13-1cdc5-ad DMSO with cdc13-1cdc5-ad 5 nM Rapa at 24 h), suggesting 
that rapamycin could function in one or more additional pathway(s) to prevent checkpoint 
adaptation. 
We then tested whether the timing of checkpoint adaptation is an orchestrated event within a 
cell population or if it is an individual cellular decision. To address this question, we used live-
cell imaging to follow the fate of individual cdc13-1 cells in a population in the presence or 
absence of rapamycin over time at the restrictive temperature. Figure 8 G summarizes the 
distribution of re-budding events observed in cdc13-1 cells during the incubation at the 
restrictive temperature. In the absence of rapamycin, approximately 77% (73 out of 95) cells 
underwent a re-budding event during the time course although kept at the restrictive 
temperature, suggesting that they adapted to the persistent DNA damage and progressed further 
through the cell cycle (Figure 8 G). The majority of cells adapted in a time window of 8 to 10 
hours after the shift to the restrictive temperature. This suggests that the exact timing of 
adaptation is an individual cellular decision. However, the fact that the majority of cells adapted 
within a 3 hour time period could be an indication for the existence of a more general counting 
mechanism that regulates the onset of checkpoint adaptation. Importantly, in the presence of 
rapamycin, only approximately 4% (4 out of 110) cells re-budded while the majority remained 
arrested with a dumbbell morphology characteristic for a G2/M cell cycle arrest. This supports 
the hypothesis that rapamycin prevents checkpoint adaptation by preserving Rad53 
phosphorylation (Figure 8 E) and thereby maintaining the damage checkpoint-induced cell 
cycle arrest (Figure 8 F and G). Interestingly, the majority of cells that underwent checkpoint 
adaptation as judged by re-budding event(s) eventually underwent cell lysis (data not shown) 
which is consistent with previous analyses of temperature-sensitive cdc mutants (Hartwell et 
al., 1973).  
 
2.2 Preventing adaptation requires a functional DNA damage checkpoint  
Cdc5 can drive adaptation by overriding the Rad53-mediated DNA damage checkpoint 
(Donnianni et al., 2010; Vidanes et al., 2010). In agreement with the idea that Cdc5 requires a 
functional DNA damage checkpoint, cdc5-ad mutants are unable to prevent adaptation in a rad9 
background (lacking the Rad9 checkpoint adaptor protein) after a HO-induced DSB (Toczyski 
et al., 1997). Consistently, when we diminished Rad53 function using the rad53-11 allele, 
viability in cdc13-1 mutants conferred by the cdc5-ad allele was decreased (Figure 9 A). The 
rad53-11 allele, which is also known as mec2-1, harbours a glycine to glutamic acid point 
mutation at amino acid position 653 (Dohrmann and Sclafani, 2006) and is checkpoint-
defective (Weinert et al., 1994), probably due to decreased kinase activity both in vivo (Sun et 
al., 1996) and in vitro (Sidorova and Breeden, 2003). Interestingly, in this experiment, also 
rapamycin was unable to rescue the viability of cdc13-1cdc5-adrad53-11 triple mutants after 
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prolonged incubation at the restrictive temperature (Figure 9 A). We then repeated the 
experiment in CDC5 wild-type cells and found that rapamycin failed to promote cell viability 
in checkpoint-defective cdc13-1rad53-11 mutants (Figure 9 B). We also included mutants 
lacking MEC1 (and SML1 as the Suppressor of mec1 Lethality) in our analysis, which is the 
most upstream and initial checkpoint kinase. As seen in Figure 9 C, rapamycin failed to preserve 
cell viability in cdc13-1 mutants when the DDC cannot be activated. Taken together, these 
results suggest that preventing adaptation after prolonged telomere dysfunction in cdc13-1 cells 
either using the adaptation-defective cdc5-ad allele or by rapamycin treatment requires a 
functional DDC.  
 
2.3 The role of TORC1 effectors in preventing adaptation in cdc13-1 mutants 
Inhibition of TORC1 signalling by rapamycin mimics nutrient starvation even in standard rich 
growth conditions. Therefore, diminished TORC1 activity elicits multiple cellular responses 
including the induction of catabolic processes like autophagy. We set out to determine the role 
of autophagy in mediating the rapamycin-induced prevention of checkpoint adaptation in 
cdc13-1 cells. As shown in Figure 10 A, loss of ATG5, which is involved in autophagosome 
formation, did not abolish the rescue of cell viability upon rapamycin treatment. Also other 
branches of autophagy and protein sorting have been implied to play a role in checkpoint 
Figure 9. The cdc5-ad allele and rapamycin both require a functional DNA damage checkpoint to
prevent checkpoint adaptation in cdc13-1 mutants. (A) Yeast strains with the indicated genotypes
were grown overnight at the permissive temperature of 23°C. Subsequently, cells were diluted in the 
presence of 5 nM rapamycin or DMSO as a vehicle control and shifted to the restrictive temperature
(37°C). At the indicated time points, cells were spotted in serial dilutions on YPD agar plates and colony
formation was assessed after recovery at the permissive temperature. (B) - (C) Yeast cells of the 
indicated genotypes were treated as described in (A). Panel (B) has been published in (Klermund et al., 
2014). 
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adaptation. It was reported that yeast cells lacking VPS51, a component of the Golgi-associated 
retrograde protein (GARP) complex, are adaptation defective after a HO-cut induced DSB 
although Rad53 phosphorylation was abolished (Dotiwala et al., 2013). The GARP complex 
resides at the cytosolic face of the Golgi apparatus and functions in retrograde protein 
trafficking (Bonifacino and Hierro, 2011) and in the cytoplasm-to-vacuole targeting (Cvt) 
pathway (Reggiori et al., 2003). The adaptation defect in vps51 mutants has been shown to be 
caused by the mislocalization of Esp1 and Pds1 to the cytoplasm, thereby preventing the onset 
of mitosis (Dotiwala et al., 2013). In addition to loss of VPS51, rapamycin-mediated induction 
of autophagy was shown to be sufficient to achieve a permanent cell cycle arrest after damage 
caused by an irreparable endonuclease-induced DSB (Dotiwala et al., 2013). We therefore 
tested whether loss of VPS51 could also rescue cell viability in cdc13-1 mutants. We found that 
cdc13-1vps51 double mutants were able to form colonies after 24 h incubation at the restrictive 
temperature to a similar extent as cdc13-1 mutants incubated in the presence of rapamycin 
(Figure 10 B). A previous study had found that the adaptation defect in vps51 mutants required 
bulk autophagy mediated by Atg5 (Dotiwala et al., 2013). In order to test if this was true in the 
rescue of cdc13-1 mutants as well, we created a cdc13-1vps51atg5 triple mutant. We found that 
the vps51-mediated rescue seemed independent of bulk autophagy, since loss of ATG5 did not 
decrease cdc13-1vps51 viability (Figure 10 C). The differences observed regarding the role of 
Atg5 could be explained by the use of an irreparable single DSB system employed by Dotiwala 
and colleagues (Dotiwala et al., 2013). Of note, vps51 mutants were very sensitive to rapamycin 
treatment and therefore hampered the analysis of cell viability of the respective double or triple 
mutants in the presence of rapamycin (compare Figure 10 B-D). Since the adaptation defect in 
vps51 mutants occurred independently of Rad53 (Dotiwala et al., 2013), we tested the ability 
of VPS51 loss to exert its beneficial function in the viability rescue of cdc13-1 in a MEC1-
deficient background. We hypothesized that loss of the most upstream checkpoint kinase Mec1 
should not affect the vps51-mediated rescue. Indeed, mutant cdc13-1 cells lacking VPS51, 
MEC1 (and SML1 as the Suppressor of mec1 Lethality) were as proficient in colony formation 
as cdc13-1vps51 double mutants (Figure 10 D), indicating that the rescue effect conferred by 
loss of VPS51 is largely checkpoint independent.  
We then aimed to address if nucleus-specific autophagy (piecemeal autophagy of the nucleus, 
PMN) could play a role in the removal of adaptation-promoting factors from the nucleus. In 
fact, Cdc5 requires relocalization from the nucleoplasm to the cytoplasm to promote exit from 
mitosis (reviewed in (Botchkarev and Haber, 2017)). Therefore, we hypothesized that 
abolishment of the PMN proteins Nvj1 or Vac8 should hamper the rapamycin-mediated rescue 
of cdc13-1 mutants. As shown in Figure 10 E and F, defects in PMN did not influence viability 
after prolonged telomere dysfunction. These results suggested that rapamycin does not prevent 
adaptation by triggering the selective removal of adaptation-promoting factors from the nucleus 
via the PMN pathway. However, further experiments are required to exclude a role of PMN in 
preventing checkpoint adaptation upon telomere dysfunction. 
The heterotrimeric phosphatase PP2A constitutes another TORC1 effector and in addition, 
PP2A plays important roles during cell cycle control. Associated with its regulatory subunit 
Cdc55, PP2A is involved in retaining Cdc14 in the nucleolus thereby delaying mitotic exit 
(Queralt et al., 2006). Furthermore, Cdc55-associated PP2A regulates the correct cellular 
localization of Cdc5 (Nakashima et al., 2008). Under nutrient rich conditions, active TORC1 
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binds to the Tap42-PP2A heterodimer and thereby negatively regulates PP2A activity via 
phosphorylation of Tap42 (Di Como and Arndt, 1996; Jiang and Broach, 1999). Upon TORC1 
inhibition, for example by rapamycin treatment, the TORC1-Tap42-PP2A complex dissociates 
and PP2A causes the dephosphorylation of Tap42 leading to the full activation of PP2A (Di 
Como and Jiang, 2006; Jiang and Broach, 1999; Yan et al., 2006). A genetic screen identified 
Tip41 as a Tap42-interacting protein and therefore, also Tip41 was implicated in TORC1-
mediated control of PP2A (Jacinto et al., 2001). Although a TORC1-mediated phosphorylation 
Figure legend: see next page 
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of Tip41 resulting in a tighter association of Tip41 and Tap42 has been shown, this appears to 
have a greater impact on the PP2A-like phosphatase, Sit4 (Jacinto et al., 2001). Given the 
important role of PP2A in mitotic exit control and Cdc5 localization and knowing it as a TORC1 
downstream target, we sought to test the idea if PP2A might contribute to the rapamycin-
mediated rescue of cdc13-1 mutants. We hypothesized that rapamycin-mediated TORC1 
inhibition would cause the release and activation of PP2A eventually leading to a delayed 
mitotic exit due to nucleolar Cdc14 retention (see model Figure 10 G). To test this idea, we 
sought to interfere with PP2A function. However, simultaneous deletion of the two redundant 
catalytic PP2A subunits PPH21 and PPH22 rendered the mutants temperature sensitive and 
conferred a previously documented growth defect (Sakumoto et al., 2002), thereby hampering 
the analysis of their effect on cdc13-1 viability (data not shown). Instead, we chose to use a 
temperature-sensitive allele of Tap42 (tap42-11), which was reported to cause a proliferation 
defect due to G1 cell cycle arrest at the restrictive temperature (Cherkasova and Hinnebusch, 
2003; Di Como and Arndt, 1996). The temperature-sensitive phenotype has been attributed to 
the inability of tap42-11 to interact with phosphatases (Wang et al., 2003). We hypothesized 
that shifting cdc13-1tap42-11 double mutants to elevated temperatures should lead to PP2A 
activation and consequently, rescue of the cdc13-1-conferred viability loss upon DNA damage. 
To be able to analyse the effects of tap42-11 allele upon checkpoint-induced cell cycle arrest 
and to avoid a G1 cell cycle arrest due to interfering with Tap42 protein, cdc13-1tap42-11 
mutants were first shifted to 30°C, which is sufficient to inactivate Cdc13, and subsequently 
shifted to 37°C, the restrictive temperature for tap42-11. As shown in Figure 10 H, inactivation 
of Tap42 in cdc13-1 cells rescued cell viability after prolonged DNA damage even in the 
absence of rapamycin suggesting that the Tap42-PP2A axis might indeed have an impact on 
cell viability in the presence of DNA damage. However, we were unable to reliably determine 
the cell cycle distribution or Rad53 phosphorylation status in cdc13-1tap42-11 double mutants 
Figure 10. The influence of TORC1 downstream targets on preventing checkpoint adaptation and
preserving viability in cdc13-1 mutants after DNA damage. (A) – (F) Yeast strains with the indicated
genotypes were grown overnight at the permissive temperature (23°C). Cells were then diluted in the
presence of either 5 nM rapamycin or DMSO as the vehicle control and shifted to the restrictive 
temperature (37°C). At the indicated time points, cells were spotted in serial dilutions onto YPD agar
plates and colony formation was assessed after recovery at the permissive temperature. (G) Schematic 
model for the regulation of PP2ACdc55 activity. Active TORC1 phosphorylates Tap42 thereby promoting
its association with the PP2A complex. Upon TORC1 inhibition, Tap42 phosphorylation decreases and
releases PP2ACdc55. Once liberated, PP2ACdc55 activity causes further dephosphorylation of Tap42 and
the PP2A phosphatase complex can act on Cdc5. The role of Tip41 in regulating PP2ACdc55 is not fully 
characterized and putative connections are indicated in dark grey. (H) Yeast strains of the indicated
genotypes were grown overnight at the permissive temperature (23°C) and diluted in the presence of 5
nM rapamycin or DMSO (as control). Cultures were pre-arrested in G2/M due to checkpoint activation
at 30°C for 3 h and then shifted to 37°C to inactivate mutant Tap42 (tap42-11). Serial dilutions were 
spotted onto YPD agar plates and colony formation was documented after recovery at the permissive
temperature. (I) Yeast strains with the indicated genotypes were treated as described for panels (A) - (F). 
(J) Co-immunoprecipitation of endogenously tagged proteins was performed either from exponentially
growing cells or in the presence of 15 µg/mL nocodazole to mimic cdc13-1-mediated checkpoint arrest 
in G2/M following the temperature shift to 37°C. Cell extracts were incubated with beads coupled to
anti-GFP antibody fragments, subjected to SDS-PAGE on gradient 4-15% polyacrylamide gels and
transferred to membranes that were subsequently probed with anti-HA or anti-GFP antibodies. Proteins 
were detected by chemiluminescence. Panel (A) and (H) have been published in (Klermund et al., 2014).
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and therefore cannot rule out a DDC-independent effect of the tap42-11 mutation in preserving 
viability in cdc13-1 cells.  
In addition to using the tap42-11 allele, we analysed the effect of TIP41 deletion as a Tap42-
regulatory factor. However, cdc13-1tip41 double mutants were neither viable after prolonged 
DNA damage nor did TIP41 loss affect the rapamycin-mediated rescue of cdc13-1 cells (Figure 
10 I). This is likely to be due to Tip41 influencing mainly a different phosphatase, Sit4 or 
unknown regulatory factors influencing the Tip41-Tap42 interaction. Since interfering with 
Tap42 to manipulate PP2A activity rescued cell viability in cdc13-1 mutants and given the fact 
that PP2A is a phosphatase we wondered whether activated PP2A due to DNA damage might 
interact with Cdc5. Such an interaction could lead to Cdc5 dephosphorylation at critical 
activating phosphorylation sites and thereby cause or maintain Cdc5 inhibition. Consequently, 
the DNA damage checkpoint and cell cycle arrest would be reinforced (see model Figure 10 
G). This scenario has been reported for higher eukaryotes where DNA damage increased the 
interaction between PP2A with its regulatory subunit B55α, the mammalian orthologue of 
Cdc55, and Polo-like kinase 1 (Wang et al., 2015). In order to test this idea in our cdc13-1 
background, we created epitope-tagged proteins of Cdc5, the PP2A regulatory subunit Cdc55, 
and one of the two redundant catalytic subunits, Pph21, expressed from their endogenous 
promoters (Figure 10 J). Using these strains, we performed co-immunoprecipitations followed 
by Western Blot to reveal a possible interaction between Cdc5 and PP2A complex members. 
After arresting cells in G2/M with nocodazole to mimic a damage-induced cell cycle arrest, 
pull-down of Pph21-GFP co-purified Cdc5-HA, an effect that was slightly increased if cells 
were treated with rapamycin in addition (Figure 10 J). When the cdc13-1 allele was present and 
cells were shifted to the restrictive temperature to elicit a DNA damage response, Pph21-GFP 
and Cdc5-HA were also found to interact, however, this interaction seemed decreased in the 
presence of rapamycin (Figure 10 J). Importantly, both in the input and co-immunoprecipitation 
fraction, rapamycin treatment seemed to decrease Cdc5 protein levels. This unexpected finding, 
together with the observed interaction of Cdc5 with PP2A, implicated that rapamycin might 
prevent checkpoint adaptation in cdc13-1 cells by regulating Cdc5 protein levels or by keeping 
Cdc5 via PP2A phosphatase inactivated to ensure cell cycle arrest and maintain cell viability.  
 
2.4 Regulation of Cdc5 protein levels by rapamycin to prevent adaptation 
One possibility to explain the prevention of adaptation by rapamycin could be that rapamycin 
regulates Cdc5 levels at the protein level and therefore prevents mitotic progression. We based 
our hypothesis on the involvement of TORC1 in the regulation of cap-dependent translation 
and its role in controlling autophagy because both processes are potent regulatory pathways for 
protein abundance. In order to test our idea, we analysed Cdc5 protein levels by Western 
Blotting in the absence and presence of rapamycin. To be able to compare Cdc5 protein levels 
in cdc13-1 mutants in the presence and absence of rapamycin, we used G1-synchronized 
cultures and released them into the cell cycle at the restrictive temperature (37°C), thereby 
ensuring that all cells in the population arrested uniformly in G2/M due to DDC activation. 
After two hours, when cdc13-1 cells had arrested at the restrictive temperature, we split the 
culture and treated with rapamycin or the solvent DMSO (Figure 11 A). As seen in Figure 11 
B, Cdc5-HA levels were very low in G1-arrested cells and increased as cells arrested in G2/M. 
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This is consistent with Cdc5 protein levels peaking in mitosis before anaphase and subsequently 
declining during anaphase and telophase (Cheng et al., 1998; Hardy and Pautz, 1996). In the 
presence of DNA damage, Cdc5 protein levels were slowly reduced in control treated cells over 
time (Figure 11 B, DMSO). However, in the presence of rapamycin, there was a strong decrease 
in Cdc5 protein levels observed already one hour after treatment, an effect that was exacerbated 
during the time course (Figure 11 B, 5 nM Rapa). Of note, also total protein levels seemed to 
decrease upon rapamycin treatment as evident by the weaker signal for total protein observed 
after Ponceau S staining. This is likely to be due to the general translation inhibitory role of 
rapamycin. In summary, these observations suggest a possible regulation of Cdc5 protein levels 
mediated by rapamycin in order to maintain checkpoint activation and arrest induced by cdc13-
1 growth at the restrictive temperature.  
 
2.5 Preventing adaptation sensitizes repair-defective cells to genotoxins  
The chemotherapeutic agent camptothecin (CPT) creates DNA damage by trapping the 
topoisomerase 1 (Top1) enzyme on the DNA backbone (Hsiang et al. (1989)). Subsequently, 
the initial covalent cleavable complex can lead to DSBs after collisions between the 
transcription machinery and the Top1-DNA complex and due to the stalling of replication forks 
(Hsiang et al., 1989; Pommier et al., 2010). Rad52-mediated homologous recombination (HR) 
plays an important role in the repair of CPT-inflicted DNA damage (Pouliot et al., 2001). It is 
Figure 11. Regulation of Cdc5 protein levels by rapamycin as a possible mechanism to prevent 
checkpoint adaptation. (A) DNA content analysis of cdc13-1 cells expressing endogenously tagged
Cdc5-HA protein after αFactor (αF) arrest (1 nM) and release at the restrictive temperature. After a 2 h 
release, the culture was split and treated either with 5 nM rapamycin or DMSO as the vehicle control.
Samples for protein extracts and flow cytometry were taken at the indicated time points after splitting
the culture. (B) Total protein from samples collected in (A) were separated on gradient 4-15% 
polyacrylamide gels. After transfer, anti-HA antibody was used to detect Cdc5-HA protein and anti-
Pgk1 antibody was used as a loading control and proteins were detected using fluorescence-coupled 
secondary antibodies.  
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known that HR-deficient rad52 mutants that are unable to undergo checkpoint adaptation due 
to the presence of the adaptation-defective cdc5-ad allele are hypersensitive to X-rays 
(Galgoczy and Toczyski, 2001). We first wanted to confirm this finding by treating 
homozygous diploids that are either adaptation-proficient (CDC5) or adaptation-deficient 
(cdc5-ad) by irradiating with 45 Gy of X-rays. If not indicated otherwise, all yeast strains used 
in these experiments were homozygous diploids. To assess the effect of checkpoint adaptation 
on X-ray sensitivity, we spotted the indicated mutants in serial dilutions onto YPD agar plates 
and irradiated with 45 Gy of X-rays or left the cells untreated as a control. As shown in Figure 
12 A, repair-defective rad52 diploids are sensitive to X-ray treatment, while repair-proficient 
wild type and cdc5-ad diploids are unaffected in their growth after genotoxic treatment. 
Furthermore, rad52 diploids harbouring the cdc5-ad allele, rendering them adaptation-
deficient, are hypersensitive to X-rays as evidenced by the decreased colony formation 
compared to rad52 single mutants. YPD agar plates were supplemented with the vital dye 
Phloxine B, which accumulates in metabolically inactive or dead cells thereby causing a red 
colony colour (Minois et al., 2005). Colonies formed by repair-defective rad52 mutants as well 
as adaptation-defective rad52cdc5-ad mutants appeared in a slight pink colour especially after 
genotoxic treatment (Figure 12 A) underlining that mutants were severely affected in their 
growth and viability after experiencing irradiation. We then continued to assess the X-ray 
hypersensitivity of rad52cdc5-ad cells in a quantitative manner by plating cells and scoring for 
their ability to form colonies after X-ray irradiation (Figure 12 B). For the quantitative plating 
assay, we plated a defined number of cells on either control plates or plates that were 
subsequently subjected to genotoxic treatment. Afterwards, all colonies visible by eye were 
counted and survival relative to control cells was calculated. Consistent with Figure 12 A, 
preventing checkpoint adaptation in a rad52 diploid background significantly decreased the 
number of colonies growing after irradiation from 16.8% survival in rad52 to 2.6% survival in 
rad52cdc5-ad diploids (Figure 12 C). At the same time, repair-proficient cells remained 
unaffected in their survival after X-ray treatment independently of their ability to undergo 
checkpoint adaptation (Figure 12 C, compare wild type to cdc5-ad cells). We then continued to 
assess the effect of adaptation deficiency on cell survival in rad52 diploids in response to CPT 
treatment. In accordance with Figure 12 A, spotting cells in serial dilutions onto drug-
containing plates revealed a strong sensitivity of rad52 diploids to CPT that was further 
increased by preventing adaptation using the cdc5-ad allele (Figure 12 D). Consistently, plating 
cells onto plates containing CPT and comparing to control plates showed a significant decrease 
in cell survival of rad52cdc5-ad cells compared to adaptation-proficient rad52 cells (29.8% in 
rad52cdc5-ad vs 80.6% survival in rad52 mutants) (Figure 12 E). In agreement with our 
previous findings, adaptation deficiency in a repair-proficient background did not affect cell 
survival after CPT treatment (Figure 12 A and D). Of note, due to counting errors during cell 
number determination and technical inaccuracies while plating, cell viability (expressed as % 
survival normalized to control conditions) exceeds 100 % in some experiments. Importantly, 
rad52 diploids and, more rarely, rad52cdc5-ad diploids only formed colonies on CPT-
containing plates after 8 days, which was not due to CPT inactivation since CPT plates 
incubated for 7 days before using them were still effective in hampering the growth of rad52 
diploids (data not shown). Taken together, HR-defective rad52 diploids are able to form 
colonies after X-ray irradiation or in the presence of CPT due to undergoing checkpoint  
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Figure legend: see next page 
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adaptation. Therefore, preventing checkpoint adaptation can decrease cell survival of repair-
defective mutants following genotoxic treatment.  
As described earlier, Cdc5 promotes checkpoint adaptation by inactivating or bypassing the 
checkpoint pathway (Pellicioli et al., 2001; Toczyski et al., 1997; Vidanes et al., 2010). In order 
to strengthen the link between checkpoint adaptation and the hypersensitivity of rad52 to 
genotoxins, we investigated the role of a functional Rad53-dependent DNA damage checkpoint. 
Therefore, we introduced the checkpoint-defective rad53-11 allele and plated the cells onto 
CPT-containing plates or YPD plates that were subjected to X-ray irradiation and colonies were 
counted to assess cell survival. In cells harbouring the rad53-11 allele, the adaptation-defective 
cdc5-ad allele failed to decrease the colony number both in the presence of CPT and following 
X-ray treatment (Figure 12 F and G).  
In summary, we found that preventing checkpoint adaptation in repair-deficient cells leads to 
hypersensitivity in response to both CPT and X-ray treatment in a checkpoint-dependent 
manner. These findings are consistent with a previous report (Galgoczy and Toczyski, 2001) 
demonstrating the role of adaptation in sensitizing rad52 diploids to X-rays and underline the 
role of adaptation occurring in response to various types of damage including X-rays (Galgoczy 
and Toczyski, 2001), a single HO-mediated DSB (Sandell and Zakian, 1993) and in a cdc13-1 
model system (Klermund et al., 2014; Toczyski et al., 1997). 
 
2.6 Repair-defective cells exhibit drug resistance after genotoxic treatment 
It is possible that rad52 diploids which were able to grow after genotoxic treatment did not get 
damaged significantly and therefore were able to form colonies. Alternatively, these cells could 
have acquired resistance towards the genotoxic insult. To discriminate between these two 
possibilities, we tested if the acquisition of resistance facilitated cell growth after further 
genotoxic treatment. Therefore, we plated rad52 mutants on CPT-containing plates (as 
described for Figure 12 B) and after colonies had formed, challenged these cells again with 
CPT and other genotoxic insults. As seen in Figure 13 A, rad52 diploids experiencing CPT 
Figure 12. Preventing checkpoint adaptation using the cdc5-ad allele sensitizes repair-defective 
rad52 mutants to genotoxic agents in a checkpoint-dependent manner. (A) Diploid yeast strains of 
the indicated genotypes were spotted in serial dilutions onto YPD agar plates and either left untreated
or irradiated with a dose of 45 Gy of X-ray. Colony formation was assessed after 3 to 4 days incubation
at 30°C. Plates contained 8 µg/mL Phloxine B to visualize cellular metabolic activity. (B) Yeast cells of 
the indicated genotypes were plated onto YPD agar plates (supplemented with 8 µg/mL Phloxine B) and
either left untreated or irradiated with 45 Gy of X-rays. Plates were then incubated for the indicated
periods at 30°C and colony number was analysed by manual counting. Of note, the cell number plated
on X-ray treated plates was ten-times higher than the cell number plated on control plates. (C)
Quantification of plating assays as shown in (B). (D) Spotting assay was performed as described in (A)
but YPD agar plates contained 2 µM CPT (in DMSO) or DMSO as control. All agar plates contained 8
µg/mL Phloxine B. (E) Quantification of colony numbers after plating assays with CPT as a genotoxic
agent as described in (B). (F) – (G) Quantification of plating assays as described in (B) and (C) using
yeast strains of the indicated genotypes either in response to X-ray exposure (F) or in the presence of
CPT (G). Note the different axis scale in panel (F). Data are represented as mean values and the error
bars indicate the SEM of 3 independent experiments. Statistical analysis was performed using one-way 
ANOVA with ** as p ≤ 0.01, *** as p ≤ 0.001 and **** as p ≤ 0.0001. Experiments shown in panels
(A) – (E) have been performed by Julia Klermund and Stefanie Grimm. 
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treatment for the second time (denoted by rad52 (CPT)) had a drastic growth advantage 
compared to the parental rad52 mutants derived from a control YPD plate (denoted by rad52 
(YPD)) suggesting that they had acquired resistance to CPT. Of note, this observation was also 
true for rad52cdc5-ad diploids derived after CPT treatment. However, the frequency with 
which rad52cdc5-ad diploids were able to grow in the presence of CPT was greatly reduced 
(compare Figure 12 E). Importantly, CPT-derived rad52 diploids did not only display resistance 
to CPT but also when spotted on plates containing the radiomimetic drug bleomycin or after 
UV irradiation (Figure 13 A). This indicated that repair-defective rad52 mutants had acquired 
genotoxin resistance after CPT treatment.  
We then continued to analyse if the same observation was true for rad52 diploids forming 
colonies after X-ray irradiation. In brief, we plated rad52 mutants and subsequently subjected 
them to 45 Gy of X-ray irradiation. Subsequently, we challenged the cells that were able to 
grow after this initial irradiation again with genotoxins. In contrast to our observations using 
Figure 13. Depending on the genotoxic treatment, rad52 mutants exhibit different drug-resistance 
properties. (A) Yeast strains with the indicated genotypes were either derived from control YPD agar
plates (denoted as (YPD)) or from YPD agar plates supplemented with 2 µM CPT (denoted as (CPT))
and spotted in serial dilutions onto YPD agar plates. A second round of genotoxic treatment was 
conducted as indicated: either YPD agar plates contained DNA damaging drugs (2 µM CPT or 2.2 U/L
bleomycin) or were subjected to UV treatment (65 J/m2). Images were taken after 3 to 4 days incubation
at 30°C. (B) Analogous to the experiment described in (A), yeast strains derived from either control
YPD agar plates (denoted as (YPD)) or derived after X-ray treatment (denoted as (45 Gy)) were spotted
in serial dilutions in the presence of the indicated drugs (2.2 U/L bleomycin or 2 µM CPT) or were 
treated with 45 Gy X-ray. All YPD agar plates were supplemented with 8 µg/mL Phloxine B.
Experiment in Panel (A) has been performed by Julia Klermund. 
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CPT, only some of the rad52 mutants derived from X-ray irradiation (denoted by rad52 (45 
Gy) showed resistance to a second X-ray irradiation or bleomycin treatment (Figure 13 B). 
Moreover, when challenged with CPT as the second genotoxic agent, none of the rad52 mutants 
derived from X-ray irradiation showed increased resistance to CPT compared to the rad52 
parental strain grown on a control plate (Figure 13 B). These differences could be explained by 
the type of damage used to create resistant rad52 cells: in the case of CPT, damage is persistent 
while X-rays are a single dose-damaging agent.  
 
2.7 Resistant rad52 mutants show an altered karyotype after genotoxic treatment 
It is known that homozygous diploid rad52 cells lose chromosomes at high frequencies that can 
be further increased by X-ray irradiation (Mortimer et al., 1981). Therefore, we analysed the 
ploidy state of resistant rad52 cells generated by CPT treatment. After colonies had appeared 
on drug-containing plates, individual colonies were picked, patched onto YPD plates and then 
inoculated to subject them to DNA content analysis by flow cytometry. Strikingly, all rad52 
mutants resistant to CPT showed a nearly haploid karyotype despite the parental strain being 
diploid (Figure 14 A). This indicates that in response to CPT treatment, rad52 diploids 
experienced extensive chromosome loss. We then went on to test rad52 resistant cells derived 
from X-ray irradiation. Importantly, rad52 mutants grown after X-ray treatment displayed a 
variety of ploidy states ranging from diploid (as the parental rad52 cells) to intermediate and 
nearly haploid (Figure 14 B). The rare resistant rad52cdc5-ad cells we obtained after CPT 
treatment or X-ray irradiation showed the same karyotypes regarding their ploidy as adaptation-
proficient rad52 cells (Figure 14 C and D). To rule out that the observed extensive chromosome 
loss leading to a (near-) haploid karyotype after CPT treatment in rad52 cells was due to 
meiosis, we employed a spo11 mutant in repair-defective rad52 cells. Spo11 is a meiosis-
specific endonuclease required for meiotic DSB induction (Keeney, 2001) rendering meiosis in 
rad52spo11 diploids highly ineffective. After CPT treatment, rad52spo11 double mutants 
formed colonies as efficiently as rad52 diploids (Figure 14 E) and showed the same karyotypic 
profiles (Figure 14 F) confirming that the extensive chromosome loss in initially diploid repair-
defective cells was not due to meiosis but was rather a consequence of checkpoint adaptation.  
We then continued to analyse the chromosome loss events in resistant rad52 mutants in more 
detail by determining their karyotype using a whole genome sequencing approach (Figure 
15 A). We selected yeast cells that had been either treated with CPT or irradiated with 45 Gy 
of X-ray and cells grown under control conditions, extracted genomic DNA and performed 
whole-genome sequencing (WGS). As seen in Figure 15 A, diploid wild type cells maintained 
their karyotype even after being challenged with genotoxic treatment, a result confirmed by 
DNA content analysis using flow cytometry (Figure 15 B). Consistently with our observations 
in Figure 14 A, rad52 mutants exposed to CPT underwent excessive chromosome loss since 
they had lost one copy of each homologous chromosome except for chromosome III 
(chromosome retention displayed in red). The near-haploid karyotype of CPT-resistant rad52 
mutants revealed in our sequencing analysis was also evident with the flow cytometry assay 
(Figure 15 B). However, single chromosome losses or retentions are unlikely to be detected by  
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flow cytometry due to sensitivity limitations. After exposure to 45 Gy of X-ray we detected a 
range of ploidies in rad52 mutants, in agreement with our previous analysis (Figure 14 B). 
While one resistant rad52 mutant had lost a copy of all homologous chromosomes except for 
chromosome III and IX, a second rad52 strain kept chromosomes III, VIII, IX, XI and XIV in 
two copies but had lost one copy of every other chromosome. A third rad52 mutant had 
maintained all chromosomes in two copies except for chromosome I (chromosome loss 
displayed in green). The different degrees of chromosome loss events resulting in aneuploidy 
were reflected very well in the flow cytometry analysis (Figure 15 B). Due to the normalization 
procedure of sequencing reads, the base line for the ploidy is not the same for every individual 
sample. If cells had retained or lost chromosome can be inferred from the ploidy observed in 
our flow cytometry assay. Furthermore, we ruled out the event of chromosome gains leading to 
a 2N+1 karyotype based on our cytometry-based DNA content analysis showing only the loss 
of genetic material evident as a shift in staining intensity towards the left and based on a 
previous report documenting only chromosome loss events in rad52 mutants either 
spontaneously or exacerbated by X-ray induced DNA damage (Mortimer et al., 1981).  
Interestingly, retention of chromosome III was found in rad52 mutants after both CPT treatment 
and X-ray irradiation while the retention of chromosome IX was observed after X-ray exposure. 
Possible effects and causes for this selective retention of individual chromosomes after 
genotoxic insult are discussed below. In summary, our flow cytometry analysis together with 
the in-depth DNA sequencing approach led us to the conclusion that rad52 mutants challenged 
with genotoxic agents acquired resistance and exhibited an aneuploid karyotype through whole-
chromosome losses. 
 
2.8 Resistant and aneuploid rad52 mutants continue to lose genetic material 
We wanted to address whether the chromosome loss events observed in rad52 mutants after 
genotoxic treatment would continue when cells were passaged in unchallenging conditions. 
In order to address this question, we treated rad52 diploids with CPT to obtain resistant mutants. 
Next, we passaged the colonies formed in the presence of CPT on YPD plates in the absence of 
further DNA damaging agents in patches. With this approach, we did not streak out the cells as 
single colonies but rather analysed a bulk population. The near-haploid karyotype observed in 
rad52 mutants after CPT exposure was observed in 67% (4 out of 6) already after the first 
passage (Figure 16 A and data not shown). Two of the mutants analysed displayed a more 
diploid or intermediate karyotype after the first passage that eventually progressed to a near-
haploid DNA content over passaging time (Figure 16 A and data not shown). The DNA content 
shown in the first passage in Figure 16 A (top row of every histogram stack) was analysed by 
picking the rad52 colony directly from the plate after genotoxic treatment. The histogram  
Figure 14. Upon genotoxic stress, rad52 mutants experience extensive chromosome loss which is
not due to meiosis. (A)- (D) DNA content analysis was performed with yeast strains of the indicated
genotypes derived from either control YPD plates (denoted as (YPD)) or after genotoxic treatment
(denoted as (CPT) or (45 Gy)). (E) Quantification of plating assays. Data are represented as mean values 
and the error bars indicate the SEM of 3 independent experiments. Statistical analysis was performed
using one-way ANOVA. Ns is p = 0.3932. (F) DNA content analysis of yeast strains used in (E).
Experiments in Panel (A)-(D) have been performed by Julia Klermund and Stefanie Grimm. 
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reveals a highly unstable DNA profile with almost indistinguishable peaks reflecting severely 
damaged genetic material lacking the organization into non-replicated (2C) and replicated (4C) 
DNA content. However, already after the first round of growth on rich medium (second row of 
every histogram stack), rad52 mutants had overcome this unstable karyotype. 
We then went on to test rad52 resistant cells derived from X-ray irradiation. As shown before 
(Figure 14 A and B and Figure 15), rad52 mutants resistant to X-ray treatment displayed a 
variety of ploidy states. We found that rad52 mutants exhibiting an intermediate ploidy 
continued to lose chromosomes if further passaged. Of the six X-ray-resistant rad52 mutants 
analysed in this experiment, two mutants revealed an intermediate ploidy while the other four 
mutants still exhibited a diploid DNA content (Figure 16 and data not shown). Interestingly, 
after three passages on YPD plates the two independent rad52 mutants with an initially 
intermediate-type of ploidy eventually displayed a near-haploid karyotype (Figure 16 B and 
data not shown). This suggests that HR-defective rad52 mutants continued to lose 
chromosomes presumably to reach a more stable karyotype, i.e. either a haploid or diploid DNA 
content, to avoid the negative impact of an unbalanced karyotype.  
Our results from analysing CPT resistant rad52 cells suggested that a (near-) haploid karyotype 
might be beneficial for the growth in the presence of CPT damage. Likewise, rad52 mutants 
with an intermediate karyotype between haploid and diploid after X-ray exposure also 
continued to lose genetic material to reach a more haploid-like DNA content (Figure 16 B). To 
test the idea if a haploid karyotype could confer a growth advantage in the presence of CPT or 
after X-ray irradiation, we compared the growth of diploid and haploid repair-defective rad52 
mutants including near-haploid rad52 mutants after genotoxic treatment. Interestingly, both 
initially haploid rad52 mutants and near-haploid mutants resulting from either CPT treatment 
(Figure 16 C and D) or X-ray exposure (Figure 16 E and F) showed a growth advantage when 
challenged again with the same genotoxic agent. This suggests that a haploid DNA content 
allows repair-defective rad52 mutants to grow under DNA damaging conditions, possibly by 
enabling alternative DNA repair mechanisms like NHEJ which is suppressed in diploid yeast 
cells (reviewed in (Astrom et al., 1999)).  
 
 
 
Figure 15. Analysis of the aneuploidy observed in rad52 mutants after genotoxic treatment using
Whole Genome Sequencing (WGS). (A) Representative segmentation plots depicting chromosome
copy number variation in rad52 mutants derived from either control plates (denoted as (YPD)) or after
genotoxic treatment (denoted as (CPT) or (45 Gy)). The segmentation plot depicts the log2 ratio of 
binned reads (reads per million (RPM), y-axis) for the respective chromosome position (x-axis) 
normalized to the sample median number of reads per bin (RPM). Copy numbers above (0.6) or below
(-0.6) threshold are coloured in red for chromosome retention and in green for chromosome loss. For
more details about normalization, see Materials and Methods section 4.2.10. (B) DNA content analysis 
of the strains displayed in (A). This figure displays a subset of strains used for Figure 20. Bioinfomatical
analysis in Panel (A) has been done by Anke Busch. 
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Figure 16. Chromosome loss occurs over time in rad52 mutants after genotoxic treatment.  
(A) Yeast strains with the indicated genotypes were either plated onto YPD agar plates as controls or
plated onto YPD agar plates containing 2 µM CPT. After colonies had formed, individual clones were
picked and passaged on YPD agar plates. After every round of passage, clones were subjected to DNA
content analysis by flow cytometry. (B) Experiment was performed as described in (A) but with 45 Gy
of X-ray as the DNA damaging agent. (C) Diploid and haploid strains of the indicated genotypes were
spotted in serial dilutions on either control YPD agar plates or on YPD agar plates containing 2 µM
CPT. (D) DNA content analysis of the strains used in (C). (E) Experiment was performed analogously
to (C) but using 45 Gy of X-ray as genotoxic treatment. (F) DNA content analysis corresponding to the
yeast strains used in (E). Experiments shown in Panel (C) and (D) were performed by Julia Klermund. 
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2.9 High levels of Cdc5 do not cause aneuploidy in repair-proficient cells  
Cdc5 has been shown to act in a dose-dependent manner to drive checkpoint adaptation 
(Vidanes et al., 2010) suggesting that the levels of Cdc5 could play an important role in the 
acquisition of genotoxin resistance and aneuploidy. We hypothesized that if elevated levels of 
Cdc5 protein drove cells into aneuploidy, we could detect chromosome loss events even in a  
repair-proficient background. To test this idea, we overexpressed a Cdc5-HA fusion protein 
under a galactose-inducible promoter from a high copy plasmid (p-Gal1-Cdc5-HA, Figure 17 
A). We chose X-ray as a genotoxic treatment since repair-defective rad52 mutants displayed a 
variable response in terms of their DNA content to this treatment (Figure 14 and 15). Upon 
overexpression of Cdc5 we could not detect chromosome loss events indicating an aneuploid 
karyotype using flow cytometry-based DNA content analysis. However, due to limitations in 
flow cytometry sensitivity, we cannot exclude single chromosome loss events in this 
experimental set-up. However, our results indicated that high levels of the adaptation-
Figure 17. Role of Cdc5 protein levels and adaptation in repair-proficient cells. (A) DNA content 
analysis of diploid wild type cells transformed either with an empty vector control or a galactose-
inducible overexpression plasmid for Cdc5-HA (pGAL1-CDC5-HA). (B) Western Blot to visualize 
Cdc5-HA expression levels. Total protein lysates of the strains used in (A) were used and membranes 
were probed with anti-HA antibody to detect Cdc5-HA fusion protein or anti-actin antibody as a loading 
control. Of note, only 2/3 of the lysate volume of samples prepared from cells overexpressing Cdc5-HA 
were loaded compared to control samples. (C) Quantification of cell survival determined by plating
assays using diploid wild type and adaptation-deficient diploid cdc5-ad cells after exposure to 350 Gy
of X-rays. Data are represented as mean values and the error bars indicate the SEM of 3 independent 
experiments. Statistical analysis was performed using a two-tailed unpaired t-test summarizing groups 
either depending on the genotype or on the treatment. P-value comparing diploid wild type vs cdc5-ad / 
cdc5-ad is ns (p=0.5399), p-value comparing control vs 350 Gy treatment is *** (p ≤ 0.001). 
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promoting Cdc5 were not sufficient to drive wild-type cells into aneuploidy affecting multiple 
chromosomes after a single dose of X-ray treatment. Importantly, when we checked the 
expression levels of the Cdc5-HA fusion protein after galactose-mediated induction, we found 
drastically different protein levels (Figure 17 B) suggesting that Cdc5 might be tightly regulated 
at the protein level. However, also a highly overexpressing clone (clone #1 after 45 Gy) did not 
display an aneuploid karyotype. Of note, pro-longed overproduction of Cdc5 was very toxic 
(data not shown) which is consistent with previous results reporting aberrant cytokinesis and 
multinucleated cells after Cdc5 overexpression (Bartholomew et al., 2001; Song et al., 2000). 
As we could show, preventing checkpoint adaptation sensitizes repair-deficient cells to 
genotoxin treatment (Figure 12). We were then curious to see if inhibition of adaptation would 
also sensitize repair-proficient cells to DNA damage. In order to test this idea, we treated 
adaptation-proficient diploid wild-type cells and adaptation-deficient cdc5-ad diploids with a 
high dose of X-ray (350 Gy) that was sufficient to impair wild-type viability (decrease 
approximately 50 %). As shown in Figure 17 C, preventing adaptation in such a setting did not 
increase the sensitivity of adaptation-deficient cdc5-ad mutants to X-ray induced DNA damage 
compared to adaptation-proficient cells. In agreement with our results shown in Figure 12 C, 
this observation indicates that repair-proficient cells do not experience a growth disadvantage 
upon preventing adaptation. In contrast, repair-deficient cells (in a rad52 background) were 
sensitized to genotoxins by the inhibition of adaptation thereby presenting a way to specifically 
target them. 
 
2.10 NHEJ is not responsible for drug resistance in rad52 mutants 
The Rad52 protein possesses an annealing activity used for strand invasion during homologous 
recombination and is required for Rad51 loading onto RPA-coated ssDNA (reviewed in (Krejci 
et al., 2012)) in order to undergo homology-directed repair events. Therefore, we questioned 
how rad52 mutants could form colonies after treatment with either CPT or X-rays. An 
alternative repair pathway for DSBs is provided by non-homologous end joining (NHEJ). 
However, NHEJ is normally inhibited in diploid cells due to the repression of the NHEJ genes 
NEJ1 and LIF2 by the a1-α2 repressor encoded by the heterozygous MATa/MATα locus also 
present in our rad52 mutants (Frank-Vaillant and Marcand, 2001; Kegel et al., 2001; Valencia 
et al., 2001). To test if NHEJ was occurring and thereby allowing colony formation in rad52 
mutants in DNA damaging conditions, we used rad52 diploids lacking the crucial NHEJ factor 
DNL4 (DNA Ligase IV, (Wilson et al., 1997)). As shown in Figure 18 A and B, mutants 
defective for both Rad52-mediated HR and NHEJ (rad52dnl4 double mutants) were able to 
survive treatment with either CPT or irradiation with 45 Gy of X-rays and formed colonies. Of 
note, we found a slight but significant decrease in cell survival in rad52dnl4 double mutants 
compared to rad52 single mutants following irradiation (Figure 18 B). This indicates that re-
activation of Dnl4-dependent NHEJ in rad52 mutants most likely did not account for cell 
survival and the subsequent acquisition of genotoxic resistance accompanied by an aneuploid 
karyotype.  
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2.11 Aneuploid and resistant rad52 mutants harbour chronic DNA damage  
We hypothesized that rad52 mutants acquire resistance to genotoxins and become aneuploid as 
a consequence of Cdc5-mediated checkpoint adaptation. Therefore, adapted and resistant rad52 
mutants should still suffer from DNA damage due to their repair defect. 
To test this idea, we subjected rad52 mutants derived from either CPT or X-ray treatment to 
Western Blot and DNA content analysis after they had grown on rich medium without further 
genotoxic insults (Figure 19). All resistant rad52 mutants tested showed slight Rad53 
phosphorylation, indicating that even under unchallenged conditions the DNA damage 
checkpoint was activated. We confirmed this observation by analysing the protein levels of 
Rnr3. Rnr3 is upregulated in response to DNA damage (Huang et al., 1998) and all resistant 
rad52 mutants tested showed increased Rnr3 protein levels after growth on rich medium under 
non-damaging conditions (Figure 19 A and B). Importantly, treatment with the replication 
inhibitory drug hydroxyurea revealed that rad52 mutants were still checkpoint proficient in 
terms of Rad53 phosphorylation, Rnr3 induction (Figure 19 A and B), and cell cycle arrest in 
S phase (Figure 19 C and D). Taken together, after genotoxic insult, HR-defective rad52 
mutants proliferate although they display signs of chronic DNA damage and are checkpoint-
proficient. The finding that rad52 mutants divide and form colonies in the presence of cellular 
DNA damage even though bearing a functional DNA damage checkpoint suggests that 
checkpoint adaptation plays an important role in the acquisition of resistance to genotoxic 
treatment and the development of aneuploidy. 
 
Figure 18. The role of NHEJ in the resistance of HR-defective rad52 mutants to genotoxic 
treatment. (A) - (B) Quantification of plating assays using yeast strains with the indicated genotypes in
response to either CPT treatment (A) or after X-ray exposure (45 Gy) (B). Data are represented as mean
values and the error bars indicate the SEM of 3 independent experiments. Statistical analysis was
performed using one-way ANOVA with * as p ≤ 0.05, ** as p ≤ 0.01, *** as p ≤ 0.001 and **** as p ≤ 
0.0001.  
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2.12 Transcriptome analysis of rad52 mutants after genotoxic treatment 
 
Aneuploidy has been studied extensively in multiple organisms including budding yeast and 
higher eukaryotes such as plants, mice and humans and it has been found that all aneuploid cells 
exhibit common characteristics collectively termed the aneuploidy-associated phenotype 
(reviewed in (Tang and Amon, 2013)). These shared characteristics include altered gene 
expression profile of genes involved in metabolic processes and protein folding along with 
increased levels of proteotoxic stress. In line with this, aneuploid cells are sensitive to elevated 
temperatures and compounds interfering with protein folding as well as agents inflicting energy 
Figure 19. Resistant and aneuploid rad52 mutants harbour DNA damage and are checkpoint-
proficient. (A) Total protein lysates from the indicated strains were prepared after growth in the
presence of 250 mM hydroxyurea (HU) or under control conditions. Yeast strains were derived from
either control YPD agar plates (denoted as (YPD)) or from plates containing 2 µM CPT (denoted as
(CPT)). Total cell lysates were separated on 7.5% polyacrylamide gels and membranes were probed first
with an antibody specific for Rad53. Subsequently, the membrane was re-probed using an anti-Rnr3 
antibody and the signal was detected by chemiluminescence. (B) Experiment was performed as
described in (A) but yeast strains were derived from either control YPD agar plates or after exposure to
45 Gy of X-ray (denoted as (45 Gy)). (C) DNA content analysis of the strains used in (A). (D) DNA 
content analysis of the strains used in (B).  
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stress. In agreement with an altered and imbalanced karyotype, aneuploid cells also display 
genomic instability and increased levels of DNA damage accompanied by a high variability of 
aneuploid cells in response to various stimuli (reviewed in (Siegel and Amon, 2012)). In our 
system, creation of aneuploid cells appears to be random by increasing the frequency of 
chromosome loss in HR-defective rad52 diploid cells, as it has been reported previously 
(Mortimer et al., 1981). This is in contrast to the very controlled creation of aneuploid cells in 
most studies, especially those using yeast as a model organism. In these studies that were 
performed mostly in the Amon lab, disomic yeast strains have been employed to investigate the 
effects of aberrant chromosome numbers on gene expression and cellular physiology. In these 
instances, the aneuploid cells carried only one or few extra chromosomes, rendering them 
disomic for an individual chromosome or a small set of chromosomes (for example (Oromendia 
et al., 2012; Torres et al., 2007)). However, the degree of aneuploidy observed in these disomic 
yeast strains differs in some cases drastically from the degree of aneuploidy studied in our 
experimental set-up (Figure 14 and 15). Furthermore, in our study aneuploid cells were created 
using DNA damage as a driving force and probably simultaneously as a selection marker while 
others have created aneuploids using less invasive methods. Therefore, we set out to investigate 
the gene expression profiles in rad52 mutants after genotoxic treatment. To do so, total RNA 
was extracted from yeast strains that were subjected to DNA sequencing to assess their 
chromosome copy numbers (compare Figure 15). After depletion of ribosomal RNA, mRNA 
expression levels were analysed thereby taking into account the copy number of the respective 
chromosome harbouring the coding gene (compare Figure 15). Gene expression patterns of 
rad52 mutants that had become resistant to either CPT treatment or X-ray treatment are 
summarized in Figure 13. We first analysed rad52 mutants that had become resistant to CPT 
treatment and underwent extensive chromosome loss rendering them in a near-haploid state 
(compare Figure 14 and 15). Comparing CPT-resistant rad52 mutants to the parental (and still 
diploid) rad52 strain revealed 119 genes that were significantly expressed (Figure 20 A, column 
1). We sorted this set of genes based on their fold-change expression (log2 of their fold change, 
see legend Figure 20 A) and analysed the expression levels of the same set of 119 genes when 
comparing X-ray-resistant rad52 mutants and their parental diploid rad52 mutants (Figure 20 
A, column 2). Although there were only 4 genes whose expression changed significantly after 
gaining X-ray resistance and only 2 of them were contained in the set of genes identified in 
CPT resistant rad52 mutants, we observed a similar trend in the up- and downregulation of 
genes in response to CPT and X-ray treatment (compare color-coded differences in gene 
expression in column 1 versus 2, Figure 20 A). This indicates that genotoxic treatment of rad52 
cells leads to a fairly uniform transcriptional response. We then also compared the list of genes 
found altered in CPT-resistant rad52 mutants (119 genes shown in column 1, Figure 20 A) to 
the genes that are differentially expressed when comparing the parental and diploid rad52 strain 
(derived from control plates, denoted by (YPD)) to an untreated diploid wild type strain 
(denoted by (YPD)) (column 3, Figure 20 A). Interestingly, many of the genes significantly up-
or downregulated in CPT-resistant cells (column 1, Figure 20 A) were also significantly 
changed in their expression upon loss of RAD52 even in unchallenged conditions (column 3, 
Figure 20 A) suggesting that already loss of the RAD52 gene product, which renders the cells 
deficient for homologous recombination, causes a dramatic change in gene expression. In order  
Results 
66 
 
 
Figure legend: see next page 
 Results  
67 
 
to investigate in more detail which genes are differentially expressed when cells acquire 
resistance to CPT and to get insights into which cellular pathways might facilitate such drug 
resistance, we used the set of genes found upregulated in CPT-resistant rad52 mutants in Figure 
20 A (column 1) and performed a gene ontology (GO) term enrichment analysis (Figure 20 B). 
We summarized the top 10 enriched GO terms for biological processes into more broad 
categories, as displayed in Figure 20 B. All GO terms found enriched were associated with 
protein folding, refolding or localization to the endoplasmic reticulum, a cellular compartment 
strongly involved in protein quality control (McCaffrey and Braakman, 2016) (Figure 20 B).  
Taken together, this analysis reveals the upregulation of genes involved in protein quality 
control in aneuploid rad52 mutants after the acquisition of CPT resistance suggesting that also 
aneuploid repair-defective mutants created with our experimental set-up exhibit common 
aneuploidy-associated phenotypes.  
 
2.13 Resistance in rad52 mutants is not due to slower growth 
As outlined above, aneuploid cells display a characteristic aneuploidy-associated phenotype 
which includes slower cell cycle progression (Beach et al., 2017; Thorburn et al., 2013). 
Moreover, HR-defective rad52 mutants exhibit a delayed growth rate compared to wild type 
cells. This cell cycle delay could be beneficial in the presence of CPT which is toxic in dividing 
cells due to its mode of action and eventually allow the growth of rad52 mutants. In order to 
rule this out, we assessed the emergence of colonies in the presence of CPT at different 
temperatures. Diploid wild type, rad52 and rad52cdc5-ad cells were spotted on CPT-containing 
agar plates and colony formation was analysed after growth at low (room temperature, 23°C 
and 25°C), medium (27°C) and normal (30°C) incubation temperature. As seen in Figure 21, 
incubation at lower temperatures to slow down the vegetative growth rate did not influence 
survival in the presence of CPT. In summary with the observation that CPT is still active after 
prolonged incubation at 30°C (data not shown) this suggests that CPT resistance observed in 
rad52 mutants is not due to CPT inactivation and the slow growth phenotype associated with 
aneuploidy or the repair defect of rad52 cells.  
 
Figure 20. Transcriptional response of rad52 mutants after genotoxic treatment shows an
aneuploidy-associated gene expression pattern. (A) RNA sequencing results are summarized as a 
heatmap showing all genes (119 in total) with a significantly differential expression (based on FDR,
marked with an asterisk *) comparing rad52 mutants derived after CPT treatment and rad52 mutants 
grown on control plates (YPD) (first column). The expression patterns of the differentially expressed
genes displayed in the first column are also plotted for the comparison of rad52 mutants derived after 
X-ray treatment (denoted as (45 Gy)) versus rad52 mutants grown on control (YPD) plates (second
column) and for the comparison of rad52 mutants grown on control (YPD) plates versus wild type cells 
grown on control (YPD) plates (third column). The magnitude of expression differences (log2 fold 
change) is color-coded as displayed in the key. Differential gene expression analysis was corrected for
chromosome copy numbers. (B) Simplified GO term analysis showing the biological processes found
enriched in the list of up-regulated genes that were identified when comparing the gene expression
pattern in rad52 mutants derived after CPT treatment versus rad52 mutants grown on control (YPD)
plates. The adjusted p-value is color-coded as displayed in the key. Bioinformatical analysis has been
performed by Anke Busch. 
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2.14 Rapamycin sensitizes rad52 diploids to genotoxic treatment 
We have previously provided a link between the cellular nutritional status sensed by the TORC1 
pathway and checkpoint adaptation (Klermund et al., 2014). We then wondered if rapamycin 
could phenocopy the effect of the cdc5-ad allele in preventing checkpoint adaptation in repair-
defective rad52 diploids in the presence of CPT. In order to test this, we performed microcolony 
assays to follow cell cycle progression based on cell morphology (Figure 22 A). Unbudded or 
small budded rad52 diploids were micromanipulated onto agar plates containing either 
rapamycin, CPT or the combination of both. After 4 hours, CPT-induced cell cycle arrest in 
G2/M phase was confirmed microscopically by the presence of dumbbell-shaped cells (counted 
as 2 cell bodies, according to (Toczyski et al., 1997)). Of note, a fraction of cells arrested with 
4 cell bodies, presumably since they were progressing through S phase and therefore only 
arrested in the next round of the cell cycle. In contrast, cells incubated on rapamycin-containing 
plates progressed through the cell cycle in an unperturbed manner. After 24 hours, cell 
morphology and microcolony formation were assessed again (Figure 22 A). Cells incubated in 
the presence of CPT were counted as adapted if they had progressed past the dumbbell arrest 
point, i.e. if the microcolony contained 3, 5 or more than 5 cells. Cells that failed to arrest as 
dumbbells (for CPT) or were still unbudded (for rapamycin only plates) at the 4 hour time point 
were excluded from the analysis. As shown in Figure 22 A, more than 90% of HR-defective 
rad52 mutants had undergone adaptation and formed microcolonies in the presence of CPT. 
Rapamycin was able to decrease the occurrence of adaptation approximately two-fold. Indeed, 
50% of rad52 diploids grown in the presence of rapamycin and CPT were still arrested with a 
dumbbell morphology indicating G2/M arrest. Of note, rapamycin treatment alone decreased 
adaptation to approximately 80% (Figure 22 A). This could be due to endogenous damage 
Figure 21. Slower growth does not affect the emergence of CPT resistance in rad52 mutants.  Yeast 
strains of the indicated genotypes were spotted in serial dilutions on control YPD agar plates or plates
containing 2 µM CPT. Afterwards, plates were incubated at the indicated temperatures and pictures
were taken after the indicated times. 
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occurring in repair-defective cells and suggests an inhibitory role for rapamycin on checkpoint 
adaptation also under physiological conditions in the absence of genotoxins. 
Based on our observations indicating that rapamycin prevents checkpoint adaptation in rad52 
diploids in response to CPT treatment, we wondered if the protective effect of rapamycin 
required a functional Rad53-mediated DNA damage checkpoint. As shown in Figure 22 B, 
checkpoint-defective rad52rad53-11 cells showed decreased survival upon CPT treatment in 
the presence of rapamycin compared to rad52rad53-11 cells plated on CPT alone. Although 
Figure legend: see next page 
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rapamycin can prevent checkpoint-adaptation (Figure 22 A), this result suggests a checkpoint- 
and adaptation- independent function of rapamycin in decreasing the emergence of CPT-
resistant rad52 mutants. We then tested if the rapamycin-mediated effect was also checkpoint-
independent in response to X-ray irradiation. To address this question, we irradiated 
checkpoint-proficient rad52 diploids and checkpoint-deficient rad52rad53-11 diploids with 45 
Gy in the presence or absence of rapamycin (Figure 22 C). Rapamycin was still able to reduce 
the survival of rad52 mutants after irradiation approximately two-fold in the absence of a 
functional Rad53-mediated checkpoint, however, this decrease was not statistically significant. 
In summary, these observations are consistent with the notion that TORC1 inhibition by 
rapamycin induces autophagy (Kamada et al., 2010) and this has been suggested to maintain 
cell cycle arrest independently of Rad53 in response to DNA damage (Dotiwala et al., 2013). 
Alternatively, these results could reflect adaptation-independent consequences of rapamycin 
treatment. Since rapamycin displays a checkpoint-independent effect in preventing genotoxic 
resistance in rad52 diploids (Figure 22 B and C) but the cdc5-ad allele requires the DNA 
damage checkpoint (Figure 12 F and G), we tested if both means to prevent resistance would 
act in a synergistic manner. To address this question, we challenged adaptation-proficient rad52 
cells and adaptation-deficient rad52cdc5-ad cells with genotoxic treatment in the presence and 
absence of rapamycin (Figure 22 D and E). We found that rapamycin was able to further 
decrease survival in rad52cdc5-ad diploids compared to rad52 diploids upon treatment with 
CPT (Figure 22 D). We then went on to repeat the experiment using X-ray as a genotoxic 
treatment. As seen in Figure 22 E, rapamycin was able to further decrease the survival of 
rad52cdc5-ad mutants compared to rad52 cells. However, this decrease indicating a synergistic 
effect of rapamycin and the cdc5-ad allele in response to X-rays was not statistically significant, 
presumably since we reached the detection or sensitivity limit of our plating assay. In summary, 
our analysis of the combined effects of rapamycin and the cdc5-ad allele suggest a synergistic 
effect in decreasing the frequency of resistant and aneuploid repair-defective cells after 
genotoxic treatment.  
 
Figure 22. Rapamycin sensitizes rad52 mutants to genotoxic treatment in a manner distinct from
the cdc5-ad allele. (A) Microcolony assay to assess checkpoint adaptation to CPT-induced damage in 
rad52 diploids. Unbudded or small-budded cells were manipulated onto agar plates containing either 10
nM rapamycin (provided by a new supplier, the concentration had to be increased to observe the same
effect), 2 µM CPT or the combination of both drugs. Cell morphology and microcolony formation were
assessed after 4 and 24 hours at 30°C. For details about quantification, see section 4.2.8. The mean of 3
biological replicates is shown and error bars depict the SEM. Statistical analysis was performed using a
One-Way ANOVA with ** as p ≤ 0.01. (B) Quantification of cell survival in the presence of rapamycin
and/ or CPT. Yeast strains of the indicated genotypes were plated onto YPD agar plates containing 2 nM 
rapamycin, 2 µM CPT or the combination of rapamycin and CPT. (C) Quantification of plating assays
using strains of the indicated genotypes after growth on YPD agar plates containing 2 nM rapamycin,
after X-ray exposure (45 Gy) or exposure to X-ray in the presence of rapamycin. (D) Quantification of 
plating assays performed as described in (B) using strains of the indicated genotypes. (E) Quantification 
of cell survival using plating assays as described in (C) with yeast strains of the indicated genotypes.
Data are represented as mean values and the error bars indicate the SEM of 3 (or 4 in (C)) independent
experiments. Statistical analysis was performed using Two-way ANOVA and One-Way ANOVA with 
* as p ≤ 0.05, ** as p ≤ 0.01, *** as p ≤ 0.001.  
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3 Discussion 
 
In the work presented here, we have employed two different systems to elucidate the regulation 
and consequences of checkpoint adaptation. In the first part, we made use of the cdc13-1 system 
to elicit DNA damage arising from dysfunctional telomeres upon shifting yeast cells to the non-
permissive temperature. Importantly, when cdc13-1 mutants are shifted back to the permissive 
temperature, telomere capping is restored and cells can recover from DNA damage. In this 
experimental set-up, we were able to test the influence of different candidate mutations on the 
regulation of adaptation in repair-proficient cells. 
Using cdc13-1 mutants, we found that checkpoint adaptation in response to telomere 
dysfunction (repairable damage) can be prevented by inhibition of TORC1 signalling. In 
addition, we and others could show that an allele of Cdc5, which is specifically defective for 
adaptation, preserves cell viability upon prolonged telomere dysfunction. Moreover, our results 
not only imply an involvement of the Sch9 signalling pathway downstream of TORC1 
(Klermund et al., 2014) but also point at a regulatory role of the TORC1 effector Tap42-PP2A 
during adaptation. 
 
In the second part of the thesis, we modelled irreparable DNA damage by deleting the crucial 
HR protein Rad52. This enabled us to study the effects of adaptation with respect to genome 
stability. We employed diploid cells and therefore, NHEJ as the second major DNA repair 
pathway is suppressed leaving cells only with HR for efficient repair. We found that HR-
defective rad52 mutants treated with different genotoxins were able to form viable colonies 
after long incubation periods suggesting that cells had acquired genotoxin resistance. Indeed, 
rad52 mutants that were able to grow after the first genotoxic treatment had a growth advantage 
in a second genotoxic treatment confirming that they had become resistant. We show that 
colony formation is greatly decreased when adaptation is prevented, both genetically using the 
cdc5-ad allele and pharmacologically by treatment with the TORC1 inhibitor rapamycin. 
However, if adaptation was allowed to occur, rad52 mutants experienced chromosome loss 
leading to an aneuploid karyotype of varying degrees. Importantly, this was accompanied by a 
common aneuploidy-associated phenotype and a well-characterized aneuploidy-induced 
transcriptional profile. These results provide insights into the relationship between adaptation, 
the acquisition of genotoxin resistance and an aneuploid karyotype.  
 
3.1 Reasoning for adaptation in unicellular and multicellular organisms 
DNA damage has to be detected in a rapid and reliable manner in order to prevent the 
inheritance of damaged genetic material by daughter cells. This is achieved by the activation of 
the DNA damage checkpoint, which halts the cell cycle and provides time for damage repair. 
Therefore, the cell cycle machinery and the DNA damage response are intimately linked. On 
the other hand, permanent cell cycle arrest due to continuous signalling by the DDC prevents 
cellular proliferation. Consequently, the physiological relevance to terminate the DDC seems 
straightforward and reasonable. However, the preservation of cellular viability due to 
checkpoint termination can come at the cost of lethal genetic alterations due to checkpoint 
inactivation without successful damage repair. Therefore, the decision between adaptation (i.e. 
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checkpoint termination despite the presence of DNA damage) and loss of viability due to 
terminal checkpoint arrest has to be balanced carefully. Nevertheless, unicellular organisms like 
budding yeast have developed a mechanism allowing them to attempt cell division by 
overcoming the checkpoint arrest and this has been termed (checkpoint) adaptation. The 
unicellular model organism Saccharomyces cerevisiae has provided a useful system leading to 
the discovery, and enabling the initial characterization, of adaptation (Sandell and Zakian, 1993; 
Toczyski et al., 1997). The decision to undergo adaptation seems to be a common response to 
irreparable damage as it has been described to occur after damage arising from telomere 
dysfunction, X-ray irradiation and a nuclease-induced DSB (Galgoczy and Toczyski, 2001; 
Klermund et al., 2014; Sandell and Zakian, 1993; Toczyski et al., 1997). However, also in yeast 
cells, adaptation does not occur in all instances and the extent of DNA damage appears to play 
an important role since cells experiencing a single DSB will adapt but the introduction of two 
DSBs will arrest the cells permanently (Lee et al., 1998; Sandell and Zakian, 1993). In 
opposition to unicellular organisms, multicellular organisms including human cells seem to 
bear a higher risk associated with adaptation due to the propagation of potentially harmful 
genetic alterations that could globally affect organismal fitness. Therefore, adaptation was 
presumed to be absent in multicellular organisms. Surprisingly, adaptation has been shown to 
occur in higher eukaryotes: in Xenopus egg extracts in response to the replication stress 
inducing drug aphidicolin and in plant cells and human cancer cells in response to irradiation 
(Carballo et al., 2006; Syljuasen et al., 2006; Yoo et al., 2004). It has been proposed that 
adaptation in multicellular organisms could facilitate repair of the damage in a subsequent cell 
cycle. On the other hand, in vitro studies using cancer cells showed that most cells died in 
mitosis after undergoing adaptation, even though a small number of cells survived. Based on 
these observations, it has been proposed that cell death in G2 could be impossible or prevented 
by unknown mechanisms and therefore, cells would have to enter mitosis and die during mitotic 
catastrophe. In addition, senescence has also been postulated as a potential outcome of 
adaptation to prevent the proliferation of cells containing damaged genetic material (reviewed 
in (Roninson et al., 2001)). A third hypothesis has been put forward suggesting that cells have 
to enter the next G1 phase to undergo apoptosis or experience cell cycle arrest mediated by p53. 
Again, undergoing adaptation and entering the subsequent G1 phase could enable repair or 
facilitate cell death (reviewed in (Clemenson and Marsolier-Kergoat, 2009; Syljuasen, 2007)). 
Indeed, it had been observed that cancer cells underwent several more rounds of cell division 
after exposure to irradiation although containing damaged DNA (reviewed in (Kalsbeek and 
Golsteyn, 2017)). Importantly, this was also observed in response to treatment with 
pharmacological concentrations of CPT (Kubara et al., 2012). Also after etoposide and cisplatin 
treatment and in response to ionizing radiation, cancer cells were found to undergo adaptation 
(Swift and Golsteyn, 2016; Syljuasen et al., 2006). 
 
However, little is known about the molecular mechanisms that facilitate adaptation. Studies in 
budding yeast have led to the identification of Cdc5, the single yeast homolog of the highly 
conserved Polo kinase family, as a critical factor for adaptation (Toczyski et al., 1997). Cdc5 
plays multiple roles during an unperturbed cell cycle including the regulation of mitotic entry 
and exit and is also involved in the DNA damage response as a target of the DDC machinery. 
Despite this, the mechanisms leading to adaptation and the exact roles and targets or effectors 
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of Cdc5 remain to be identified. A critical step towards an understanding of adaptation is to 
identify how molecular targets of the DDC that are initially inactivated to achieve cell cycle 
arrest, can become re-activated to facilitate adaptation.  
It is conceivable that the nutritional environment could be a determinant in the decision to 
undergo adaptation. If the cellular environment is nutrient-poor, cells overriding the cell cycle 
arrest would have to deal with both the presence of damaged DNA and a less favourable 
environment. Both caveats could have disadvantageous outcomes regarding cell growth and 
further division thereby making adaptation a poor choice in the absence of nutrients. On the 
other hand, it is reasonable that the presence of nutrients could be a driver for adaptation as the 
process allows the resumption of the cell cycle and could permit cell growth. We therefore 
propose that the nutritional status could serve as a switch to facilitate checkpoint adaptation and 
we suggest that there is crosstalk between nutrient signalling pathways and the DNA damage 
response to modulate the decision to undergo adaptation. The existence of such crosstalk 
between the glucose-sensory PKA pathway and the cell cycle machinery has been reported 
previously. However, in this case PKA activity was sustained after DNA damage to maintain 
the cell cycle arrest (Searle et al., 2004). Our attention was drawn to the TOR nutrient signalling 
pathway by a report showing that rapamycin treatment to inactivate the TOR complex 1 
(TORC1) network rescued the viability of yeast mutants with dysfunctional telomeres as a 
trigger of DNA damage signalling (Qi et al., 2008). Prompted by these observations, we set out 
to investigate the link between nutrient signalling by TORC1 and adaptation and its impact on 
genome stability.   
 
3.2 Adaptation in higher eukaryotes: First insights from cancer cells and Xenopus  
The cellular response to DNA damage is highly conserved throughout eukaryotes. As a first 
line of defence, the cell cycle is arrested to facilitate repair and prevent the segregation of 
damaged DNA.  
In human cells, the Cdc5 homolog, PLK1, has been shown to be a target of the DNA damage 
checkpoint mediated by ATM and ATR (van Vugt et al., 2001). DDC signalling is transferred 
via CHK1, which prevents PLK1 activating phosphorylation events by inhibiting the 
responsible kinase, Aurora A (Krystyniak et al., 2006). Moreover, ATR signalling leads to the 
proteasomal degradation of the Aurora A cofactor, Bora, thereby further decreasing PLK1 
activity (Qin et al., 2013). In addition to targeting PLK1 directly, DDC activation also results 
in the inhibition of the CDC25 phosphatase family to inactivate Cyclin B-CDK1 and 
consequently, prevent entry into mitosis (reviewed in (van Vugt and Medema, 2005)). In order 
to promote mitotic entry after successful damage repair during checkpoint recovery, Aurora A 
in conjunction with Bora serves as the activating signal for PLK1 activity (Macurek et al., 
2008). Interestingly, while cells recovering from DNA damage seem to be dependent on PLK1 
to initiate mitosis, several redundant pathways can lead to the entry into mitosis in unperturbed 
conditions (van Vugt et al., 2004). In contrast, the mechanisms resulting in checkpoint 
adaptation in human cells are less well characterized. The interplay between PLK1 and CHK1 
seems to be critical as CHK1 is dephosphorylated in adapted cells. However, it is unknown if 
CHK1 dephosphorylation is a cause or consequence of adaptation and PLK1 itself does not 
seem to phosphorylate and thereby inactivate CHK1 (Syljuasen et al., 2006). As an alternative 
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to one factor being upstream of the other to facilitate adaptation, PLK1 and CHK1 could also 
act in parallel on a common target. As such, CDK1 activity has been proposed and a model was 
suggested in which the CDK1- promoting activity of PLK1 outcompetes CDK1 inhibition by 
CHK1 (reviewed in (Syljuasen, 2007)). Indeed, PLK1 targets Wee1, an inhibitor of CDK1, for 
degradation (van Vugt et al., 2004), while CHK1 inhibits CDC25, a positive CDK1 regulator 
(reviewed in (van Vugt and Medema, 2005)). It has also been hypothesized that a mitotic 
regulator could accumulate over time in G2 to promote entry into mitosis. This would suggest 
a “counting mechanism” instead of an active decision-making process to be the underlying 
decision to undergo adaptation. Again, PLK1 has been proposed to function as a molecular 
timer based on observations from Xenopus experiments (Yoo et al., 2004). So far, however, 
experimental evidence is missing to support this hypothesis. Alternatively, Cyclin B levels have 
been suggested to be critical determinants in this scenario. This is supported by the findings 
that Cyclin B transcription transiently drop in response to irradiation (Muschel et al., 1992) but 
subsequently increase during prolonged checkpoint arrest (Maity et al., 1996). Moreover, 
overproduction of Cyclin B was shown to shorten the time cells spent arrested in G2 after 
damage (Kao et al., 1997).  
Importantly, the majority of studies addressing adaptation in human cells has made use of 
cancer cells cultured in vitro. Nevertheless, it seems reasonable that adaptation also occurs 
under physiological conditions in vivo. This is supported by the notion that p53 deficiency, a 
common characteristic of human cancers, does not seem to be a prerequisite for adaptation 
(Syljuasen et al., 2006). In summary, the mechanistic details of adaptation in human cells are 
still elusive and more experimental work dedicated to the identification of the players involved 
has to be performed. 
 
Studies using Xenopus egg extracts have contributed largely to the characterization of 
adaptation in higher eukaryotes. In response to replication stress, the Xenopus ATR homolog, 
Xatr, activates Xchk1 (Xenopus homolog of CHK1). These activating phosphorylation events 
are mediated by Claspin, a functional homolog of the yeast S-phase checkpoint mediator Mrc1 
(Alcasabas et al., 2001). Like Claspin, yeast Mrc1 was found associated with stalled replication 
forks and is phosphorylated by Mec1, the yeast ATR homolog (Osborn and Elledge, 2003). In 
analogy to the checkpoint response described in human cells, activation of Xchk1 results in a 
cell cycle arrest. However, after prolonged checkpoint arrest in response to the replication 
stress-inducing drug aphidicolin, Plx1, the Xenopus PLK1 homolog, led to the inactivation of 
the checkpoint mediator Claspin (Yoo et al., 2004). After a priming phosphorylation of 
chromatin-bound Claspin by Xatr in response to a replication block, Plx1 can bind and 
phosphorylate Claspin thereby causing its release from chromatin. Consequently, continuous 
checkpoint-mediated activation of Xchk1 is abolished and entry into mitosis is allowed despite 
the persistence of replication stress (Yoo et al., 2004).  
Prompted by this report demonstrating the involvement of a checkpoint mediator protein in the 
regulation of adaptation, also other mediators like human MDC1 or 53BP1 have been 
hypothesized to be targeted by PLK1 or other mitotic kinases to facilitate inactivation of the 
DDC and hence, allow cell cycle progression. In line with this hypothesis, human Rad9, 
homologous to yeast Rad17 and part of the 9-1-1 checkpoint clamp, is sequentially 
phosphorylated by CDK complexes and PLK1 during drug-induced replication stress (Wakida 
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et al., 2017). The authors suggested a regulation of the damage response via the CDK-PLK1 
activity to allow cell cycle progression in the presence of low-level replication stress thereby 
maximizing cell proliferation. Interestingly, overexpression of the yeast PLK1 homolog, Cdc5, 
has been reported to interfere with the ability of the yeast checkpoint mediator Rad9 to promote 
Rad53 (mammalian CHK2) autophosphorylation and thereby could affect checkpoint 
maintenance (Vidanes et al., 2010). In conclusion, there seem to be many pathways for Polo 
kinases and their homologs to influence DDC signalling and it will be interesting to determine 
how the cellular targets are modulated by adaptation-promoting factors. The role of PLK1 is of 
special interest as it is commonly overexpressed in a variety of cancers (reviewed in (Liu et al., 
2017b)).  
 
3.3 Preventing adaptation in response to telomere dysfunction 
3.3.1 General regulation of adaptation by rapamycin and Cdc5 
3.3.1.1 Inhibition of adaptation by rapamycin 
We could show previously that in response to telomere dysfunction, inhibition of TORC1 
signalling using rapamycin can prevent checkpoint adaptation (Klermund et al., 2014). These 
findings implicate the TORC1 nutrient signalling pathway as an important regulator of 
checkpoint adaptation by coordinating extracellular cues such as nutrient availability with 
intracellular processes such as the DNA damage response.  
Mechanistically, we could show in our previous study that loss of the TORC1 effector Sch9 
rescues the viability of cdc13-1 cells. Similarly to inhibiting TORC1 signalling by rapamycin 
treatment, cdc13-1sch9 cells remained arrested in response to telomere dysfunction and 
maintained Rad53 in an activated state, albeit to a lesser extent (Klermund et al., 2014). The 
less pronounced effect observed by the deletion of SCH9 compared to rapamycin can be 
explained by additional pathways and targets utilized by rapamycin to prevent adaptation 
(Figure 23). One of these pathways is the TORC1 downstream effector Tap42, best 
characterized for its regulatory function on the PP2A phosphatase (Di Como and Arndt, 1996; 
Jiang and Broach, 1999). Although the molecular details regarding how adaptation is prevented 
in the absence of fully functional Tap42 remain to be addressed, we speculate that PP2A plays 
an important role, possibly by regulating Cdc5 (see discussion below). Taken together, we 
hypothesize that TORC1 signalling mediated by Sch9, Tap42 and possibly other effectors 
converge to facilitate Cdc5 activity. Although Cdc5 is initially inhibited by the DDC in response 
to damage, we speculate that the nutritional status sensed by TORC1 provides a pro-adaptation 
signal and allows proliferation despite persistent DNA damage (summarized in Figure 23). 
 
Initial studies that identified cell division cycle mutants including cdc13-1 revealed cell lysis as 
the cause of cell death in response to prolonged cell cycle arrest (Hartwell et al., 1973). Studies 
by Qi and colleagues proposed an apoptosis-like cell death in cdc13-1 cells after long-term 
incubation at the non-permissive temperature (Qi et al., 2008; Qi et al., 2003). In contrast, an 
apoptosis-like cell death occurring in cdc13-1 mutants has been ruled out by others (Wysocki 
and Kron, 2004). In our live-cell imaging approach we also frequently observed cell lysis in 
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cdc13-1 mutants after prolonged incubation at the non-permissive temperature (data not 
shown). When we prevented adaptation by rapamycin treatment, we did not observe cell lysis 
events but only an increase in cell size after prolonged cell cycle arrest. This was observed in 
the flow cytometry experiments as well as during the microscopy analysis and is consistent with 
the notion that the vacuole increases in size when autophagy is induced, for example in response 
to rapamycin (Granot and Snyder, 1991; Heitman et al., 1991a). Therefore, rapamycin could 
preserve viability in cdc13-1 cells not by inhibiting adaptation but by preventing cell lysis. 
However, several observations argue against the conclusion that rapamycin simply prevents 
cell lysis. Firstly, rapamycin in general did not seem to act by restricting the cell size and 
keeping the cells arrested in G1 to prevent cell lysis. This can be inferred from our observation 
of an increase in cell size upon rapamycin treatment during prolonged cell cycle arrest. An 
increase in cell size might not only be caused by vacuole swelling due to autophagy induction 
as rapamycin can rescue the viability of cdc13-1 mutants independently of autophagy (Figure 
10, (Klermund et al., 2014)). A likely explanation for the increased cell size could be an arrest 
in G2/M phase of the cell cycle due to DNA damage checkpoint activity. In line with this, 
rapamycin preserved checkpoint activity by maintaining Rad53 phosphorylation and prevented 
the entry into the subsequent G1 phase and not simply the occurrence of dead cells (Figure 8, 
(Klermund et al., 2014)). Lastly, the presence of damaged DNA in (attempted) subsequent cell 
cycles is a reasonable explanation for the failure of checkpoint-deficient cells to regrow at the 
permissive temperature (for example cdc13-1rad53-11 double mutants, Figure 9). This scenario 
is prevented in the presence of rapamycin due to the inhibition of adaptation and not by 
rapamycin counteracting cell lysis.  
Figure 23. Model of the rapamycin-mediated prevention of adaptation in response to telomere
dysfunction. After prolonged telomere dysfunction, Cdc5 inactivates Rad53 to terminate checkpoint
signalling (route 1). Consequently, the inhibition of Cdc5 in response to damage is alleviated and Cdc5
can promote mitotic progression (i.e. adaptation) (route 2). By modulating the TORC1 effectors Sch9 
and Tap42-PP2ACdc55, rapamycin inhibits the Cdc5-mediated inactivation of Rad53 (route 1) and
therefore, mitotic progression cannot occur (route 2 is prevented). Possible mechanisms (indicated by
“?”) to counteract adaptation by regulating the Tap42-PP2A axis are discussed in the text. In addition,
rapamycin induces autophagy and thereby inhibits mitotic progression in a pathway independent of the
DDC as described in (Dotiwala et al., 2013). The model has been modified from (Klermund et al., 2014).
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We could show previously that treatment with rapamycin improved the cell viability and 
recovery of many cdc mutants that arrest in G2/M at the non-permissive temperature including 
temperature-sensitive alleles of CDC14, CDC15, CDC16, CDC17 and CDC20. Use of the cdc5-
ad allele did not have a beneficial effect in these mutants indicating that preventing adaptation 
could have a specific role after telomere dysfunction or DNA damage in general (Klermund et 
al., 2014) Rather, inducing autophagy using an ATG13 allele that is refractory to TORC1-
mediated inhibition (Kamada et al., 2010) was sufficient for the rescue of viability. In addition, 
also cdc mutants arresting in G1, at the G1/S transition or in early S such as cdc2-2, cdc4-1, 
cdc34-1 and cdc7-4 show partially increased recovery after incubation at the restrictive 
temperature in the presence of rapamycin (Klermund et al., 2014) suggesting that lowering 
TORC1 activity might be a generally beneficial response in adverse conditions at various time 
points during the cell cycle.  
 
3.3.1.2 Prevention of adaptation by interfering with Cdc5 
Checkpoint adaptation occurs in response to various types of DNA damage, including telomere 
dysfunction, treatment with DNA damaging drugs and a nuclease-induced DSB. During 
adaptation, Rad53 phosphorylation is lost and this has been described to mark the onset of the 
adaptation process (Pellicioli et al., 2001). We wanted to follow the adaptation process to get 
insights into its timing using the cdc13-1 model system. Telomere uncapping after a 
temperature shift of cdc13-1 mutants activates the DDC and has been used for the 
characterization of adaptation regulators in yeast (Toczyski et al., 1997). Consistently with 
previous results, we observed a downregulation of the DDC evident from loss of Rad53 
phosphorylation in cdc13-1 cells grown for a prolonged period at the non-permissive 
temperature. Checkpoint inactivation was accompanied by cell cycle resumption monitored by 
flow cytometry and Western Blot analysis (this thesis and (Klermund et al., 2014). From bulk 
analysis of adaptation timing as well as following single cells during a live-cell imaging 
experiment we found that adaptation begins around 8 hours after checkpoint activation. This is 
in the range of adaptation onset reported previously in response to a single irreparable DSB 
(Lee et al., 1998). Adaptation of cdc13-1 mutants to persistent telomere dysfunction leads to 
cell death (Klermund et al., 2014; Qi et al., 2008). Therefore, the prevention of adaptation using 
the cdc5-ad allele preserves cell viability which is achieved by maintaining an active DDC and 
therefore continued cell cycle arrest in G2/M, as previously shown by us and others (Klermund 
et al., 2014; Rawal et al., 2016). The adaptation-deficient cdc5-ad mutant contains a leucine to 
tryptophan substitution at amino acid position 251 (Toczyski et al., 1997). Overall kinase 
activity seems unaffected in cdc5-ad mutants suggesting that it is not a general loss-of-function 
mutant (Charles et al., 1998; Rawal et al., 2016). However, these studies have used heterologous 
substrates such as casein to analyse the kinase activity. In fact, others have described the cdc5-
ad mutation as a gain-of-function allele and hypothesized that cdc5-ad-mediated checkpoint 
hyperactivation causes the adaptation defect (Schleker et al., 2010). The prevalent hypothesis 
to explain the cdc5-ad impairment during adaptation suggests a partial defect in substrate 
recognition and/or APC activation (Cheng et al., 1998; Toczyski et al., 1997).  
Cellular targets of Cdc5 that could influence checkpoint adaptation will be discussed in more 
detail in the following section.  
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3.3.2 Possible targets of Cdc5 to drive adaptation 
Upon DDC activation in the presence of DNA damage, Cdc5 is inhibited by Mec1- and Rad53-
mediated phosphorylation. In combination with the targeting of Pds1 and other factors, this 
inactivation of Cdc5 ensures cell cycle arrest (Cheng et al., 1998; Sanchez et al., 1999). 
Damage-induced phosphorylation of Cdc5 by the DDC components results in a decrease in 
Cdc5 activity (Zhang et al., 2009). In order for a cell to continue cell cycle progression after an 
arrest, damage signalling has to be terminated: either because the signal is removed (i.e. repair/ 
recovery) or because the signalling cascade is overridden (i.e. adaptation). Indeed, using 
irreparable DNA damage to study adaptation revealed a pivotal role for Cdc5 (Toczyski et al., 
1997).  
As we proposed previously, rapamycin regulates adaptation via the Sch9 and Tap42 branches 
of TORC1 (Klermund et al., 2014) and also autophagy induction is involved in preventing 
adaptation (Dotiwala et al., 2013). We could show that rapamycin treatment results in 
maintenance of Rad53 in a highly phosphorylated state and requires a functional DDC to 
prevent adaptation (Figures 8, 9 and 23 and (Klermund et al., 2014)). In agreement with this 
assumption, the rapamycin-mediated rescue is largely diminished but not abolished in Rad53-
compromised cells (Figure 9). Therefore, it is reasonable that rapamycin also prevents 
adaptation by affecting the status of the DDC. The remaining positive effect of rapamycin could 
be due to checkpoint-independent pathways to prevent mitotic progression in the presence of 
damage, such as autophagy (Figure 23). Moreover, in addition to being regulated by the DDC 
in response to damage, Cdc5 also regulates checkpoint signalling at multiple steps. Taking all 
these observations into account, we decided to focus on Cdc5 as a possible rapamycin-regulated 
target to prevent adaptation. 
Studies addressing the role of Cdc5 after DNA damage have not been fully elusive as there are 
opposing results regarding Cdc5 activity. A report by Hu and colleagues demonstrated that 
Bfa1, a target of Cdc5 to prevent mitotic exit, remains phosphorylated upon DNA damage (Hu 
et al., 2001). However, in its phosphorylated state, Bfa1 is inactive and cannot inhibit Tem1, 
which in turn is a positive regulator of MEN (reviewed in (Weiss, 2012)). Hu and colleagues 
therefore postulated two hypotheses: (1) DNA damage does not restrain Cdc5 activity as 
evident from subsequent Bfa1 phosphorylation but rather (2) Rad53 and Dun1 collaborate to 
add an additional, non-inhibitory phosphorylation onto Bfa1 that supports Bfa1’s role as a 
negative regulator of MEN to ensure cell cycle arrest. Hu et al hypothesized that the additional 
checkpoint-mediated modification counteracts or prevents the inhibitory Cdc5 activity on Bfa1 
(Hu et al., 2001). Based on these results, the authors ruled out the previously proposed inhibition 
of Cdc5 by Rad53 activation in response to DNA damage (Sanchez et al., 1999) (Figure 24). In 
this second but alternative scenario, activation of the DDC leads to the phosphorylation of Cdc5 
in a manner dependent on Mec1, Rad53 and Rad9 (Cheng et al., 1998; Sanchez et al., 1999). 
Consequently, Cdc5 activity is inhibited leading to a hypo-phosphorylation of Bfa1 and 
therefore, retaining Bfa1 in an active state (i.e. MEN is prevented, Figure 24) (Valerio-Santiago 
et al., 2013). This model is supported by the finding that Rad53-mediated inhibition of Cdc5 
allows the sustained activity of the APC co-factor Cdh1, which ultimately prevents the 
extension of the mitotic spindle and thereby prevents mitotic exit (Zhang et al., 2009). During 
adaptation, the levels of Cdc5 appear to be dose-dependent (Vidanes et al., 2010) and Rad53 
phosphorylation is lost when cells adapt (Pellicioli et al., 2001). These findings suggest that 
 Discussion  
79 
 
Cdc5 could in turn inactivate Rad53 to terminate DDC signalling and allow cell cycle 
progression. Indeed, overproduction of Cdc5 results in the complete loss of Rad53 
phosphorylation and accelerates adaptation (Donnianni et al., 2010; Pellicioli et al., 2001; 
Vidanes et al., 2010). We therefore hypothesized that rapamycin prevents adaptation by 
reinforcing the checkpoint and keeping Cdc5 in an inactive state. In support of this idea, we 
could show that rapamycin suppresses the phosphorylation of Bfa1 upon telomere dysfunction 
indicating that Cdc5 is inactivated in this scenario. Further, rapamycin treatment maintains 
Rad53 phosphorylation indicative for an active DDC but this effect is abolished in CDC5 
overexpressing cells (Klermund et al., 2014). Taken together, these findings favour our 
hypothesis that rapamycin acts on Cdc5 to prevent adaptation and maintaining an active 
checkpoint in response to telomere dysfunction. Consequently, telomere dysfunction mutants 
remain arrested at the metaphase-to anaphase transition and therefore retain viability. 
The identification of the adaptation-defective cdc5-ad allele has fuelled the investigation of 
adaptation in response to various types of DNA damage. Nevertheless, the exact defect of the 
cdc5-ad allele remains to be elucidated. In agreement with the idea that adaptation occurs by 
shutting off the DDC, the absence of a functional checkpoint in rad53-11 or mec1 (in absence 
of SML1) mutants abolishes the protective effect of both rapamycin and the cdc5-ad allele on 
cell viability (Figure 9). However, the lack of the central checkpoint kinases Rad53 and Mec1 
renders cells genetically unstable due to increased mutation rates. This phenotype is not only 
due to an impairment of the DDC but also caused by de-regulated origin firing during DNA 
replication causing higher mutation frequencies (Craven et al., 2002; Lang and Murray, 2011). 
This might be a plausible explanation for the only partially observed rescue by the cdc5-ad 
allele in cdc13-1 mutants derived from a checkpoint-compromised diploid cell and the 
Figure 24. Simplified schemes depicting different models for the prevention of mitotic exit in the 
presence of damage. (A) Based on (Hu et al., 2001), DNA damage induces Rad53 which in turn keeps
Bfa1 in an active state. Bfa1 is inactivated after phosphorylation by Cdc5, therefore the Rad53-mediated 
phosphorylation could prevent modification of Bfa1 by Cdc5. When Bfa1 remains active due to
checkpoint signalling, the mitotic exit network is prevented and cells stay arrested. (B) Alternatively 
and as suggested by (Valerio-Santiago et al., 2013) and others, checkpoint activation leads to the
inhibition of Cdc5. Consequently, Cdc5-mediated inactivation of Bfa1 is prevented and cell cycle arrest
is maintained. See text for more details and references. 
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acquisition of suppressor mutations in cdc13-1 mutants (Figure 9 A). In any case, these results 
suggest that the prevention of adaptation by the cdc5-ad allele requires a functional DDC. 
Consistently, checkpoint signalling must be continuous for a permanent cell cycle arrest (i.e. 
adaptation defect or the prevention of adaptation). This has been concluded from the finding 
that adaptation-defective cdc5-ad mutants resumed cell cycle progression in the presence of 
damage when Mec1 was prematurely degraded using degron alleles (Pellicioli et al., 2001). 
Since loss of Mec1 signalling results in the inactivation of Rad53 and this was still observed in 
a cdc5-ad mutant, this experiment also suggests the adaptation defect in cdc5-ad cells is not 
due to a defect in Rad53 dephosphorylation (Pellicioli et al., 2001). To add another layer of 
complexity, Cdc5 has been shown to phosphorylate Rad53 in a cell cycle-dependent manner in 
association with Cdc28. Although these phosphorylation events occurred during an unperturbed 
mitosis independently of DNA damage, their absence caused the premature loss of Rad53 
phosphorylation during the DNA damage response, i.e. accelerated adaptation (Schleker et al., 
2010). This suggested positive role for Cdc5 in checkpoint maintenance seems contradictory to 
the adaptation-defect observed in cdc5-ad mutants and it has been hypothesized that Rad53 is 
continuously active in cdc5-ad mutants causing the inability to override the checkpoint 
(Schleker et al., 2010). In line with this, a kinase-deficiency due to the amino acid substitution 
at position 251 (a leucine to tryptophan mutation) does not seem to be the cause of the cdc5-ad 
adaptation defect (Charles et al., 1998; Rawal et al., 2016). Rather, cdc5-ad cells showed a 
hyperactive kinase activity (Charles et al., 1998) and furthermore, Cdc5 kinase activity was 
required to cause Rad53 dephosphorylation (Vidanes et al., 2010). Likewise, cdc5-ad does not 
appear to be regulated differently on the protein level during the cell cycle (Rawal et al., 2016). 
Moreover, generation of ssDNA as a trigger for checkpoint activation was not altered in 
cdc5- ad mutants supporting the idea that the adaptation defect does not stem from a failure to 
activate the checkpoint in the first place (Pellicioli et al., 2001). As mentioned before, a defect 
in recognizing certain substrates has been suggested as the underlying cause for the adaptation 
defect in cdc5-ad cells as APC activity was stimulated less efficiently in the mutant (Charles et 
al., 1998). This could cause an inability to degrade Clb2 by the APCCdh1 complex and therefore, 
hamper mitotic exit (Schwab et al., 1997). An independent report has also suggested that 
cdc5- ad mutants fail to adapt due to a defect in mitotic exit. Consistently, the authors showed 
that also mutants with defects in the FEAR pathway that initiates mitotic exit, display an 
adaptation defect (Jin and Wang, 2006).Taking all these observations into account, the exact 
defect of cdc5-ad mutants still remains uncharacterized. Based on our results presented in 
Figure 9, we hypothesize that rapamycin prevents adaptation largely by modulating the 
Cdc5- Rad53 interplay, although we note the checkpoint-independent effects of rapamycin such 
as autophagy and possibly additional pathways (Figure 23).  
In agreement with the observation of a cell-cycle dependent modification of Rad53 by Cdc5 
(Schleker et al., 2010), a second study reported an interaction of Cdc5 and Rad53 in the absence 
of damage (Vidanes et al., 2010). In support of this, a cell cycle- and DNA damage-regulated 
interaction has been observed between human CHK2 (homolog to yeast Rad53) and PLK1 
(homolog to yeast Cdc5) (Tsvetkov et al., 2005). Interestingly, in addition to loss of Rad53 
phosphorylation, also Chk1 is inactivated during adaptation and this was prevented in a 
cdc5- ad mutant background suggesting that downregulation of the checkpoint involves both 
branches of Mec1 signalling (Pellicioli et al., 2001).  
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Irrespective of our complete understanding of the mechanisms used by Cdc5 to inactivate the 
DDC and alleviate cell cycle arrest in the presence of DNA damage, the question remains how 
Cdc5 is regulated to become active (again). We hypothesize that TORC1 activity serves as the 
promoting signal in such a scenario (this thesis, (Klermund et al., 2014)). According to this 
model, active TORC1 provides the activating signal for Cdc5 to inactivate Rad53 and shut-off 
the DDC cascade. In contrast, decreasing TORC1 signalling by rapamycin impacts on Cdc5 via 
several possible mechanisms (see below) and prevents its reactivation. Hence, DDC signalling 
via Rad53 is maintained and cells stay arrested. Interestingly, Tel2, a protein initially identified 
due to its role in telomere biology (Runge and Zakian, 1996), was then shown to be a regulator 
of PIKK assembly and stability (reviewed in (Boulton, 2008)), the conserved kinase family that 
also comprises Mec1, Tel1 and the Tor proteins. If and how Tel2 also plays a role in adaptation 
remains to be addressed experimentally and could provide interesting insights into the 
regulation of adaptation.  
 
3.3.3 Possible targets for PP2A in preventing adaptation 
As described above, Cdc5 is a critical player in the adaptation process. On the other hand, 
nutrient signalling by TORC1, the target of rapamycin, has been shown to influence adaptation 
(Klermund et al., 2014) and is involved in Cdc5 regulation (Nakashima et al., 2008). Therefore, 
we hypothesized that, in addition to other targets, rapamycin treatment resulting in the 
inhibition of TORC1 prevents adaptation by acting on Cdc5. We could previously provide 
mechanistic insights into the involvement of Sch9 in the adaptation process (Klermund et al., 
2014). Therefore, we decided to focus on PP2ACdc55 as a TORC1 downstream effector and 
possible mediator of rapamycin to prevent adaptation. In the section below, I will present 
several possible mechanisms how the effect of rapamycin could be mediated in budding yeast. 
 
3.3.3.1 A model for the direct regulation of Cdc5 by PP2A 
An important unanswered question in studying checkpoint adaptation is its temporal regulation. 
We and others could show that adaptation starts to occur approximately 6 to 8 hours after the 
checkpoint arrest has been elicited (Figure 8, (Lee et al., 1998; Toczyski et al., 1997)). This 
would suggest that one or more critical factors responsible for initiating and executing 
adaptation become active or re-activated at this time point. Since Cdc5 is a main driver of 
adaptation (Toczyski et al., 1997) and becomes inactivated by DDC proteins (Donnianni et al., 
2010; Pellicioli et al., 2001) after damage has been detected, Cdc5 constitutes a reasonable 
candidate. Furthermore, activity of Cdc5 is governed by its phosphorylation status (reviewed in 
(Botchkarev and Haber, 2017)) with phosphorylation being one of the most versatile and 
important regulatory tools for protein activity (Salazar and Hofer, 2007). However, it is 
mechanistically unknown how Cdc5 overcomes inhibition by the DDC to downregulate 
checkpoint players itself and thereby facilitate cell cycle progression. Although initially 
phosphorylated by the DDC in response to DNA damage to inactivate its kinase activity (Cheng 
et al., 1998; Zhang et al., 2009), Cdc5 is released from this block to drive adaptation. We have 
proposed previously that nutrients could serve as a trigger to allow the regaining of Cdc5 
activity (Klermund et al., 2014) and therefore adaptation. Nutrient availability sensed by 
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TORC1 has been linked to Cdc5 regulation in several studies. Active TORC1 signalling allows 
the nuclear accumulation of Cdc5 via the Tap42-PP2A effector branch and thereby promotes 
mitotic entry (Nakashima et al., 2008). Intriguingly, genotoxic treatment of Xenopus laevis egg 
extracts led to an increased interaction between PP2A and Plx1, the Xenopus Plk1 homolog. 
This interaction was mediated by B55α, which is the homolog of yeast Cdc55, and resulted in 
dephosphorlyation of the activating phosphorylation site within Plx1 (Wang et al., 2015). These 
observations revealed a DNA damage-induced downregulation of Plk1 activity via the PP2A 
phosphatase and could implicate PP2A in regulating checkpoint adaptation. As in yeast, also 
mammalian PP2A activity is regulated by mTOR signalling via a Tap42 homolog, alpha4 
(Murata et al., 1997; Nanahoshi et al., 1998). Since DNA damage downregulates TOR 
signalling (Budanov and Karin, 2008) this results in PP2A activation. We observed a rescue of 
cell viability in cdc13-1 mutants lacking Tap42, a negative regulator of PP2A, suggesting that 
PP2A activation could prevent adaptation (Figure 10). Taking these observations into account, 
we hypothesized that PP2A dephosphorylates Cdc5, thereby retaining it in an inactive state, 
similarly to what has been shown in the Xenopus system (Wang et al., 2015). This could be a 
possible mechanism to prevent Cdc5 from regaining activity and driving adaptation in the 
presence of persistent DNA damage. In agreement with these findings, we observed an 
interaction between Cdc5 and Pph21, one of the two redundant catalytic subunits of PP2A. 
However, the Cdc5-PP2A interaction seemed independent of DNA damage but rather cell 
cycle-regulated since it was also observed in nocodazole-arrested cells (Figure 10). This is 
consistent with PP2A being a regulator of Cdc5 localization during the cell cycle (Nakashima 
et al., 2008). We were therefore interested if inhibition of TORC1 would increase the interaction 
between PP2A and its possible target Cdc5. We hypothesized that downregulation of TOR 
signalling by rapamycin would strengthen or prolong the binding between phosphatase complex 
and Cdc5 and therefore inactivate Cdc5. Instead of increased binding, we observed a weakened 
interaction between Cdc5 and Pph21 in the presence of rapamycin and DNA damage (in a 
cdc13-1 background). However, future experimental work is required to investigate the 
regulation of this interaction. A possible influence on total Cdc5 protein levels upon rapamycin 
treatment is discussed below (see section 3.3.4). 
Taken together, we could provide evidence for a physical interaction between the PP2A 
catalytic subunit Pph21 and the Polo-like kinase Cdc5 during unperturbed conditions and after 
DNA damage induced by telomere dysfunction. It has been suggested that TORC1 only impacts 
Cdc5 during entry into mitosis (Nakashima et al., 2008), however, rapamycin treatment is able 
to prevent checkpoint adaptation in cells arrested at the metaphase-to-anaphase transition after 
DDC activation (Klermund et al., 2014) suggesting that there is also an involvement of TORC1 
signalling at later time points. These two conflicting observations could be explained by a Cdc5-
independent rescue effect of rapamycin, for example via autophagy induction. Alternatively, 
rapamycin could sustain PP2A activity, possibly by preventing the re-binding of Tap42. This 
would maintain a cell cycle arrest prior to sister chromatid segregation as downregulation of 
PP2A is necessary to facilitate mitotic exit during an unperturbed cell cycle. This inhibition is 
mediated by separase at the onset of anaphase (Queralt et al., 2006).  
The importance of correct PP2A regulation is highlighted by its tumour suppressor function 
(reviewed in (Ruvolo, 2016)). Downregulated PP2A activity has been found in many cancers 
and could be linked to increased mTOR signalling. Importantly, although proposed to act 
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downstream of mTORC1, PP2A has also been shown to signal upstream of mTOR (reviewed 
in (Wlodarchak and Xing, 2016)). 
 
3.3.3.2 Additional mitotic factors as PP2A targets 
In addition to a possible regulation of Cdc5 by PP2ACdc55 after rapamycin treatment, the PP2A 
phosphatase complex could also influence adaptation by regulating other factors critical for 
mitosis. Such a regulatory role for PP2ACdc55 has been shown during adaptation to the spindle 
assembly checkpoint (SAC). This checkpoint operates in metaphase and monitors the correct 
attachment of kinetochores to the mitotic spindle to ensure proper chromosome segregation. In 
order to allow adaptation to the SAC, Clb2 levels are gradually increasing during a prolonged 
metaphase arrest. This allows the activation of the APCCdc20 complex which in turn targets Clb2 
for proteasomal degradation evidenced by a rapid drop in Clb2 levels. However, the activating 
phosphorylation of APCCdc20 complexes by Clb2/Cdc28 is counteracted by the PP2ACdc55 
phosphatase. This leaves the question how Clb2/Cdc28 can phosphorylate enough APCCdc20 
complexes before being degraded by APC and while APC phosphorylation is actively 
counteracted. A model involving both a negative and positive feedback loop has been proposed 
(Vernieri et al., 2013): In a negative feedback loop, Clb2/Cdc28 promotes APCCdc20 activation 
due to increasing Clb2 levels thereby leading to the rapid degradation of Clb2 as APCCdc20 
activity increases. At the same time, increasing activity of APCCdc20 targets PP2ACdc55 and 
thereby creates a positive feedback loop since PP2ACdc55 acts as an inhibitor of APCCdc20. This 
bistable switch between opposing APC and PP2A activity states has been hypothesized to 
regulate the metaphase-to-anaphase transition during adaptation to the SAC (Vernieri et al., 
2013). 
Another study has implicated PP2ACdc55 as a functional link between the FEAR and MEN 
pathway. When PP2ACdc55 is downregulated at anaphase onset in a separase-dependent manner 
during the FEAR pathway to trigger a first wave of Cdc14 activity ((Queralt et al., 2006), 
reviewed in (Weiss, 2012)), this allows Cdc5 to phosphorylate and thereby inhibit Bfa1 leading 
to the activation of the MEN (Baro et al., 2013; Queralt et al., 2006). However, in the absence 
of PP2ACdc55 activity, MEN was not initiated prematurely suggesting that this first and 
incomplete Cdc14 release from the nucleolus is not sufficient to trigger mitotic exit. It has been 
proposed that MEN activity is restrained due to the inhibitory effect of Clb2-Cdc28 complexes 
on core MEN components Cdc15 and Dbf2-Mob1 (Baro et al., 2013). Taken together, 
PP2ACdc55 activity seems required for the activation of both FEAR and MEN. Since Bfa1 
appears to be a key player in the regulation of mitotic exit, it is possible that rapamycin prevents 
adaptation by keeping Bfa1 in an active state to prevent MEN. This would be consistent with 
the finding that rapamycin prevented the Cdc5-dependent phosphorylation of Bfa1 in response 
to telomere dysfunction (Klermund et al., 2014). In the absence of BFA1, cdc13-1 mutants had 
already lost viability after short-term telomere dysfunction (J. Klermund, personal 
communication), a condition in which cdc13-1 viability is usually not compromised even in the 
absence of rapamycin (Figure 8, (Klermund et al., 2014; Qi et al., 2008)). In support of our 
observation, also others have found that damage arising from dysfunctional telomeres requires 
Bfa1 to ensure metaphase arrest (Valerio-Santiago et al., 2013). Strikingly, cdc13-1bfa1 double 
mutants could still be rescued by rapamycin treatment (J. Klermund, personal communication). 
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There are at least two different possible explanations for these results: First, rapamycin could 
prevent adaptation by acting upstream of Bfa1, for example by maintaining Rad53 
phosphorylation. Alternatively, it is conceivable that rapamycin does not prevent adaptation via 
Bfa1 but by regulating a parallel pathway to achieve cell cycle arrest. Indeed, PP2ACdc55 also 
acts as a negative regulator of MEN by dephosphorylating Tem1 (Wang and Ng, 2006), a 
critical positive regulator of mitotic exit that is inhibited by Bfa1/Bub2. Further experiments 
taking into account the phosphorylation status of Tem1 in the presence of rapamycin could 
provide insights into the role of MEN regulation during adaptation.  
 
3.3.4 Other Cdc5 regulatory mechanisms to counteract adaptation 
In addition to a possible regulation via PP2A (discussed above), also other TORC1 signalling 
pathways modulated by rapamycin could result in the prevention of adaptation by acting on 
Cdc5.  
As described above, preliminary results led us to hypothesize that rapamycin treatment prevents 
checkpoint adaptation in response to telomere dysfunction by decreasing Cdc5 protein levels 
(Figure 10). This could be explained by the induction of an ubiquitin ligase in response to 
TORC1 inhibition which targets Cdc5 for degradation. During unperturbed conditions, Cdc5 is 
degraded by the proteasome after ubiquitination by APCCdh1. However, this E3 ligase complex 
can only form after Cdc14 has been released in anaphase and is still inactive at the cdc13-1 
arrest point at the non-permissive temperature (reviewed in (Weiss, 2012)). Therefore, it is 
highly unlikely that Cdc5 is degraded by APCCdh1 triggered by rapamycin treatment. Rather, 
APC in conjunction with Cdc20 as a specificity factor could target Cdc5 to decrease protein 
levels and thereby prevent checkpoint adaptation. APCCdc20 targets include Pds1 (Visintin et al., 
1997) and the mitotic cyclin Clb5 (Shirayama et al., 1999) and its activity can be regulated by 
PP2ACdc55, although this has been shown to occur in response to activation of the spindle 
assembly checkpoint (Vernieri et al., 2013). Recently, mammalian TORC1 has been reported 
to activate the E3 ubiquitin ligase ZNRF2, the putative homolog of yeast Pib1 (Hoxhaj et al., 
2016). However, yeast Pib1 has been suggested to target endosomal and lysosomal proteins 
(Shin et al., 2001) and therefore, most likely does not represent a candidate E3 ubiquitin ligase 
regulating Cdc5 protein levels. It will be interesting to address a possible rapamycin-induced 
degradation of Cdc5 as a mechanism to prevent adaptation. Future experiments aiming at the 
identification of candidate E3 ubiquitin ligases will hopefully provide experimental evidence 
for this hypothesis. Intriguingly, the regulation of the transcription factor Stp1 at the protein 
level has been described in response to TORC1 inactivation and has been attributed to the 
PP2A-like phosphatase, Sit4. Although the mechanistic details remain elusive, decreased 
TORC1 signalling was shown to lead to the disappearance of Stp1 from the nucleus (Shin et 
al., 2009). This report indicates the potential of cytoplasmic TORC1 to regulate the abundance 
of specific proteins in the nucleus although further experiments are required to provide further 
details. 
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Preliminary results using the proteasome inhibitor MG132 indicated that the decrease of Cdc5 
protein levels in response to rapamycin treatment is independent of proteasomal function (data 
not shown). However, TORC1 inhibition, for example by rapamycin treatment, was shown to 
induce proteasome abundance by inducing Adc17, a chaperone that couples stress conditions 
to proteasome assembly (Rousseau and Bertolotti, 2016). Therefore, proteasome inhibition in 
this experimental set-up could have been incomplete. To address the hypothesis of proteasome-
dependent degradation of Cdc5 in response to rapamycin treatment, the experiment should be 
performed in an adc17 mutant background and proteasome inactivation should be monitored 
by an accumulation of total ubiquitin signal.  
Assessing the stability of Cdc5 protein in response to rapamycin treatment using a classical 
cycloheximide-chase experiment is difficult to interpret due to the observation that the increase 
in free amino acids triggered by cycloheximide serves as an activating signal for TORC1 
(Beugnet et al., 2003; Urban et al., 2007). However, the low rapamycin concentrations used in 
this study and in our previous report (Klermund et al., 2014) are substantially lower than the 
concentrations used for full TORC1 inhibition resulting in G1 cell cycle arrest (Barbet et al., 
1996). To circumvent this complications, a promoter shut-off experiment could be employed. 
However, since CDC5 is an essential gene, such an experiment is only feasible within a short 
time range to avoid cell death.  
Figure 25. Possible regulatory roles of rapamycin on the transcription of Cdc5 mRNA to prevent
adaptation. (A) Scheme representing transcription from the CLB2 cluster in an unperturbed cell cycle.
Assembly of the transcription factor complex with the positive regulator Ndd1 allows Cdc5 mRNA and
protein production allowing progression through mitosis. (B) Upon DNA damage, Ndd1 is
phosphorylated by Rad53 which impairs CLB2 cluster transcription resulting in cell cycle arrest due to
the lack of critical mitosis-promoting factors such as Cdc5. Rapamycin could reinforce G2/M arrest 
induced by DNA damage by indirectly maintaining the inhibitory Ndd1 phosphorylation. Alternatively,
rapamycin could lead to the translocation of one or both Fkh transcription factors to the cytoplasm 
thereby negatively regulating CLB2 cluster transcription and resulting in continued cell cycle arrest (i.e.
prevention of adaptation). 
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Taken together, these experiments could provide further evidence for a rapamycin-mediated 
degradation of Cdc5 protein to prevent adaptation in response to telomere dysfunction. 
 
In addition to preventing adaptation by regulating Cdc5 on the protein level, rapamycin could 
also exert its effect by acting at the transcriptional level. One possibility to regulate Cdc5 
mRNA is by affecting the forkhead transcription factors, Fkh1 and Fkh2. Together with a third 
transcription factor, Mcm1, the Fkh proteins mediate transcription of the CLB2 cluster including 
CLB2 itself but also CDC5 (Kumar et al., 2000; Zhu et al., 2000). As outlined in section 1.1.3, 
Fkh2 interacts with Ndd1 (Koranda et al., 2000), a positive regulator of the CLB2 transcription 
cluster. This interaction is abrogated upon DNA damage due to Rad53-mediated 
phosphorylation of Ndd1 thereby contributing to the cell cycle arrest (Edenberg et al., 2014). 
In metazoans, the highly conserved PI3K-Akt-mTOR signalling axis negatively regulates the 
forkhead box O class of transcription factors, termed FOXO (reviewed in (Hay, 2011)). 
Inhibition of FOXO transcription factors results in a pro-survival signal and consistently, 
FOXO transcription factors are thought to act as tumour suppressors (reviewed in (Dansen and 
Burgering, 2008)). In agreement with the idea that FOXO family members must be inhibited to 
allow proliferation, PLK1 has been shown to be a negative regulator of FOXO3 (Bucur et al., 
2014), another member of the FOXO transcription factor family, thereby counteracting its 
tumour-suppressive activity. Although the PI3K/Akt/mTOR signalling node is often aberrantly 
active in cancer cells and acts as an oncogenic signal, inhibition of mTOR signalling by 
rapamycin as the sole therapeutic agent was ineffective (reviewed in (Xie et al., 2016)). Rather, 
rapamycin treatment was reported to cause the phosphorylation of FOXO1 resulting in the 
nuclear export of the transcription factor rendering it inactive as a tumour suppressor 
(Abdelnour-Berchtold et al., 2010). This provided one explanation for the less promising 
efficacy of rapamycin in cancer therapy. Nevertheless, the study showed a direct implication of 
TOR signalling in the regulation of forkhead transcription factors. Given the high conservation 
of the signalling pathways amongst eukaryotes, a possible mode of action for rapamycin to 
prevent checkpoint adaptation in budding yeast could be by regulating Cdc5 on the 
transcriptional level via the Fkh transcription factors. In this scenario, rapamycin treatment 
would lead to a change in the subcellular localization of one or both Fkh transcription factor 
paralogues resulting in decreased transcription of the CLB2 cluster and thereby lowering Cdc5 
mRNA levels to prevent checkpoint adaptation. Alternatively, one could speculate that 
rapamycin regulates CLB2 cluster transcription by impinging on the positive regulator Ndd1, 
for example by maintaining its inhibitory Rad53-mediated phosphorylation to reinforce 
damage-induced cell cycle arrest (Figure 25).  
 
3.3.5 The influence of autophagy on adaptation 
3.3.5.1 The role of macroautophagy 
The induction of autophagy is one of the best characterized effects in response to TORC1 
inhibition. The molecular mechanisms leading to autophagic degradation when TORC1 is 
inactivated have been addressed by many different labs. However, also other nutrient sensory 
pathways were shown to influence autophagy, for example the Ras/PKA (protein kinase A) 
network responding to glucose availability. Importantly, simultaneous inhibition of PKA and 
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Sch9 signalling leads to the activation of autophagy independently of TORC1 activity 
(Yorimitsu et al., 2007). This observation could not unambiguously place PKA signalling in 
parallel or downstream of TORC1. Another study analysing the interplay between PKA and 
TORC1 signalling found TORC1 responsible for the localization of PKA subunits and 
therefore, it was hypothesized that PKA signalling occurs downstream of the TORC1 signalling 
node (Schmelzle et al., 2004).  
Independent of the exact molecular pathway causing its induction, autophagy has been 
proposed as a determinant factor for genome stability (Matsui et al., 2013). Acute nutrient 
deprivation or rapamycin treatment leading to TORC1 inactivation arrests yeast cells in G1 
before they enter stationary phase (Barbet et al., 1996; Johnston et al., 1977). However, 
malfunction of TORC1 also affects cell cycle progression at the G2/M transition due to the 
mislocalization of Cdc5 (Nakashima et al., 2008). Further experiments led to the conclusion 
that autophagy is required to provide the building blocks which are needed to complete the cell 
cycle and arrest in the subsequent G1 phase in response to nutrient starvation (Matsui et al., 
2013). In autophagy-deficient cells, nutrient limitation caused an increased occurrence of 
aneuploidy by facilitating pre-mature mitosis thereby suggesting autophagy as positive 
regulator of genome stability. The critical role of autophagy in this scenario has been explained 
by the hypothesized benefits to re-initiate cell growth and division from G1 phase when 
nutrients are favourable again (Matsui et al., 2013). The observation that autophagy can protect 
genome integrity has also been made in mammalian cells (Mathew et al., 2007).  
In our experiments using cdc13-1 mutants, rapamycin led to an induction of autophagy, both at 
the early time point (6 h) and late time point (24 h of telomere dysfunction) (Klermund et al., 
2014). However, we did not observe a requirement for autophagy to prevent adaptation by 
rapamycin treatment (Figure 10 and (Klermund et al., 2014)). This suggests that rapamycin can 
regulate adaptation independently of autophagic degradation, for example by modulating post-
translational modifications of positive regulators of checkpoint adaptation. On the other hand, 
induction of macroautophagy using an allele of ATG13 that is refractory to the inhibition by 
active TORC1 (Atg13-8SA, (Kamada et al., 2010)) is sufficient to rescue cell viability in cdc13-
1 mutants (Klermund et al., 2014). Taken together these results indicate that upon telomere 
dysfunction, autophagy is not necessary but sufficient to prevent checkpoint adaptation by 
rapamycin.  
 
3.3.5.2 A link between selective autophagy and adaptation 
Consistent with a general protective role for genome stability, autophagy is directly induced in 
response to DNA damage. The checkpoint kinases Mec1, Tel1 and Rad53 mediate the induction 
of autophagy in response to DNA damaging agents in a process termed genotoxin-induced 
targeted autophagy (GTA) (Eapen et al., 2017). Importantly, GTA utilizes proteins involved in 
the selective Cvt pathway in addition to the core autophagic machinery and is different from 
starvation- or rapamycin-induced autophagy which highlights the specificity of the response 
(Eapen et al., 2017).  
Autophagy induction in response to DNA damage seems to be temporally regulated. An acute 
and transient upregulation of autophagy mediates cell cycle arrest via the partial destruction of 
Pds1 through the Cvt pathway (Dotiwala et al., 2013). Pds1 functions not only as an inhibitor 
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of Esp1 but is also important for Esp1’s nuclear localization (Agarwal and Cohen-Fix, 2002). 
Therefore, autophagy-induced Pds1 degradation in response to damage causes the 
mislocalization of Esp1 and thus prevents sister chromatid separation. This process seems to be 
enhanced in cells lacking VPS51 that have a defect in the Cvt pathway and that suffer from 
permanent cell cycle arrest (which is the failure to undergo checkpoint adaptation) (Dotiwala 
et al., 2013). While Dotiwala and colleagues argue that vps51 mutants display hyperactive 
autophagy, others have proposed that loss of VPS51 impairs autophagy (Reggiori et al., 2003). 
In support of their hypothesis that hyperactive and prolonged autophagy after DNA damage in 
vps51 cells causes an adaptation defect by completely excluding Pds1 from the nucleus and 
thereby preventing sister chromatid separation, Dotiwala et al report the restoration of 
adaptation by blocking autophagy in vps51atg5 double mutants (Dotiwala et al., 2013). Taken 
together, these results imply that a transient induction of autophagy in response to DNA damage 
is important to establish cell cycle arrest in G2/M. Eventually, autophagy has to decrease to 
normal physiological levels to allow checkpoint adaptation.  
Utilizing cdc13-1 mutants in our study, we observed that loss of VPS51 was sufficient to rescue 
cell viability upon telomere dysfunction (Figure 10). In contrast to the observation by Dotiwala 
and colleagues, impairment of non-selective autophagy by deleting ATG5 did not abolish the 
vps51-mediated rescue of cdc13-1 mutants. Moreover, the absence of a functional DDC in 
mec1sml1 mutants did not compromise the rescue of cell viability in cdc13-1vps51 double 
mutants (Figure 10). This is consistent with the study by Dotiwala and colleagues where the 
adaptation defect in vps51 cells persisted even in the absence of an active Rad53-mediated DDC 
(Dotiwala et al., 2013). One could hypothesize that in our experimental set-up, loss of VPS51 
leads to the degradation, mislocalization or inactivation of one or more yet uncharacterized 
factor(s) independently of non-selective autophagy (via Atg5) and the DDC (via Mec1). 
Consequently checkpoint adaptation is prevented and therefore cell viability upon telomere 
dysfunction is preserved. A likely explanation for the discrepancy between our analysis and the 
report by Dotiwala et al could be given by the tools to induce DNA damage. 
Further experiments including the assessment of the cell cycle profile in cdc13-1vps51 double 
mutants will be required to investigate the involvement of the Cvt pathway in preventing 
adaptation. Since Vps51 is not only part of the Cvt pathway, also crosstalk to other selective 
autophagic processes or protein sorting pathways could account for the positive effect observed 
in vps51 mutants. Another interesting observation is the rapamycin sensitivity of vps51 mutants 
irrespective of DNA damage (Figure 10). This has been observed previously in genetic screens 
(Parsons et al., 2004; Xie et al., 2005) but the underlying mechanism remains elusive. In 
accordance with the hypothesis that loss of Vps51 induces autophagy (Dotiwala et al., 2013), 
one could speculate that further excessive induction of autophagic degradation by rapamycin 
causes lethality.  
In addition to the nuclear exclusion of Pds1 after DNA damage-induced autophagy, also Rnr1 
protein levels have been shown to be regulated via autophagic degradation and the degradation 
was exacerbated upon TORC1 inhibition (Dyavaiah et al., 2011). As hypothesized by the 
authors, these findings highlight that crosstalk between TORC1 signalling leading to autophagy 
induction and the DDC is required to fine-tune the cellular response.  
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3.3.6 An involvement of other nutrient sensory pathways in regulating adaptation 
The yeast TOR signalling pathway is mainly responding to nitrogen availability. Glucose levels 
are primarily sensed and integrated by the Ras/ PKA (Protein Kinase A) signalling network. 
However, extensive crosstalk between nutrient sensory cascades exists to achieve optimal 
growth in the nutritional environment (reviewed in (Zaman et al., 2008)). For example, activity 
of the Sch9 kinase, a well-characterized downstream effector of TORC1 and the closest yeast 
homolog to mammalian Akt, is also coupled to glucose levels ((Urban et al., 2007), reviewed 
in (Zaman et al., 2008)).  
Ras1 and Ras2 are small GTPases that trigger rapid intracellular accumulation of cyclic 
adenosine monophosphate (cAMP) which in turn serves as an activating signal for PKA. 
Eventually, PKA promotes ribosome biogenesis and actively prevents expression of stress-
responsive and stationary phase genes (reviewed in (Conrad et al., 2014)). The Ras GTPase 
family is highly conserved throughout eukaryotic cells as demonstrated by the ability of 
mammalian Ras to complement yeast Ras mutants (Kataoka et al., 1985). The impact of the 
Ras signalling cascade is highlighted by the identification of hyperactivating Ras mutations as 
the first oncogenic alterations in cancers (reviewed in (Fernandez-Medarde and Santos, 2011)). 
However, despite the remarkable conservation of Ras proteins, the signalling networks and 
target proteins differ in yeast and mammalian cells.  
A yeast mutant allele of Ras2, containing a single amino acid substitution to create RAS2 G19V 
(Kataoka et al., 1984), has been shown to constitutively activate PKA signalling (Toda et al., 
1985). Consistently, comparable hyperactivating mutations in the N-terminus of a mammalian 
Ras isoform were described to increase its tumorigenic potential (Tabin et al., 1982). Given its 
growth-promoting role, we hypothesized that also the yeast Ras signalling pathway could play 
a role in promoting adaptation in cdc13-1 telomere dysfunction mutants. However, disrupting 
the signalling cascade by deletion of RAS2 did not rescue the cell viability of cdc13-1 mutants 
(Klermund et al., 2014). Moreover, expressing the hyperactive RAS2 G19V mutant did not 
compromise the rapamycin-mediated rescue of cell viability (data not shown). This is consistent 
with the notion that also other pathways like the Gpa2 network regulate the cellular cAMP 
levels which activate PKA (reviewed in (Zaman et al., 2008)). Indeed, high PKA activity after 
DNA damage has been reported to help maintain a stable checkpoint arrest by phosphorylating 
the APC co-factor, Cdc20. In addition to a damage-induced phosphorylation of Cdc20 by Chk1, 
the PKA-mediated Cdc20 modification decreases APC activity towards Pds1 and Clb2. 
However, degradation of both Pds1 and Clb2 are required for mitotic progression and thereby 
link PKA signalling and the DDC (Searle et al., 2004). A follow-up study revealed that PKA 
activity in response to damage is due to the checkpoint-mediated phosphorylation and re-
localization of the inhibitory regulatory subunit of PKA, Bcy1 (Searle et al., 2011). 
Furthermore, hyperactivation of Ras signalling by deletion of the GTPase-activating proteins 
(GAPs) Ira1 and Ira2 led to a recovery defect after transient incubation of cdc13-1 cells at the 
non-permissive temperature (Wood and Sanchez, 2010). In this study, it was suggested that 
PKA activity needs to be downregulated when the checkpoint is terminated in order to allow 
recovery. However, this cannot be achieved in cells lacking IRA1 and IRA2 since these mutants 
display continuous Ras activity leading to high cAMP levels that ultimately stimulate PKA 
activity (Wood and Sanchez, 2010). In contrast, we did not observe a recovery defect in cdc13-
1 cells expressing the hyperactive RAS2 G19V allele (data not shown). A more careful analysis 
Discussion 
90 
 
of the checkpoint status and cell cycle distribution of the RAS2 mutant expressing cdc13-1 cells 
will reveal an influence of the Ras/PKA signalling pathways on adaptation.  
 
3.4 Consequences of adaptation 
3.4.1 Adaptation, DNA damage repair and tolerance  
In the previous sections I have outlined mechanisms to influence the cellular decision to 
undergo adaptation. Together with the results obtained during our previous study (Klermund et 
al., 2014), the findings presented here have led to the hypothesis that TORC1 activity provides 
the growth-promoting signal which ultimately allows Cdc5 to override the DDC and drive 
adaptation (Figure 23). In addition, we set out to address the cellular consequences of 
adaptation. It seems obvious that continued cell division in the presence of unrepaired DNA 
damage could be lethal for the cell. Nevertheless, checkpoint adaptation has been observed in 
eukaryotic model organisms ranging from yeast to cancer cells. Possible explanations for the 
existence of such a potentially detrimental process have been outlined before (see section 3.1). 
 
Initial studies in yeast had already indicated the consequences of adaptation. In these 
experiments, preventing adaptation using the adaptation-deficient cdc5-ad allele decreased the 
frequency of translocations and chromosome loss induced by X-ray treatment (Galgoczy and 
Toczyski, 2001) suggesting adaptation as a major source of genome instability. On the other 
hand, this study also clearly pointed out that the ability to undergo adaptation was required to 
achieve maximal cell viability in response to irreparable DNA damage. In other words, 
adaptation allows cell to acquire damage resistance at the expense of genomic aberrations. 
Already in this initial study, the authors reasoned that there might be no beneficial effect of 
checkpoint adaptation on damage resistance (i.e. the survival after damage) in haploid cells. 
They proposed this was due to the fact that adaptation causes chromosomal rearrangements and 
loss of genetic information that cannot be tolerated by haploid cells. Rather, they used diploid 
yeast cells to study the consequences of adaption with respect to genome stability and therefore, 
mimic the genetic situation in diploid cells of higher eukaryotes.  
Employing a similar experimental set-up, we were able to recapitulate the observation that 
diploid yeast cells harbouring a homozygous deletion of the RAD52 gene were eventually able 
to recover from DNA damage induced either by CPT treatment or X-ray exposure (Figure 12 
and (Galgoczy and Toczyski, 2001)). Strikingly, preventing adaptation using the cdc5-ad allele 
lead to a decrease in colony formation after genotoxin exposure (either CPT or X-ray, Figure 
12 and (Galgoczy and Toczyski, 2001)). In the study that identified the cdc5-ad allele, 
approximately 90% of rad52cdc5-ad cells experiencing an irreparable nuclease-induced DSB 
remained arrested (Toczyski et al., 1997). In our experiments, we observed an approximate 
reduction of cell survival (i.e. adaptation) of 2.5-fold in the case of CPT and 5.5-fold for X-ray 
treatment (Figure 12) which is likely to be explained by differences in the damage source. In 
agreement with the hypothesis that it is indeed checkpoint adaptation that allows rad52 mutants 
to grow in this situation, we found that abolishment of a functional Rad53-mediated checkpoint 
abolished the effect of the cdc5-ad allele (Figure 12). Using the cdc13-1 mutation to elicit 
telomere dysfunction, we also observed a failure of cdc5-ad to rescue the viability in Rad53-
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compromised cells (Figure 9 and discussion above). Taken together with our observations in 
rad52 cells, this suggests that the effect of cdc5-ad is mediated by active Rad53 signalling.  
Having observed that adaptation allows rad52 mutants to form colonies after genotoxic 
treatment, we set out to investigate these adapted mutants. When we challenged them with a 
second genotoxic treatment, we observed that adapted HR-defective rad52 cells had a growth 
advantage compared to the parental strain that had never been challenged before (Figure 13). 
Strikingly, rad52 mutants that had adapted to CPT-induced DNA damage showed this 
improved growth in response to a broader variety of damaging agents, including the DSB-
inducing radiomimetic drug bleomycin and UV irradiation, which mainly induces bulky DNA 
adducts. This difference in the response to CPT and X-ray treatment could be due to different 
modes of actions, the cellular response in terms of repair pathway choices and treatment 
regimes. CPT is present continuously in our experiments and its toxicity requires cell 
proliferation as it causes the stabilization of the transient Top1-cc involving the Top1 protein 
and the DNA. Consequently, this stabilized complex leads to collisions with the replication and 
transcription machinery ultimately resulting in DSBs (reviewed in (Pommier et al., 2010)). On 
the other hand, X-rays are used as a single-dose damaging agent and due to their ionizing 
potential induce a variety of lesions affecting both bases and the DNA backbone. In order to 
address if this difference comes from the exposure duration, the delivery of X-rays in 
fractionated doses could be employed. During radiotherapy, fractionation of irradiation has 
been shown to promote the occurrence of radioresistant cancer cells (reviewed in (Kim et al., 
2015)). These findings suggest that indeed, the amount of damage delivered at a given time 
point largely affects the cell`s probability to survive. With adaptation being the cause for cell 
survival in the presence of damage, this again would argue that the decision to undergo 
adaptation is determined by the damage load, as it has been suggested for yeast (Lee et al., 
1998). However, also the second possibility to explain the difference between CPT and X-rays, 
which is the complexity of the induced damage, might influence adaptation. In support of this 
idea, we observe approximately 80% survival in rad52 cells after CPT treatment while less than 
10% of mutants are able to form colonies after X-ray exposure (Figure 12).  
 
An important open question concerns the repair pathways employed in rad52 mutants. We 
observe that rad52 cells still harbour DNA damage after forming a colony and further passages 
in unchallenged conditions (Figure 19). This observation could have different explanations: 
either repair has been successful and the observed damage is due to spontaneous and yet 
unrepaired damage or damage has only been repaired partially (and presumably faulty). It has 
been shown that although rad52 mutants undergo adaptation, they repair DNA damage, at least 
to an extent (Galgoczy and Toczyski, 2001). One explanation for this could be that cells attempt 
to lower the DNA damage load to allow adaptation. This idea would be consistent with the 
hypothesis that the decision to undergo adaptation is influenced by the amount of damage 
present in the cell. We were therefore interested in understanding possible repair pathways used 
in rad52 mutants to be able to form colonies after genotoxic treatment.   
Rad52 is a crucial mediator of homology-directed repair (HDR) as it is required to remove the 
ssDNA binding protein RPA from the newly generated ssDNA in the early steps of DSB site 
processing (Game and Mortimer, 1974; Sung, 1997a). RPA removal is the necessary step to 
facilitate binding of Rad51 resulting in the formation of a nucleoprotein filament that scans the 
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genome searching for a homologous repair template (reviewed in (Symington et al., 2014)). 
However, Rad52-independent repair pathways have been documented in yeast. For example, in 
the presence of extensive homology around the break site as found at the rDNA locus, Rad52 
is dispensable for HR-mediated repair (Ozenberger and Roeder, 1991). Still, yeast cells lacking 
RAD52 display an approximately 500-fold decrease in repair efficiency by homologous 
recombination (Bartsch et al., 2000) and therefore, deletion of RAD52 in yeast can be used as a 
tool to study a defect in HDR. This raises the question if there are other repair pathways used 
in rad52 mutants to allow colony formation after genotoxic treatment. NHEJ could represent a 
reasonable candidate to facilitate repair in the absence of HR. However, diploid cells actively 
suppress the error-prone NHEJ pathway through the a1-α2 heterodimer encoded by the 
heterozygous mating loci. Thus, HR is used as the preferred repair mechanism in all cell cycle 
stages due to the availability of a homologous repair template (Frank-Vaillant and Marcand, 
2001; Kegel et al., 2001; Valencia et al., 2001). Nevertheless, we wanted to address the 
possibility that diploid rad52 mutants aberrantly succeeded in NHEJ and therefore were able to 
repair CPT- and X-ray- induced damage. Deletion of DNL4, which encodes DNA Ligase IV 
required during NHEJ, did not affect cell survival after genotoxic treatment compared to NHEJ-
proficient rad52 mutants (Figure 18). Therefore, we conclude that HR-defective yeast cells do 
not form colonies upon genotoxic treatment after NHEJ-mediated repair based on three 
different observations: (1) The ligation step is essential for successful NHEJ, (2) Dnl4 is the 
only ligase implicated in this process so far and (3) NHEJ is suppressed in diploid yeast cells.  
In an attempt to gain further insight into the possible involvement of other repair pathways used 
in rad52 mutants, we analysed their transcriptional response to genotoxic treatment (both CPT 
and X-ray, Figure 20). Strikingly, we observed already a dramatic change on the transcriptional 
level in response to RAD52 deletion. Nevertheless, analysing significantly different expressed 
genes in rad52 mutants after genotoxic treatment compared to the parental rad52 strain revealed 
a common transcriptional pattern. Of note, this pattern was different from the changed 
expression behaviour induced by loss of Rad52 per se indicating that the pattern reflects the 
response to genotoxic treatment. Another interesting observation is the number of significantly 
different expressed genes in our comparisons (Figure 20). While we found 119 genes 
differentially expressed in CPT-treated cells, only 4 were found altered in X-ray treated rad52 
mutants. This could be due to the different natures of the genotoxic agents (as discussed above) 
or reflect different consequences on the cellular physiology, for example on the ploidy 
(discussed below). Break-induced replication (BIR), an error-prone and mutagenic repair 
pathway, has been reported to play an important role during adaptation (Galgoczy and 
Toczyski, 2001). This study utilized rad51 mutants to investigate the role of BIR during 
adaptation. In the absence of RAD51, cells can still perform BIR, however, this is not the case 
for loss of RAD52 (reviewed in (Symington et al., 2014)). Because we are employing rad52 
mutants, we hypothesize that BIR is not a relevant repair pathway to allow the formation of 
genotoxin resistant colonies in our experimental set-up. 
In addition to HR and classical NHEJ as the major DSB repair pathways, an alternative NHEJ 
mechanism using microhomology-mediated end joining (MMEJ) has been described. During 
alternative NHEJ, a DSB is repaired using 2 to 20 bp stretches of overlapping sequence 
(microhomology) and does not require classical repair proteins such as Rad52 or the Ku 
complex. This process is considered highly error-prone and therefore, could contribute to 
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genome instability due to its propensity to cause deletions and genomic rearrangements 
(reviewed in (Seol et al., 2017)). It is tempting to speculate that survival of rad52 mutants after 
genotoxic treatment could be mediated by this alternative repair mechanism and future 
experimental work will focus on a potential role of alternative NHEJ using microhomologies 
in this context.  
It could also be possible for rad52 mutants to somehow re-establish HR. Plasmid-based assays 
to monitor a cell’s ability to use HR to repair genotoxin-induced damage to the plasmid are 
commonly used to address this question. However, depending on the experimental set-up, these 
assays differ in the exact HR pathway and genetic requirements necessary to repair the reporter 
construct and therefore appeared not suitable in our situation. A second possibility allowing 
genotoxin-treated rad52 cells to perform HDR could be given by their diploidy which is still 
manifested by the heterozygous mating locus although cells might have experienced extensive 
chromosome loss. Therefore, a possible explanation for rad52 survival in the presence of 
genotoxins could be the use or upregulation of recombination proteins normally used during 
meiosis, for example the meiosis-specific recombinase Dcm1 (Bishop et al., 1992). However, 
we did not observe the differential expression of such meiosis-specific factors after genotoxic 
treatment in our transcriptional analysis. Alternatively, one could speculate that diploid rad52 
mutants could decrease the damage load by meiotic division and thus, display a haploid 
karyotype observed in our analysis. We addressed this possibility by deleting SPO11, which 
encodes a meiosis-specific endonuclease that is required to induce DSBs in order to initiate 
meiotic recombination. Therefore, spo11 mutants fail to produce viable spores during meiosis 
(Bhuiyan and Schmekel, 2004), reviewed in (Lam and Keeney, 2014)). The absence of SPO11 
did not change the survival rate of rad52 mutants in the presence of CPT suggesting that 
chromosome loss as a mean to decrease the amount of DNA damage is not the case for the 
observed growth of rad52 mutants after genotoxic treatment. Moreover, loss of RAD52 as a 
central factor for recombination renders cells meiosis-defective (reviewed in (Symington, 
2002)) providing additional support for our conclusion. Furthermore, one would expect that 
regular meiosis yields a euploid karyotype, yet we consistently observe aneuploid rad52 
mutants monosomic for chromosome III suggesting that our observations are not due to meiosis.  
As outlined briefly in section 1.4, the localization of damaged DNA within the nuclear space 
appears as an important determinant of repair pathways and outcomes. Damage sites that are 
more challenging to repair or irreparable relocalize to nuclear pores or the inner nuclear 
membrane. The differential localization seems to depend on the cell cycle stage since 
relocalization to the inner nuclear membrane was observed during G2 and S phase while 
association of damaged DNA with nuclear pore complexes was found throughout the cell cycle. 
The mechanisms facilitating the relocalization steps are not yet fully understood but 
SUMOylation seems to play an important role (reviewed in (Freudenreich and Su, 2016)). In 
addition, also the DDC factors Mec1 and Rad9 as well as recombination proteins seem to be 
involved in relocalization of damaged DNA, possibly due to their role in facilitating mobility 
of a DSB (see section 1.4.2.1, (Dion et al., 2012)). The insights provided so far suggest that 
relocalization of damaged DNA could allow alternative repair mechanisms. It has been 
hypothesized that this occurs to prevent cell death and gross chromosomal rearrangements 
(GCR) although alternative, less preferred repair pathways are usually associated with the risk 
of mutations (reviewed in (Freudenreich and Su, 2016)). Consistently, artificial tethering of a 
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damaged locus, in this case a subtelomeric DSB, to the nuclear pores was shown to increase 
BIR (Chung et al., 2015). BIR is proposed to increase genome instability by producing GCRs 
(reviewed in (Anand et al., 2013)). However, the increase in BIR in such a scenario seemed 
dependent on Rad52 as well as other factors previously linked to BIR ((Chung et al., 2015), 
reviewed in (Anand et al., 2013)). Therefore, it seems unlikely that the irreparable damage 
created in our experiments in rad52 cells trigger such ectopic BIR events. Importantly, Rad52 
itself does not seem to be required for the relocalization of damaged DNA to the nuclear 
periphery per se, at least based on observations using an endonuclease-induced DSB (Horigome 
et al., 2014). The positioning of damaged DNA within the nuclear space might play an 
important role in understanding possible repair mechanisms in rad52 cells leading to genotoxin 
resistance and future studies will try to gain insights into this. 
 
3.4.2 Rapamycin and its influence on DNA repair 
Our findings demonstrate a role for rapamycin in preventing adaptation (this thesis and 
(Klermund et al., 2014)). Importantly, in our experiments using the cdc13-1 mutant to elicit 
telomere dysfunction that results in checkpoint activation, we could confirm that rapamycin did 
not affect recovery from the checkpoint as rapamycin-treated cdc13-1 mutants were fully viable 
and proficient in colony formation after shifting them back to the permissive temperature 
(Figure 8). Likewise, recovery-defective mutants did not interfere with the rapamycin-mediated 
rescue of cdc13-1 cells (J. Klermund, personal communication) suggesting that rapamycin did 
not affect repair in our experiments. In general, studies in human cells have demonstrated a 
negative effect of rapamycin on HR: rapamycin treatment caused the transcriptional 
suppression of SUV39H1 (Mo et al., 2016), a chromatin compaction factor with an emerging 
role during the DNA damage response and HR-mediated repair (Ayrapetov et al., 2014). In 
addition, rapamycin impairs BRCA1 and RAD51 recruitment and thereby negatively effects 
HR efficiency (Chen et al., 2011a). 
It has been established that rapamycin treatment leads to the induction of autophagy and this 
anabolic pathway is emerging as an important player in the DNA damage response as well as 
in DSB repair pathway choice. In yeast, autophagy is induced by DNA damage to facilitate cell 
cycle arrest (Dotiwala et al., 2013; Eapen and Haber, 2013), and a specific autophagic 
subpathway termed genotoxin-induced targeted autophagy (GTA) depending on checkpoint 
proteins has been identified recently (Eapen et al., 2017). Also in mammalian cells, DNA 
damage has been shown to cause autophagy induction, however, this has been described to 
function both as a pro- and anti-survival signal. The consequences of autophagy induction seem 
to be dependent on p53 signalling which has a bi-functional role as an inducer and inhibitor of 
autophagy in a damage situation (reviewed in (Rodriguez-Rocha et al., 2011)). Moreover, a 
recent report has suggested autophagy as a protective mechanism for cells against the adverse 
effects of aneuploidy (Ariyoshi et al., 2016). In summary, rapamycin can modulate damage 
repair at least via 3 different mechanisms: via the induction of autophagy downstream of TOR 
signalling and in a transcription-dependent manner as in the case of SUV39H1. Moreover, the 
fact that proteins involved in the DNA damage checkpoint such as the MRX complex are crucial 
factors for DNA repair already indicates cross-talk between these two fundamental processes. 
Thus, it is not surprising that checkpoint factors determine repair efficiency and outcomes 
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(Haghnazari and Heyer, 2004). Therefore, as a third possibility, rapamycin could modulate 
DNA repair also indirectly by maintenance of the checkpoint to prevent adaptation. 
 
Rapamycin has been identified as a specific inhibitor of TORC1 signalling by forming a 
complex with the cellular FKBP12 protein and eventually, forming a ternary complex 
consisting of rapamycin-FKBP12-TORC1 (reviewed in (Loewith and Hall, 2011)). The binding 
interface of the rapamycin-FKBP12 complex is adjacent to the TOR kinase domain, however, 
it remains unclear how TOR signalling is inhibited mechanistically in the presence of 
rapamycin. It seems unlikely that rapamycin directly inhibits TOR kinase activity since 
rapamycin treatment arrests cells in G1 while abolishing Tor2 kinase activity (which 
participates in both TORC1 and 2) by mutation is lethal (reviewed in (Raught et al., 2001)). 
The observation that rapamycin requires FKBP12 to have an inhibitory effect while loss of 
FPR1, which encodes the yeast FKBP12, does not have an obvious phenotype, led to a new 
idea of drug activity where the drug requires a cellular component and only then can exert its 
function (reviewed in (Loewith and Hall, 2011)). Despite the incompletely characterized mode 
of action, rapamycin is considered a specific inhibitor for TORC1 in all model organisms. This 
has been recently confirmed by the finding that Avo3, a subunit unique to TORC2, masks the 
binding site of the rapamycin-FKBP12 complex in Tor2 when it is engaged in TORC2 (Gaubitz 
et al., 2015). In addition to a link between the DNA damage response and TORC1, also TORC2 
is involved in ensuring genome stability. This mainly has been attributed to TORC2`s role in 
actin cytoskeleton organization (Shimada et al., 2013).  
 
3.4.3 A connection between adaptation and aneuploidy 
It has been noted a long time ago that rad52 mutants lose chromosomes at a higher frequency 
than wild-type cells and these chromosome loss events were found exacerbated after DNA 
damage (Mortimer et al., 1981). In addition, adaptation was shown to cause and precede 
different kinds of genetic aberrations including translocations and chromosome loss (Galgoczy 
and Toczyski, 2001). Although the majority of human cancer cells undergoing adaptation were 
found to die, surviving adapted cells could pass on damaged genetic material thereby 
contributing to cancerogenesis. This hypothesis is supported by experiments using plant cells: 
in this set-up, adapted cells entered mitosis harbouring broken or acentric chromosomes as well 
as chromosome bridges (Carballo et al., 2006). Similarly, a connection between adaptation in 
human cancer cells and the incidence of micronuclei has been described (Chang et al., 1999). 
Micronuclei frequently contain damaged or broken DNA and are associated with errors during 
mitosis, aneuploidy and genome instability (reviewed in (Kalsbeek and Golsteyn, 2017)). 
Indeed, DNA content analysis of rad52 mutants that formed a colony after genotoxic treatment 
revealed chromosome losses to varying degrees (Figure 14 and 15) suggesting that adaptation 
was accompanied by chromosome loss events. However, based on a flow cytometry read-out 
we could not determine the exact extent of chromosome loss and if the loss events affected 
whole chromosomes. Therefore, we used whole genome sequencing to assess the karyotype of 
adapted rad52 mutants. This in-depth analysis revealed extensive whole chromosome loss 
events resulting in a nearly haploid DNA content after CPT treatment and a mix of different 
ploidies in response to X-ray exposure (Figure 15). The different karyotypes characterized by 
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more or less pronounced loss of chromosomes in response to X-rays seemed to be unstable as 
rad52 mutants continued to lose genetic material in subsequent passages (Figure 16). This could 
be due to subsequent adaptation events, however, we cannot conclude this from our 
experiments. Interestingly, we observed a preferred maintenance of chromosome III (Figure 
15). This chromosome is the second smallest in S. cerevisiae with 184 open reading frames 
(covering 75% of the sequence). A striking feature of chromosome III is that it harbours the 
mating type locus. As the strains used in our studies have been created by mating isogenic 
haploid strains of mating type a and α, the resulting diploid yeast cells are homozygous except 
for the mating locus. Heterozygosity at the mating type locus has long been known to influence 
sensitivity to DNA damage (Heude and Fabre, 1993). It has been reported that several genes 
under the control of the mating type locus could suppress the sensitivity of recombination 
mutants including cells with RAD52 truncations to DNA damaging agents. Interestingly, loss 
of the prolyl isomerase Fpr3 rescued the CPT sensitivity of Rad52 truncation mutants, however, 
the FPR3 gene itself did not appear to be regulated directly by the mating type locus (Valencia-
Burton et al., 2006). Fpr3 belongs to a family of prolyl isomerases that also includes Fpr1, the 
yeast rapamycin-binding protein required for the rapamycin-mediated inhibition of TORC1 
(reviewed in (Loewith and Hall, 2011)). Thus, Fpr3 was described as a novel rapamycin-
binding protein localizing to the nucleolus. However, the authors proposed that despite the 
formation of a rapamycin-Fpr3 complex, this did not cause a growth defect upon rapamycin 
treatment due to TORC1 inhibition because of the limited accessibility of the cytoplasmic TOR 
complex by the nucleolar Fpr3-rapamycin complex (Benton et al., 1994). Taking these 
observations into account, TOR signalling is presumably not involved in this phenomenon but 
rather TOR-independent functions of Fpr3. 
A study interested in the effect of aneuploidy on heterochromatin silencing found that especially 
chromosome III and X were gained in randomly created aneuploid yeast strains with a silencing 
defect (Mulla et al., 2017). The authors further commented that gain of chromosome III alone 
seem insufficient to cause a silencing defect and argued that an abnormal silencing pattern 
might not necessarily be a consequence of aneuploidy but rather, aberrant copy numbers of a 
set of chromosomes contribute to this phenotype. 
Studies of aneuploidy in yeast have often used sets of disomic yeast strains, i.e. cells that only 
harbour one additional copy of a specific chromosome. Strikingly, strains disomic for 
chromosome III or VI are usually not included in these studies. In the case of chromosome VI, 
this is due to the detrimental effects caused by the overexpression of some genes, including the 
TUB2 gene. Simultaneous overexpression of TUB1 allows the generation of cells disomic for 
chromosome VI. In the case of chromosome III, the presence of the mating locus has been 
suggested as an inhibitory factor for the creation of chromosome III disomic strains. However, 
disomic strains are usually obtained due to the stochastic and spontaneous failure of 
chromosome segregation. In contrast, another method based on the specific inhibition of the 
segregation of a target chromosome yielded yeast cells disomic for chromosome III and VI 
(Anders et al., 2009).  
A beneficial effect of a “selectively aneuploid” karyotype, in this case a monosomy for 
chromosome VIII, has been reported in the context of telomerase insufficiency in yeast (Millet 
et al., 2015). In this case, growth of haploid yeast cells at high temperature resulted in telomere 
shortening caused by limited telomerase activity. Yeast survivors emerged that exhibited a near-
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diploid karyotype with duplicated chromosome copy number for all chromosomes except 
chromosome VIII. Further analysis revealed that chromosome VIII encodes the TORC1 subunit 
Kog1. The authors suggested that by decreasing KOG1 expression, TOR complex 1 assembly 
was hampered leading to decreased activity. Ultimately, this resulted in a decrease in ribosome 
biogenesis and shifted the capacity of the cellular translation machinery towards less abundant 
proteins including telomerase holoenzyme components (Millet et al., 2015). These findings 
highlight that modulation of the copy number of a single chromosome can have fundamental 
impact on cell physiology and allow an adaptation to a changing environment.   
In summary, the reason why initially diploid rad52 cells that experience DNA damage and 
chromosome loss leading to aneuploidy have a propensity to maintain chromosome III in two 
copies remains elusive. Further, future studies will have to address if this selective retention of 
chromosome III is related to the influence of the mating type locus or caused by other unknown 
factors.  
 
Independently of the mating locus influence, the ploidy status itself has been linked to damage 
resistance and the stability of the cellular genome. For example, a study using tetraploid yeast 
cells (increased ploidy but not aneuploid) identified genes that caused “ploidy-specific 
lethality” and further analysis of these genes revealed their involvement in ensuring genome 
stability (Storchova et al., 2006). In agreement with the idea that increased ploidy is a challenge 
for genome stability, tetraploidization in human cells appears to promote chromosomal 
instability and render the cells more tolerant to mitotic errors and genotoxic treatment 
(Kuznetsova et al., 2015). However, studies in yeast also suggested that an increased base 
ploidy can partially buffer adverse aneuploidy-associated effects, i.e. a tetraploid cell is more 
tolerant to an additional chromosome than a diploid cell (Beach et al., 2017).  
In our experiments, we observed a growth advantage of haploid cells compared to diploid cells 
in response to both CPT and X-ray exposure (Figure 16). A likely explanation for this is the 
ability of haploid cells to repair damage via NHEJ, which is prevented in diploid cells (as 
discussed above). Therefore, the improved survival of haploid cells should be abolished in 
rad52dnl4 double mutants compromised in both NHEJ and HR pathways. However, these 
findings seem to be in contrast to previous findings (for example in (Galgoczy and Toczyski, 
2001)) which show that diploid yeast cells have an increased tolerance to damage compared to 
haploids. These different findings could be due to the time frame and set-up of the experiments. 
While the previous study quantified colony formation after genotoxic treatment in a plating 
assay (Galgoczy and Toczyski, 2001), we used a more qualitative approach in our spotting 
assay (Figure 16). Therefore, it is possible that after longer incubation or in a plating assay to 
quantify colony numbers, we would also eventually observe the expected growth advantage in 
diploid rad52 mutants. While adapted diploid cells should be able to form colonies, adapted 
haploid rad52 mutants would probably fail to do so due to lethal rearrangements or 
chromosome loss, as reasoned by previous studies. 
It could be possible that near-haploid rad52 mutants observed after CPT treatment switch 
between a near-haploid and diploid state by mating with each other and thereby are more 
resistant to genotoxic treatment, as expected for a diploid cell. We speculate that such a switch 
between haploid and diploid phase is not the cause for our observations since neither our flow 
cytometry-based DNA content analysis nor the sequencing-based karyotyping indicated such a 
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behaviour. However, when we tested the ability of adapted and aneuploid rad52 mutants 
created by CPT treatment, we observed a bipolar mating pattern (J. Klermund, personal 
communication). To rule out the possibility that rad52 mutants in our experimental set-up 
transit from a nearly-haploid state to a diploid state by mating, we will employ sterile rad52 
mutants that are unable to mate with each other. In support of our hypothesis that mating most 
likely does not occur, one would expect that the diploids resulting from mating between near-
haploid rad52 mutants would have to undergo meiosis to exhibit the (near-) haploid karyotype 
that we observe in our analysis (flow cytometry and DNA sequencing). However, we could 
already demonstrate that the decreased chromosome number in rad52 mutants is most likely 
not due to meiosis (as discussed above). 
 
3.4.4 The relationship between adaptation, aneuploidy and genome instability 
Studies in yeast cells were crucial to get insights into the connection between adaptation and 
genome instability. Adaptation has been identified as the causative event preceding multiple 
forms of genomic rearrangements that compromised genomic stability (Galgoczy and Toczyski, 
2001). At the same time, aneuploidy has been described as a driver for genome instability 
including increased mutation rates, sensitivity to genotoxic treatment and further instability 
affecting whole chromosomes (Sheltzer et al., 2011). However, the relationship between 
adaptation, aneuploidy and genome instability has not been fully understood. Using HR-
defective rad52 yeast cells, we could show that adaptation is linked to the development of an 
aneuploid karyotype as the vast majority of adaptation-proficient rad52 mutants that was able 
to form a colony after genotoxic treatment showed chromosome loss events to varying degrees. 
When adaptation is prevented, spontaneous and X-ray-induced chromosome loss rates in rad52 
cells are decreased (Galgoczy and Toczyski, 2001) and also the number of colonies formed by 
rad52 mutants after genotoxic treatment is diminished (Figure 12). Nevertheless, all resistant 
rad52cdc5-ad mutants that we analysed showed the same characteristics as adaptation- 
proficient cells. The ability of these cells to adapt despite the cdc5-ad allele could be due to 
other mechanisms influencing adaptation or an incomplete prevention of adaptation by the 
cdc5-ad allele. The idea that also other factors could be regulating adaptation in rad52 cells is 
supported by the finding that rapamycin and the cdc5-ad allele are partially synergistic 
(significant synergy in response to CPT treatment but not X-ray exposure, Figure 22). Vice 
versa, these findings also indicate that rapamycin has a checkpoint-independent function. This 
is in agreement with our studies on the regulation of adaptation using the cdc13-1 model system 
which revealed a checkpoint-dependency for the cdc5-ad allele (Figure 9) thereby placing 
Cdc5-ad and Rad53 in the same genetic pathway. Indeed, while rapamycin was able to 
phenocopy the effect of the cdc5-ad allele in preventing the survival of rad52 mutants after 
genotoxic treatment, this was independent of a Rad53-mediated checkpoint. This observation 
raised the possibility that rapamycin could prevent resistant and aneuploid rad52 mutants by a 
mechanism other than preventing checkpoint adaptation. To address this concern, we performed 
a microcolony assay, a classical experimental set-up to study adaptation. Indeed, rapamycin 
was able to maintain the checkpoint-induced cell cycle arrest in rad52 cells in the presence of 
CPT (Figure 22). This is consistent with our previous findings using cdc13-1 mutants to 
investigate mechanisms involved in the regulation of adaptation and demonstrates the 
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involvement of the nutrient signalling TORC1 pathway in preserving genome stability. 
Interestingly, aneuploid cells, both in yeast and mammalians, are sensitive to compounds 
inducing metabolic stress, such as rapamycin (Tang et al., 2011; Torres et al., 2007). This is 
also the case in aneuploid rad52 mutants after X-ray exposure as rapamycin significantly 
increases the doubling time even in nutrient-rich conditions (O. Vydzhak, personal 
communication). As aneuploid cells exhibit elevated levels of proteotoxic stress due to protein 
imbalances (see 1.6.1) (Donnelly et al., 2014; Oromendia et al., 2012; Tang et al., 2011; Torres 
et al., 2007), these cells have an increased energy demand thereby likely explaining their 
hypersensitivity to starvation-mimetic compounds. As rapamycin treatment leads to the 
induction of autophagy and since autophagy is up-regulated in aneuploid cells (Ariyoshi et al., 
2016; Stingele et al., 2012), rapamycin could also be toxic to aneuploid cells by further 
increasing autophagy. It has become clear that sustained autophagy is linked to cell death, 
however, the causal relationship is not fully understood (reviewed in (Kroemer and Levine, 
2008)). We suspect that the checkpoint-independent effect of rapamycin in decreasing the 
survival of rad52 mutants after genotoxic treatment could be due to the induction of autophagy. 
However, we have not yet addressed this possibility in our experiments. A recent study has 
suggested that aneuploidy-induced imbalances in protein homeostasis that lead to proteotoxic 
stress, cause the upregulation of master regulators of autophagic and lysosomal degradation 
(Santaguida et al., 2015). Consistently, aneuploid cells are not only sensitive to inhibitors of 
autophagy but also to compounds that interfere with lysosomal function (Tang et al., 2011). It 
is tempting to speculate that the aneuploidy-associated increase of degradation products in the 
vacuole, which is the yeast equivalent of mammalian lysosomes, could trigger the activity of 
TORC1 via the EGO complex, which responds to intravacuolar nutrients. Thereby, aneuploidy 
could ultimately facilitate further adaptation by increasing TORC1 activity. However, this 
hypothesis lacks experimental proof and requires validation. Such a scenario where TORC1 is 
hyperactivated is reminiscent of the situation in many cancers that show aberrant high mTOR 
signalling accompanied by a failure to downregulate this activity in response to DNA damage 
((Zhou et al., 2017), reviewed in (Xie et al., 2016)).  
Figure 26. A model for the dual function of rapamycin to prevent adaptation and resistance associated
with aneuploidy. Rapamycin prevents adaptation directly by inhibiting TORC1 and possibly by 
regulating Cdc5 levels (described as pathway 1). In addition, rapamycin sensitizes aneuploid cells that
are resistant to genotoxic treatment (pathway 2).  
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In addition to the previously reported rapamycin sensitivity of aneuploid cells (see above), we 
could also show that aneuploid rad52 cells exhibited proteotoxic stress. Transcriptome analysis 
of cells that were able to form colonies after CPT treatment and had acquired an aneuploid 
karyotype showed an upregulation of transcripts that encode for factors involved in protein 
folding and refolding (Figure 20). This suggests that also aneuploid rad52 mutants after 
genotoxic treatment suffer from proteotoxic stress, a well-established and characteristic trait of 
aneuploidy (reviewed in (Oromendia and Amon, 2014)). 
Taken together, we speculate that in rad52 mutants treated with genotoxins, rapamycin could 
have a dual function: in agreement with our previous results, rapamycin can prevent adaptation 
and thereby decrease the number of damage-resistant and aneuploid rad52 mutants. However, 
in case these cells adapt, rapamycin can be used as a sensitizing agent in the aftermath of 
adaptation (Figure 26). The role of autophagy induction for the prevention of adaptation and 
the sensitization of aneuploid rad52 mutants will be addressed in future studies. We envision 
that the checkpoint-independent effect of rapamycin, indicated by its ability to prevent the 
Figure 27. Repair and adaptation as fundamentally different consequences of DNA damage checkpoint 
activation. In the absence of repair, adaptation is the only possible route to attempt cell survival. 
However, also adaptation can have two possible outcomes: it can lead to further adaptation events in 
subsequent cell cycles, non-lethal aneuploidy and possibly other genome instabilities and resistance to 
genotoxic treatment. Alternatively, adaptation can result in cell death due to multiple reasons including 
loss of essential genetic information caused by lethal aneuploidy. 
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survival of rad52 cells after genotoxic treatment in a checkpoint-compromised genetic 
background (Figure 12, 22 and 26), is due to its role in autophagy induction and sensitization 
of aneuploid cells.  
Based on our findings and previous studies conducted by many others, we hypothesize that in 
the absence of faithful and error-free DNA damage repair, cells undergo adaptation as a means 
to maximize cell viability. In order to allow adaptation or as a result, cells experience whole 
chromosome loss events and acquire an aneuploid karyotype. These genetic alterations allow 
them to survive in the presence of further genotoxic agents, possibly acting as a trailblazer for 
further rounds of adaptation (Figure 27). An indication that genome instability can also act as 
a driver for adaptation is given by the observation that a fusion oncogene, resulting from a 
frequently found translocation in a subtype of rhabdomyosarcomas, drives the transcription of 
crucial adaptation-promoting factors including PLK1 (Kikuchi et al., 2014). However, our 
results cannot establish the exact causal relationships between adaptation, aneuploidy and 
genome instability. One possibility would be that adaptation causes genome instability by 
promoting aneuploidy (scenario A, Figure 28) or in conjunction with an aberrant karyotype 
(scenario B, Figure 28). However, it is also reasonable that aneuploidy, facilitated by the 
inherently unstable karyotype of repair-defective mutants, allows adaptation. In the second 
scenario, adaptation could be the initial cause for the inherently unstable and altered karyotype 
(scenario C, Figure 28). In order to get insights into the interconnections between adaptation 
and aneuploidy, we overexpressed Cdc5 in repair-proficient wild type yeast to investigate if 
accelerating adaptation could lead to aneuploidy (Figure 17). Overexpression of CDC5 has been 
shown to override the checkpoint and accelerate the adaptation process (Donnianni et al., 2010; 
Pellicioli et al., 2001; Vidanes et al., 2010), however, we could not observe indications for 
aneuploidy in response to X-ray treatment in this experiment. Importantly, in this experimental 
set-up, adaptation is not the only possibility for cell survival as cells were repair-proficient. 
Another caveat is the time required to develop an aneuploid karyotype. It could also be possible 
that multiple successive adaptation events are required to become aneuploid. We cannot 
exclude this possibility based on our experimental data as we usually passage rad52 mutants 
that had formed a colony after genotoxic treatment once more in the absence of exogenous 
damage before subsequent analysis (to obtain more cells). Therefore, it is possible that further 
adaptation events occur as cells proliferate and only these lead to aneuploidy. Nevertheless, the 
results described in Figure 17 might suggest that accelerated adaptation alone, caused by 
increased levels of Cdc5, is not sufficient to induce aneuploidy. In contrast, a recent report 
revealed that PLK1 overexpression in combination with irradiation was sufficient to promote 
tumorigenesis accompanied by aneuploidy in mice. The authors suggested that this was due to 
decreased checkpoint signalling resulting from PLK1-mediated transcriptional repression of 
DDC factors and reduced phosphorylation of critical DDC players (Li et al., 2017). These 
observations suggest a causative role for adaptation in the development of an aneuploid 
karyotype. Further experimental work will be required to improve our understanding of this 
relationship.  
Genome instability has already been recognized as an enabling characteristic of cancer cells 
(reviewed in (Hanahan and Weinberg, 2011)) and also adaptation and aneuploidy are emerging 
players in cancerogenesis. Interestingly, p53, together with ATM, has been proposed as an 
aneuploidy-counteracting factor in human cells and by doing so, limit aneuploidy-induced 
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tumorigenesis (Li et al., 2010; Thompson and Compton, 2010). At the same time, p53 is listed 
as one of the most common mutations across all cancers at this point (Kandoth et al., 2013) and 
ATM belongs to the group of genes that are most likely to carry a cancer-driving mutation 
(Greenman et al., 2007). These findings indicate that cells have not only evolved elaborate 
pathways to counteract aneuploidy, they also do so by using the same mechanisms that deal 
with DNA damage which highlights the detrimental effects of aneuploidy on genome stability. 
 
3.4.5 Adaptation, aneuploidy and drug resistance 
Even though the initial causes and ultimate consequences of adaptation, aneuploidy and genome 
instability are not yet fully established, their importance especially with regards to cancer has 
become clear. Based on our observations, we hypothesize that adaptation is the cause for the 
acquisition of genotoxin resistance in rad52 mutants and we speculate that the resistance to 
damage is accompanied by aneuploidy (Figure 27). Although we observe that colonies formed 
by adapted rad52 cells in response to genotoxic treatment are initially metabolically 
compromised as evident from the accumulation of Phloxine B (Minois et al., 2005) and even 
contain a large fraction of dead cells (Figure 12 and 16), cellular fitness seems to improve over 
time with successive passaging in the absence of exogenous damage. This could be explained 
by our observation that karyotypically unstable cells that show a DNA content intermediate 
between haploid and diploid (after X-ray treatment) continuously lose chromosomes until they 
reach a seemingly more advantageous near-haploid DNA content (Figure 16). Moreover, this 
could also be supported by the idea that aneuploid cells have the ability to adjust faster to a 
changing environment and thus have a growth advantage although they exhibit various growth 
defects during cultivation (reviewed in (Giam and Rancati, 2015)). These growth defects have 
been largely attributed to the presence of unrepaired DNA damage (Blank et al., 2015; Passerini 
et al., 2016). Consistently, we could also show that aneuploid rad52 mutants displayed chronic 
DNA damage as evident from phosphorylated Rad53 and an upregulation or Rnr3 (Figure 19). 
Together with the finding that the same cells are still checkpoint-competent (Figure 19) and the 
observation that colony formation after genotoxic treatment is prevented by the adaptation-
defective cdc5-ad allele (Figure 12) we suggest that cell survival after CPT or X-ray exposure 
Figure 28. Models for the relationships between adaptation, aneuploidy and genome instability. Panel 
A describes adaptation as a cause for genome instability thereby promoting aneuploidy. Panel B depicts 
a scenario in which adaptation and aneuploidy together give rise to genome instability. Alternatively, 
genome instability could lead to aneuploidy and further facilitate adaptation. Aneuploidy could thereby 
also cause the initial genome instability (depicted in panel C). 
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of rad52 mutants is indeed facilitated by adaptation (Figure 27). In agreement, we could provide 
direct evidence that rapamycin treatment prevents adaptation in rad52 mutants treated with 
CPT (Figure 22), consistent with our report using telomere dysfunctional mutants (Klermund 
et al., 2014). In addition, we observed a downregulation of Mcm5, a helicase involved in DNA 
replication, in our transcriptional analysis of aneuploid rad52 mutants emerging from CPT 
treatment. This finding is consistent with a previous report in human cells demonstrating that a 
single supernumerous chromosome was sufficient to trigger genome instability by decreasing 
the levels of MCM helicase complex members on the transcriptional level (Passerini et al., 
2016). Why components of the DNA replication machinery such as the MCM complex are 
consistently found to be transcriptionally downregulated in aneuploid cells is not yet fully 
understood. 
Adaptation has been proposed as a cellular response to persistent DNA damage in an attempt 
to maximize survival and thereby promotes tolerance (or resistance) to genotoxins. Based on 
this and our observations, we hypothesize that the emergence of aneuploid rad52 mutants that 
are genotoxin-resistant is a consequence of adaptation (Figure 12 and 27). Strikingly, rad52 
mutants that had adapted and were thus able to form a colony in the presence of CPT, 
subsequently displayed a growth advantage in the presence of various other genotoxic agents 
(Figure 13). This suggests that adaptation had caused the acquisition of resistance. 
Alternatively, it could be possible that rad52 cells are less sensitive to genotoxic treatment as 
they had become aneuploid and therefore show aneuploidy-associated growth defects (as 
discussed above). However, slowing down the proliferation rate by incubation at lower 
temperatures did not cause an increased resistance to CPT (Figure 21). This indicates that a 
growth defect due to aneuploidy is most likely not the cause for the observed resistance to CPT 
and further suggests that aneuploidy could be a consequence of adaptation and not the cause in 
rad52 cells.  
Our transcriptome analysis of adapted and aneuploid rad52 mutants (Figure 20, corrected for 
the varying chromosome copy numbers based on DNA sequencing in Figure 15) revealed an 
upregulation of factors involved in protein homeostasis. This is consistent with previous reports 
focusing on the physiological consequences of aneuploidy in both yeast and mammalian cells 
(see 1.6.1). Our results suggest that the development of an aneuploid karyotype during the 
acquisition of genotoxin resistance in repair-defective cells could provide helpful insights into 
de-regulated pathways that can be exploited to prevent such resistance. Investigating the 
sensitivity of aneuploid rad52 mutants arising after genotoxic treatment as possible targeting 
strategies will be the subject of future studies. Importantly, preventing adaptation (in this case 
genetically with the cdc5-ad allele) in repair-proficient cells did not cause a hypersensitivity to 
X-ray treatment (Figure 17). This observation indicates that inhibition of adaptation can be 
specifically used to target repair-defective cells by inducing DNA damage. With regard to a 
pathophysiological situation, this finding suggests that repair-defective cells forming a tumour 
would be hypersensitive to genotoxic treatment when adaptation is prevented 
pharmacologically, however, repair-proficient surrounding tissue would not be affected (Figure 
27, left side versus right side). 
In cancer therapy, the acquisition of resistance is a major obstacle to curative treatment. In fact, 
radiotherapy constitutes one of the major approaches to treat various types of cancer and 
radioresistance leading to tumour relapse is an emerging complication. The repair status of a 
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cell (e.g. BRCA-deficiency) and the tumour microenvironment (e.g. tumour hypoxia) have 
proven to be two critical determinants of radioresistance (reviewed in (Huber et al., 2013)). 
Inhibitors of mTOR as well as compounds targeting the upstream PI3K signalling pathway have 
been shown to sensitize radioresistant cancer cells (Gottschalk et al., 2005; Miyasaka et al., 
2015). In light of the results described here, we speculate that this could at least partially be due 
to the prevention of adaptation in response to decreased TOR signalling as well as a growth-
inhibitory effect of low TOR activity on adapted and possibly aneuploid cells. Thus, future 
experiments will aim at investigating the TORC1 activity status in rad52 cells after genotoxic 
treatment.  
A prominent example of chemoresistance is given by the resistance of HR-defective BRCA-
deficient cancer cells to PARP inhibitors. As described in section 1.4.2.1.2, PARP inhibition 
concomitant to a DNA damaging agent channels repair in BRCA-deficient cells towards error-
prone repair pathways which drive cells into cell cycle arrest or apoptosis (reviewed in (Ohmoto 
and Yachida, 2017)). However, by forcing cells to use error-prone repair pathways, the 
acquisition of secondary mutations that restore BRCA2 function and thus the ability to perform 
HDR has been shown to be a major cause of resistance in this scenario (Edwards et al., 2008; 
Sakai et al., 2008). Mammalian BRCA2 plays a mediator function during homologous 
recombination and this role is taken over by Rad52 in budding yeast (reviewed in (Liu and 
Heyer, 2011)). Therefore, our experiments performed in rad52 cells to understand the 
consequences of adaptation could provide useful insights for the acquisition of resistance in 
BRCA2-deficient cancers. By investigating which repair pathways are utilized in yeast rad52 
mutants to form colonies after genotoxic treatment, we could speculate which pathways 
facilitate repair in BRCA2-deficient cancers treated with PARP inhibitors. Moreover, the 
regulation of adaptation by modulating TOR activity as well as the inhibitory effect of 
rapamycin could be useful tools to prevent resistance in this cancer model. Importantly, 
resistance to chemotherapeutic agents has not only been observed in response to 
BRCA2-deficiency but also in cancers lacking BRCA1. A recent report showed that HR can be 
restored leading to resistance to PARP inhibition in these cells by concomitant loss of REV7 
(Xu et al., 2015), a subunit of the translesion polymerase complex zeta (reviewed in (Gan et al., 
2008)). Already some time ago, mTOR signalling was found induced in response to ionizing 
radiation exposure (Sunavala-Dossabhoy et al., 2004) indicating that mTOR activity functions 
as a pro-survival signal. Consistently, several studies could show that rapamycin had a 
radiosensitizing effects in various cancer models including breast and prostate cancer cell lines 
(Albert et al., 2006; Cao et al., 2006). Indeed, a rapalog was even found more efficient in 
radiosensitization than the previously used cisplatin but showed less negative side effects 
(Ekshyyan et al., 2009). Moreover, inhibition of mTOR signalling seems to be beneficial also 
during fractionated radiotherapy (Eshleman et al., 2002), even though this approach has been 
shown to increase the emergence of radioresistant cells (reviewed in (Kim et al., 2015)). 
Molecular insights into the beneficial effect of rapamycin in preventing resistance associated 
with PARP1 inhibitors came from a study in 2014. The authors reported that the ribosomal 
protein S6, a target of mTOR, showed increased phosphorylation in BRCA1-deficient cells that 
had acquired PARP1 inhibitor resistance. This observation gave a rationale for the prevention 
of resistance by co-treatment with rapamycin (Sun et al., 2014). Importantly, rapamycin can act 
synergistically with PARP1 inhibitors to inhibit the proliferation of BRCA1-defective breast 
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and lung cancer cells (Osoegawa et al., 2017). This report together with previous studies 
indicates that also in cancer cells, rapamycin could have a dual effect: it affects repair pathways 
and their outcomes (therefore, can act synergistically with PARP1 inhibitors) and sensitizes 
cancer cells that have acquired resistance. This would be consistent with our observations in 
HR-defective yeast cells (see Figure 26) and highlights the relevance of our findings.  
 
3.5 Future perspectives 
Together with our previous study (Klermund et al., 2014), the experiments presented here 
describe the regulation of adaptation in response to telomere dysfunction. This can be achieved 
by modulating Cdc5 function directly as seen from our results using the adaptation-defective 
cdc5-ad allele. Moreover, we could show that TORC1 signalling fine-tunes the cellular decision 
to undergo adaptation. However, the experimental system used here was telomere dysfunction. 
It has been established that cells activate the DNA damage checkpoint in response to eroded 
telomeres, nevertheless the damage signalling pathways and their cellular consequences might 
be regulated differently than in response to genotoxin-induced damage or an intrachromosomal 
DSB.  
Future work will investigate the role of TORC1 downstream effectors such as the phosphatase 
PP2A in preventing adaptation. We hypothesize that this regulation might be achieved by 
impinging on Cdc5 and we plan to further investigate this possibility. In addition, it will be 
interesting to address the role of CKII, a second important regulator of adaptation (Toczyski et 
al., 1997) and possible target of TORC1 signalling (Sanchez-Casalongue et al., 2015). 
Moreover, we could provide insights into the mechanisms that lead to the acquisition of 
genotoxin resistance in mutants that are deficient in homologous recombination. We could 
show that the resistance to DNA damage is tightly linked with adaptation and aneuploidy, both 
acting as critical determinants of genome instability. On the other hand, genome instability is 
known to influence the response to DNA damage and thus, also adaptation. Moreover, 
compromised genome stability is intimately linked to aneuploidy. Therefore, investigating the 
interplay between adaptation, aneuploidy and genome instability in the model organism 
Saccharomyces cerevisiae will provide useful insights in the mechanisms leading to the 
acquisition of resistance, an emerging obstacle in cancer treatment. 
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4 Materials and Methods 
4.1 Materials 
4.1.1 Reagents and Kits 
Reagents and Kits Supplier 
1 kb DNA ladder New England Biolabs 
100 bp DNA ladder  New England Biolabs 
Acetone Sigma Aldrich 
Agar Sigma Aldrich 
Agarose Sigma Aldrich 
alpha-factor (α-Factor) Zymo Research 
Ampure XP beads Beckman Coulter 
Bacto Yeast BD Biosciences 
Bleomycin AppliChem 
Boric acid Sigma Aldrich 
Bradford Solution AppliChem 
Bromphenol blue Sigma Aldrich 
Camptothecin (CPT) Sigma Aldrich 
cOmplete Mini EDTA-free Protease 
Inhibitor Cocktail Tablets  
Roche 
Concanavalin A Sigma Aldrich 
Dimethylsulfoxide (DMSO) Sigma Aldrich 
D-sorbitol Sigma Aldrich 
Ethanol, absolute Sigma Aldrich 
Ethylenediaminetetraacetic acid disodium 
salt dihydrate (EDTA) 
AppliChem 
G418 disulfate solution (Kanamycin) AppliChem 
Glucose (D+) AppliChem, Merck Millipore 
Glycerol Grüssing 
Hydroxyurea Sigma Aldrich 
Hygromycin B InvivoGen 
Isopropanol Sigma Aldrich 
Lyticase Sigma Aldrich 
Magnesium chloride (MgCl2) AppliChem 
Mini-Protean TGX stain free precast gels BioRad 
Nitrocellulose membrane 0.45 µm pore 
size 
GE Healthcare Amersham 
Nocodazole Sigma Aldrich 
Nonidet P40 (NP40) AppliChem 
Nourseothricin-dihydrogen sulfate 
(ClonNaT) 
WERNER BioAgents 
Peptone Sigma Aldrich 
Phenol (solid) Fluka 
Phenol:chloroform:isoamylalcohol 
(25:24:1) 
AppliChem 
Phenylmethansulfoylflouride (PMSF) AppliChem 
Phloxine B Sigma Aldrich 
Phusion HF mastermix 2x New England Biolabs 
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Poly(ethylenglycol) 400 (PEG) Sigma Aldrich 
Ponceau S Sigma Aldrich 
Potassium chloride (KCl) Sigma Aldrich 
Potassium phosphate monobasic  
(KH2PO4) 
Sigma Aldrich 
Prestained protein marker, broad range 
(11-190 kDa) 
New England Biolabs 
Prestained protein marker, broad range 7-
175 kDa) 
New England Biolabs 
Proteinase K Qiagen 
QiaPrep Spin Miniprep Kit Qiagen 
Qubit dsDNA HS Assay Kit Life Technologies 
Raffinose x 5 H2O (D+) AppliChem 
Rapamycin AppliChem, Sigma Aldrich, Selleckchem 
RedSafe Nucleic Acid Stain iNtRON 
Ribo-Zero rRNA Removal Kit (Yeast) Illumina 
RNase A Qiagen 
RNase-Free DNase Set including DNase I, 
buffer and water 
Qiagen 
RNaseOUT recombinant ribonuclease 
inhibitor 
Invitrogen 
RNeasy MinElute Qiagen 
Skim milk powder Sigma Aldrich 
Sodium acetate (Na-acetate) Sigma Aldrich 
Sodium chloride (NaCl) Sigma Aldrich 
Sodium dodecyl sulfate (SDS) AppliChem 
Sodium hydroxide (NaOH) Sigma Aldrich 
Sodium phosphate dibasic  
(Na2HPO4 x 2 H2O) 
Sigma Aldrich 
ß-Mercaptoethanol Sigma Aldrich 
SuperSignal West Dura Extended 
Duration Substrate   
Thermo Scientific 
SuperSignal West Pico Chemiluminescent 
Substrate 
Thermo Scientific 
Sytox Green Thermo Scientific 
Taq Mastermix 2x  New England Biolabs 
Trichloroacetic acid (TCA) Sigma Aldrich 
Tris (Trizma base) Sigma Aldrich 
TruSeq stranded Total RNA LT Sample 
Prep Kit 
Illumina 
Tween-20 Sigma Aldrich 
Urea Sigma Aldrich 
Yeast Marker Carrier DNA Clontech 
Yeast Nitrogen Base without amino acids Sigma Aldrich 
Yeast Synthetic Dropout Medium 
Supplement without amino acid (SC or 
SD) 
MP Biomedicals 
β-Mercaptoethanol Sigma Aldrich 
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4.1.2 Buffers and solutions  
Buffers and solutions Composition 
1 x PBST 1 x PBS (diluted in ddH2O), 0.1 % Tween-20 
10 x PBS 1.37 M NaCl, 0.03 M KCl, 0.08 M Na2HPO4 
x 2 H2O, 0.02 M KH2PO4, adjusted to pH 7.4 
with HCl, autoclaved 
10 x SDS Running buffer 25 mM Tris, 192 mM glycine, 0.1 % SDS, 
adjusted to pH 8.3, autoclaved 
10 x TBE 0.89 M Tris base, 0.89 M boric acid, 0.02 M 
EDTA pH 8.0, autoclaved 
10 x TE 0.1 M Tris base pH 7.5, 0.01 M EDTA pH 
8.0 
10 x Transfer buffer 25 mM Tris, 192 mM glycine, 0.45 µm filter-
sterilized 
6 x DNA loading buffer 15% Ficoll, 10 mM EDTA pH 8.0, Orange G  
AE buffer 50 mM sodium acetate pH 5.3, 10 mM 
EDTA, adjust to pH 5.3 with NaOH 
Blocking buffer 5% (w/v) skim milk powder in 1x PBST 
EDTA pH 7.5 or 8.0 0.5 M disodium EDTA x 2H2O, adjusted to 
pH 7.5 or 8.0 with NaOH 
gDNA buffer 1 0.9 M sorbitol, 0.1 M EDTA pH 7.5 
gDNA buffer 2 0.27 M EDTA pH 8.5, 0.44 M Tris, 2.2 % 
SDS 
IP buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 
mM MgCl2, 1 mM PMSF, 4 protease 
inhibitor cocktail tablets  
LiAc mix 0.1 M lithium acetate, 1 x TE, ddH2O ad final 
volume 
PEG mix 40 % (w/v) PEG 400, dissolved in LiAc mix, 
autoclaved 
Solution 1 1.85 M NaOH, 1.09 M β-mercaptoethanol 
Solution 2 50 % TCA 
Urea buffer 120 mM Tris-HCl pH 6.8, 5 % glycerol, 8 M 
urea, 143 mM β-mercaptoethanol, 8 % SDS, 
bromphenol blue 
If indicated, solutions were sterilized by autoclaving at 121°C for 20 minutes. 
 
4.1.3 Technical equipment, software and additional materials 
Technical equipment, software and 
additional materials 
Supplier 
2100 Bioanalyzer Agilent Technologies 
Agarose gel chambers Custom made 
Analytical balance ED224S Sartorius 
BD FACSVerse Becton Dickinson (BD) 
Benchtop Shaker Excella E24 Eppendorf 
CellRad X-ray cell irradiator Faxitron 
Centrifuge 5430 R Eppendorf 
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Centrifuge 5810 R Eppendorf 
ChemiDoc Touch Imaging System BioRad 
Dissection Microscope MSM 400 Singer Instruments 
DNA 1000 chip Agilent Technologies 
EndNote X5 Thomson Reuters 
Excel 2013 Microsoft 
FACSuite 1.0.5 and FACSDiva™ Becton Dickinson 
Fast Prep-25 MP Biomedicals 
Fiji 1.51d ImageJ 
FileMaker Pro 10   FileMaker Inc 
FlowJo Miltenyi Biotec 
Heraeus Pico 17 Centrifuge Thermo Scientific 
HiSeq 2500  Illumina  
IKA VORTEX genius 3  Sigma Aldrich 
Illustrator CC 2017 and CS5 Adobe 
ImageLab 5.2 BioRad 
Incubator Heratherm IMC18 Thermo Scientific 
Incubator Heratherm IMH60 Thermo Scientific 
Leica DM1000 LED Leica 
Microscopy chambers 8 wells Lab-Tek 
Mini Centrifuge CD1008  Phoenix Instrument 
NanoDrop 2000 Thermo Scientific 
Neubauer counting chamber Assistent Germany 
NextSeq 500 Illumina 
Ovation Ultralow System V2 (2014-2017) NuGEN 
pH-Meter PB-11 Sartorius 
PowerPac Basic BioRad 
Prism 7.02 GraphPad 
Qubit 2.0 Fluorometer Life Technologies 
S2 ultrasonicator Covaris 
Shaker Duomax 1030 Heidolph 
Shaker Multitron Standard Infors HT  
Sonifier Branson 
Spectrophotometer Ultrospec 2100 pro Biochrom 
Test tube rotator Labinco 
Thermal Cycler C1000 Touch BioRad 
UV Stratalinker 2400 Stratagene 
Western Blot equipment BioRad 
Word 2013 Microsoft 
 
4.1.4 Antibodies 
Antibodies Dilution Source Figure 
Primary antibodies 
mouse anti-Rad53 1:16 Gift from M. Foiani 8A, 8C, 8E, 19A-B 
rabbit anti-Clb2 1:1000 Santa Cruz, #y-180 8C, 8E 
rabbit anti-Sic1 1:2000 Gift from E. Schiebel 8C, 8E 
mouse anti-GFP 1:1000 Roche, #11 814 460 001 10J 
mouse anti-HA 1:2000 Covance, #MMS-101P 10J, 11B, 17B 
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mouse anti-Pgk1 1:400 000 Invitrogen, #459250 11B 
rabbit anti-Rnr3 1:300 Agrisera, #AS09 574 19A-B 
mouse anti-actin 1:2000 Millipore, MAB1501R 17B 
Secondary antibodies 
goat anti-mouse (HRP 
conjugate) 1:3000 BioRad, #170-5047 
8A, 8C, 8E, 10J, 
19A-B 
goat anti-rabbit (HRP 
conjugate) 1:3000 BioRad, #170-5046 8A, 8C, 8E, 19A-B 
goat-anti mouse 
IRDye 680RD 1:10 000 LI-COR, #926-68070 11B 
Antibody-coupled beads 
anti-GFP VHH 
coupled to agarose 
beads 
25 µL/ 
sample Chromotek, #gta-10 10J 
 
4.1.5 Oligonucleotides 
Oligo-
nucleotide 
Database 
name sequence (5`- 3`) Comments 
Cdc5-3xHA 
tagging fw 
 
oKB19 TGGTAATTT 
CGTATTCGTATTTCTTTCT
ACTTTAATATTGGTTTAAT
CGATGAATTCGAGCTCG 
based on S2 primer design 
published in (Janke et al., 
2004) 
Cdc5-3xHA 
tagging rev 
oKB20 ATAAAGGAAGGTTTGAAG
CAGAAGTCCACAATTGTT
ACCGTAGATCGTACGCTG
CAGGTCGAC 
 
based on S3 primer design 
published in (Janke et al., 
2004) 
Cdc5-3xHA 
confirmation 
fw 
oKB21 TGGCAGATGCAGAAGAGT
TTTG  
Forward primer to confirm 
C-terminal Cdc5-3xHA 
tagging 
 
Cdc5-3xHA 
confirmation 
rev 
oBL29 CTGCAGCGAGGAGCCGTA
AT 
Reverse primer to confirm 
C-terminal Cdc5-3xHA 
tagging 
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4.1.6 Yeast strains 
All yeast strains used in this study were originally derived from the BY4741 background with 
the genotype MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0. For spotting experiments in Figures 8-10, 
one representative experiment is shown and the diploid strain from which the individual haploid 
mutant sets are derived is listed. Genotoxin-treated diploids from Figures 12-22 were usually 
not frozen down except for the strains used in sequencing experiments. Strains are partially 
published in (Klermund et al., 2014). All yeast strains were generated using yeast genetic 
protocols described previously (Guthrie and Fink, 1991). 
 
Database 
name Genotype Figure 
YBL7 MATa 8B-E, 16C-F, 20A-B 
YJK710 MATa/MATalpha CDC13/cdc13::cdc13-1 
(KAN) CDC5/cdc5::cdc5-ad (URA) 
ATG5/atg5::NAT 
8C 
YKB239 MATa CDC13::cdc13-1 (KAN) bar1::NAT 
CDC5::Cdc5-3xHA (HYG) 
8A 
YJK628 MATa CDC13::cdc13-1 (KAN) 
CDC5::cdc5-ad (URA) 
8B, 8F 
YJK625 MATa CDC5::cdc5-ad (URA) 8B 
YJK31 MATa CDC13::cdc13-1 (KAN) 8B-F 
YJK511 MATalpha CDC13:: cdc13-1 (KAN) 
TUB1::Tub1-GFP (HIS) 
8G 
YKB99 MATa/MATalpha CDC13/cdc13::cdc13-1 
(KAN) CDC5/cdc5::cdc5-ad (URA) 
RAD53/rad53::rad53-11 (NAT) 
9A 
YJK458 MATa/MATalpha CDC13/Cdc13::cdc13-
1(HIS) RAD53/Rad53::rad53-11(URA) 
9B 
YJK456 MATa/MATalpha CDC13/Cdc13::cdc13-
1(NAT) MEC1/mec1::HIS 
SML1/sml1::KAN 
9C 
YJK664 MATa/MATalpha CDC13/cdc13::cdc13-1 
(HIS)ATG5/atg5::KAN 
10A 
YJK813 MATa/MATalpha CDC13/cdc13::cdc13-
1(HIS) VPS51/vps51::KAN 
10B 
YKB98 MATa/MATalpha CDC13/cdc13::cdc13-1 
(HIS) VPS51/vps51::KAN ATG5/atg5::NAT 
10C 
YJK854 MATa/MATalpha CDC13/cdc13::cdc13-
1(NAT) MEC1/mec1::HIS 
SML1/sml1::KAN VPS51/vps51::HYG 
10D 
YKB89 MATa/MATalpha CDC13/cdc13::cdc13-1 
(HIS) NVJ1/nvj1::KAN 
10E 
YKB90 MATa/MATalpha CDC13/cdc13::cdc13-1 
(HIS) VAC8/vac8::KAN 
10F 
YJK986 MATa/MATalpha CDC13/cdc13::cdc13-1 
(HIS) TAP42/tap42::tap42-11 (KAN) 
10H 
YJK987 MATa/MATalpha CDC13/cdc13::cdc13-1 
(HIS) TIP41/tip41::KAN 
10I 
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YKB114 MATa/MATalpha CDC13/CDC13::cdc13-
1 (HIS) CDC5/CDC5::CDC5-3xHA (HYG) 
CDC55/CDC55::CDC55-GFP (HIS) 
10J 
YKB115 MATa/MATalpha CDC13/CDC13::cdc13-
1 (HIS) CDC5/CDC5::CDC5-3xHA (HYG) 
PPH21/PPH21::PPH21-GFP (HIS) 
10J 
YKB238 MATa CDC13::cdc13-1 (KAN) 
CDC5::Cdc5-3xHA (HYG) bar1::NAT 
11A-B 
YJK1049 MATa/MATalpha  12A-E, 13A, 14A-B, 16C-F, 
17C, 19A, 19C, 22D-E 
YJK1050 MATa/MATalpha 12A-E, 16B, 17C, 22D-E 
YJK1051 MATa/MATalpha CDC5::cdc5-ad (URA)/ 
CDC5::cdc5-ad (URA)  
12A-E, 13A, 14A-B, 17C, 
22D-E 
YJK1052 MATa/MATalpha CDC5::cdc5-ad (URA)/ 
CDC5::cdc5-ad (URA) 
12A-E, 17C, 22D-E 
YJK1053 MATa/MATalpha RAD52::KAN / 
RAD52::KAN 
12A-E, 13A, 14A-B, 19A, 
19C, 22D-E 
YJK1054 MATa/MATalpha RAD52::KAN / 
RAD52::KAN 
12A-E, 16B, 22D-E 
YJK1055 MATa/MATalpha RAD52::KAN 
CDC5::cdc5-ad (URA) / RAD52::KAN 
CDC5::cdc5-ad (URA) 
12A-E, 13A, 14A, 14C-D, 
19A, 19C, 22D-E 
YJK1056 MATa/MATalpha RAD52::KAN 
CDC5::cdc5-ad (URA) / RAD52::KAN 
CDC5::cdc5-ad (URA) 
12A-E, 22D-E 
YKB258 MATa/MATalpha RAD52::KAN / 
RAD52::KAN 
12F-G, 22A-E 
YKB262 MATa/MATalpha RAD52::KAN 
CDC5::cdc5-ad (URA) / RAD52::KAN 
CDC5::cdc5-ad (URA) 
12F-G, 21, 22D-E 
YKB264 MATa/MATalpha RAD52::KAN 
CDC5::cdc5-ad (URA) RAD53::rad53-11 
(NAT) / RAD52::KAN CDC5::cdc5-ad 
(URA) RAD53::rad53-11 (NAT) 
12F-G, 22B 
YKB269 MATa/MATalpha RAD52::KAN / 
RAD52::KAN 
12F-G, 22B-C 
YKB273 MATa/MATalpha RAD52::KAN 
CDC5::cdc5-ad (URA) / RAD52::KAN 
CDC5::cdc5-ad (URA) 
12F-G 
YKB275 MATa/MATalpha RAD52::KAN 
CDC5::cdc5-ad (URA) RAD53::rad53-11 
(NAT) / RAD52::KAN CDC5::cdc5-ad 
(URA) RAD53::rad53-11 (NAT) 
12F-G 
YJK1252 MATa/MATalpha 13B, 15A-B, 20A-B 
YJK1253 MATa/MATalpha after X-ray 13B, 15A-B, 19B, 19D, 
20A - B 
YJK1254 MATa/MATalpha CDC5::cdc5-ad (URA)/ 
CDC5::cdc5-ad (URA) 
13B 
YJK1255 MATa/MATalpha CDC5::cdc5-ad (URA)/ 
CDC5::cdc5-ad (URA) after X-ray 
13B 
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YJK1256 MATa/MATalpha RAD52::KAN / 
RAD52::KAN 
13B, 19B, 19D, 20A-B 
YJK1267 MATa/MATalpha RAD52::KAN 
CDC5::cdc5-ad (URA) / RAD52::KAN 
CDC5::cdc5-ad (URA) 
13B 
YKB405 MATa/MATalpha 14E-F, 16A, 16E-F 
YKB406 MATa/MATalpha SPO11::KAN / 
SPO11::KAN 
14E-F 
YKB407 MATa/MATalpha RAD52::NAT / 
RAD52::NAT 
14E-F, 16A, 16E-F, 21 
YKB408 MATa/MATalpha RAD52::NAT 
SPO11::KAN / RAD52::NAT SPO11::KAN 
14E-F 
YJK1156 MATa/MATalpha after CPT treatment 15A-B, 20A-B 
YJK1256 Derived from YJK1053  15A-B 
YJK1158 MATa/MATalpha RAD52::KAN / 
RAD52::KAN after CPT treatment 
15A-B, 20A-B 
YJK1160 MATa/MATalpha RAD52::KAN / 
RAD52::KAN after CPT treatment 
15A-B, 19B, 19D, 20A-B 
YJK1262 MATa/MATalpha RAD52::KAN / 
RAD52::KAN after X-ray treatment 
15A-B, 19B, 19D 
YJK1259 MATa/MATalpha RAD52::KAN / 
RAD52::KAN after X-ray treatment 
15A-B, 16E-F, 19B, 19D, 
20A-B 
YJK1261 MATa/MATalpha RAD52::KAN / 
RAD52::KAN after X-ray treatment 
15A-B, 16E-F, 20A-B 
YJK1026 MATa RAD52::KAN 16C-F 
YJK1262 MATa/MATalpha RAD52::KAN / 
RAD52::KAN after X-ray treatment 
16E-F, 20A-B 
YKB257 MATa/MATalpha 17A-C, 22B-E 
YKB260 MATa/MATalpha CDC5::cdc5-ad (URA)/ 
CDC5::cdc5-ad (URA) 
17C, 22D-E 
YKB317 MATa/MATalpha RAD52::KAN / 
RAD52::KAN 
18A-B 
YKB318 MATa/MATalpha DNL4::NAT / 
DNL4::NAT 
18A-B 
YKB319 MATa/MATalpha RAD52::KAN 
CDC5::cdc5-ad (URA) / RAD52::KAN 
CDC5::cdc5-ad (URA) 
18A-B, 21 
YKB320 MATa/MATalpha RAD52::KAN 
DNL::NAT / RAD52::KAN DNL4::NAT 
18A-B 
YKB321 MATa/MATalpha RAD52::KAN / 
RAD52::KAN 
18A-B 
YKB322 MATa/MATalpha DNL4::NAT / 
DNL4::NAT 
18A-B 
YKB323 MATa/MATalpha RAD52::KAN 
CDC5::cdc5-ad (URA) / RAD52::KAN 
CDC5::cdc5-ad (URA) 
18A-B 
YKB324 MATa/MATalpha RAD52::KAN 
DNL::NAT / RAD52::KAN DNL4::NAT 
18A-B 
YKB333 MATa/MATalpha RAD52::KAN / 
RAD52::KAN 
18A-B, 22A 
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YKB334 MATa/MATalpha DNL4::NAT / 
DNL4::NAT 
18A-B 
YKB335 MATa/MATalpha RAD52::KAN 
CDC5::cdc5-ad (URA) / RAD52::KAN 
CDC5::cdc5-ad (URA) 
18A-B 
YKB336 MATa/MATalpha RAD52::KAN 
DNL::NAT / RAD52::KAN DNL4::NAT 
18A-B 
YKB337 MATa/MATalpha RAD52::KAN / 
RAD52::KAN 
18A-B, 22A 
YKB338 MATa/MATalpha DNL4::NAT / 
DNL4::NAT 
18A-B 
YKB339 MATa/MATalpha RAD52::KAN 
CDC5::cdc5-ad (URA) / RAD52::KAN 
CDC5::cdc5-ad (URA) 
18A-B 
YKB340 MATa/MATalpha RAD52::KAN 
DNL::NAT / RAD52::KAN DNL4::NAT 
18A-B 
YJK1265 MATa/MATalpha RAD52::KAN / 
RAD52::KAN after X-ray treatment 
19B, 19D, 20A-B 
YJK1157 MATa/MATalpha RAD52::KAN / 
RAD52::KAN after CPT treatment 
20A-B 
YJK1159 MATa/MATalpha RAD52::KAN / 
RAD52::KAN after CPT treatment 
20A-B 
YJK1161 MATa/MATalpha RAD52::KAN / 
RAD52::KAN after CPT treatment 
20A-B 
YJK1162 MATa/MATalpha RAD52::KAN / 
RAD52::KAN after CPT treatment 
20A-B 
YJK1260 MATa/MATalpha RAD52::KAN / 
RAD52::KAN after X-ray treatment 
20A-B 
YJK1264 MATa/MATalpha RAD52::KAN / 
RAD52::KAN after X-ray treatment 
20A-B 
YKB368 MATa/MATalpha 21 
YKB369 MATa/MATalpha 21 
YKB353 MATa/MATalpha RAD52:: KAN / 
RAD52::KAN 
21 
YKB372 MATa/MATalpha RAD52:: KAN / 
RAD52::KAN 
21 
YKB375 MATa/MATalpha RAD52:: KAN / 
RAD52::KAN 
21 
YKB259 MATa/MATalpha RAD53::rad53-11 (NAT) 
/ RAD53::rad53-11(NAT) 
22B-C 
YKB261 MATa/MATalpha RAD52::KAN 
RAD53::rad53-11 (NAT) /  
RAD52::KAN RAD53::rad53-11 (NAT) 
22B-C 
YKB268 MATa/MATalpha 22B-C 
YKB270 MATa/MATalpha RAD53::rad53-11 (NAT) 
/ RAD53::rad53-11(NAT) 
22B-C 
YKB272 MATa/MATalpha RAD52::KAN 
RAD53::rad53-11 (NAT) /  
RAD52::KAN RAD53::rad53-11 (NAT) 
22B-C 
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4.1.7 Plasmids 
Name Description Source 
pBL183 BG1766 Gal ORF control 
vector 
B. Greyhack 
pBL186 pRS423-GAL-HIS3, empty 
vector  
M. Peter 
pBL211 pRS425-Gal-LEU2, empty 
vector 
M. Peter 
pBL299 pRS41-hygB, empty vector M. Knop 
pBL303 pRS42-KAN, empty vector M. Knop 
pBL304 pRS42-NAT, empty vector M. Knop 
pBL328 pYM24, for C-terminal 3x 
HA tagging 
Yanke et al., 2004 
pBL504 BG1805-Gal-CDC5 ORF collection, Dharmacon 
  
4.1.8 Yeast media 
YP liquid medium 2.5x stock for 1 liter 
Peptone 44 g 
Bacto Yeast 22 g 
H2O ad 1 L 
autoclave 20 minutes at 121°C 
to prepare 1 x YP + 2% glucose (1 liter) 
2.5 x YP medium stock 400 mL 
20 % glucose 100 mL 
H2O ad 1 liter 
 
YPD agar plates for 1 liter 
YPD agar 65 g 
H2O ad 1 L 
autoclave 20 minutes at 121°C 
 
final concentration of antibiotics for YPD drug plates: 
Nourseothricin-dihydrogen sulfate 
(ClonNaT) 
100 µg/mL 
Hygromycin B 300 µg/mL 
G418 disulfate solution (Kanamycin) 250 µg/mL 
Combinations of antibiotics are possible. 
 
 
S-Gal/Raff-Ura liquid medium  
(2% galactose/2% raffinose) 
for 1 liter 
Yeast synthetic dropout medium supplement 
without uracil 
1.92 g 
Yeast nitrogen base without amino acids 6.7 g 
Raffinose x 5 H2O 23.6 g 
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H2O 900 mL 
autoclave 20 minutes at 121°C 
20 % galactose 100 mL 
To prepare complete medium, the amino acid lacking in the dropout medium supplement was 
added. 
 
 
S-Gal/Raff-Ura plates  
(2% galactose/2% raffinose) 
for 1 liter 
Yeast synthetic dropout medium supplement 
without uracil 
1.92 g 
Yeast nitrogen base without amino acids 6.7 g 
agar 20 g 
Raffinose x 5 H2O 23.6 g 
H2O 900 mL 
autoclave 20 minutes at 121°C 
20 % galactose 100 mL 
To prepare complete medium, the amino acid lacking in the dropout medium supplement was 
added. 
 
 
SC/SD liquid medium (2% glucose) for 1 liter 
Yeast synthetic dropout medium supplement 
without amino acid 
1.92 g 
Yeast nitrogen base without amino acids 6.7 g 
H2O 900 mL 
autoclave 20 minutes at 121°C 
20 % glucose 100 mL 
 
 
SC-Trp liquid medium (2% glucose) for 1 liter 
Yeast synthetic dropout medium supplement 
without tryptophan 
1.92 g 
Yeast nitrogen base without amino acids 6.7 g 
H2O 900 mL 
autoclave 20 minutes at 121°C 
20 % glucose 100 mL 
To prepare complete medium, the amino acid lacking in the dropout medium supplement was 
added. 
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4.2 Methods 
4.2.1 Spotting assay 
4.2.1.1 For cdc13-1 experiments 
Yeast strains were grown in 5 mL overnight cultures in YPD at the permissive temperature of 
23°C. Cells were then diluted to OD600 0.3 in 5 mL YPD and treated with 5 nM rapamycin 
dissolved in DMSO or the appropriate volume of DMSO as vehicle control if indicated. 
Subsequently, cells were shifted to the indicated restrictive temperatures. At the indicated time 
points of 6 and 24 h after the temperature shift, cells were spotted in tenfold serial dilutions 
starting with OD600 0.5 in the first dilution. To allow cell recovery visualized as colony 
formation, plates were incubated at the permissive temperature of 23°C. Plates were imaged 
using the ChemiDoc™ Touch Imaging System (BioRad) using the settings for “Blot 
colorimetric” and a “small” field of view (9.5 cm x 7.6 cm). Images created by the BioRad 
software were exported as TIFFs with a 600 dpi resolution and imported into Illustrator CC 
2017 (Adobe) for labelling and arrangement. 
 
4.2.1.2 For rad52 experiments 
Cells were grown in 5 mL overnight cultures in YPD at 30°C. Subsequently, cells were spotted 
in tenfold serial dilutions starting with OD600 0.5 in the first dilution onto plates containing the 
indicated drugs or onto YPD plates that were either treated with the indicated genotoxic agent 
or left untreated (control plates). Plates were imaged after 3 to 4 days (unless indicated 
otherwise) as described for spotting assays using cdc13-1 strains. YPD agar plates contained 
the vital dye Phloxine B at a final concentration of 8 µg/mL. 
 
4.2.2 Western Blot 
4.2.2.1 Protein extraction 
For the preparation of total cell lysates, 2 OD units of culture were harvested by centrifugation 
at 13 000 rpm for 2 minutes. Cell pellets were either stored at -20°C until further processing or 
proteins were extracted immediately after harvesting. For extraction, cell pellets were 
resuspended in 150 µL of solution 1 and incubated on ice for 10 minutes. Subsequently, 150 
µL of solution 2 were added and the suspension was mixed briefly by vortexing. Following 
another incubation on ice for 10 minutes, samples were cleared by centrifugation at 13 000 rpm 
for 2 minutes at 4°C. The pellet was washed in 1 mL acetone and centrifuged at 13 000 rpm for 
2 minutes at 4°C. Subsequently, the pellet was resuspended in 100 µL urea buffer and incubated 
at 75°C (or 50°C when analysing Rad53 phosphorylation) for 5 minutes. If the sample turned 
yellow due to an acidic pH, 1 to 2 µL of Tris-HCl at pH 7.5 were added. Samples were 
centrifuged at 13 000 rpm for 1 minute to precipitate insoluble material and either processed 
further or stored at -20°C. 
 
4.2.2.2 SDS-PAGE, transfer and signal detection 
Samples were loaded onto Mini-PROTEAN® TGX Stain-Free™ precast gels (BioRad) using 
15-well gels with 7.5% polyacrylamide for Rad53 detection or 15-well gels with a gradient of 
4-15% polyacrylamide for all other proteins (as indicated in the figure legends). All gels were 
run in Mini-PROTEAN® electrophoresis chambers (BioRad). For Rad53 detection, gels were 
run at 100 V for 2 hours in 1x SDS running buffer, while all other proteins were separated by 
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running gels at 200 to 250 V for approximately 30 minutes. Subsequently, proteins were 
transferred to nitrocellulose membranes with 0.45 µm pore size (GE Healthcare) either by wet 
blot in 1x transfer buffer using Mini Trans-Blot® Cell chambers (BioRad) for detection of 
Rad53 or by semi-dry blot using the Trans-Blot® Turbo™ Transfer System (BioRad) with the 
pre-set 10 minutes blotting program for high molecular weight proteins. Transfer efficiency 
was visualized by staining the membrane with Ponceau S followed by rinsing in water. 
Blocking was performed for at least 1 hour at room temperature in blocking buffer followed by 
incubation with the primary antibodies diluted in blocking buffer over night at 4°C. After 
washing the membrane four times in 1x PBS + 0.1 % Tween-20, the secondary antibody diluted 
in blocking buffer was added and incubated for 1 hour at room temperature. After three washing 
steps in 1x PBS + 0.1 % Tween-20 followed by a last wash in 1x PBS, proteins were visualized 
by chemiluminescence using ECL Western Blotting substrate (Pierce). Alternatively, secondary 
antibodies coupled to fluorophores were used and protein detection was performed on an 
Odyssey CLx Imaging system (LI-COR). All antibodies used are described in section 4.1.4. 
 
4.2.3 DNA content analysis using flow cytometry 
Cell pellets equivalent to 0.18 OD600nm units were harvested by centrifugation at 13 000 rpm for 
1 minute. Afterwards, pellets were washed once in 1 mL water to remove medium and 
resuspended in 300 µL water. After the addition of 700 µL 100% ethanol, cells were fixed at 
4°C and stored until further processing or fixed for 1 hour at room temperature on a rotating 
wheel. Subsequently, cells were centrifuged at 3000 rpm for 5 minutes to remove ethanol and 
washed in 1 mL water. After centrifugation at 3000 rpm for 5 minutes, pellets were resuspended 
in 500 µL 50 mM Tris-HCl pH 7.5 containing 10 mg/mL RNase A and incubated at 37°C for 3 
hours or overnight. After centrifugation at 3000 rpm for 5 minutes, pellets were resuspended in 
500 µL 50 mM Tris-HCl pH 7.5 containing 1 mg/mL Proteinase K and incubated at 50°C for 
45 minutes. Cells were then centrifuged at 3000 rpm for 5 minutes and resuspended in 500 µL 
50 mM Tris-HCl pH 7.5. Sonification was performed for 10 seconds at level 1 using “constant” 
mode with a 3 mm sonification tip (Branson). Subsequently, 500µL 50 mM Tris-HCl pH 7.5 
containing 2µM Sytox Green were added (final concentration 1 µM), cells were transferred to 
FACS tubes (Falcon) and cells were analysed immediately on a FACSVerse flow cytometer 
(BD) using FACS Suite software (BD).  
 
4.2.4 Yeast transformation for creation of homozygous diploids 
In order to create homozygous diploids, isogenic haploids of mating type a or α, respectively, 
were transformed with different plasmids and after mating (standard procedure as described in 
Guthrie and Fink, 1991), diploid selection was performed using the plasmid-borne markers. For 
transformation, cells were grown to exponential phase (OD600nm 0.6-0.8) in 25 mL YPD at 30°C 
and then harvested by centrifugation at 3000 rpm for 2 minutes. Cells were washed in 5 mL 
LiAc mix, centrifuged again at 3000 rpm for 2 minutes and then resuspended in 250 µL LiAc 
mix. 100 µL of competent cells were incubated together with 150 ng of the respective plasmids, 
10 µL Yeast Marker Carrier DNA and 700 µL PEG mix at 30°C for 30 minutes. After a heat 
shock at 42°C for 15 minutes, cells were centrifuged at 3000 rpm for 1 minute and resuspended 
in 300 µL YPD to allow plasmid expression. For antibiotic selection, cells were incubated for 
2 hours at 30°C, for auxotrophy-based selection for only 30 minutes. Subsequently, 100 µL 
cells were plated on appropriate selection plates and single colonies were used for mating. 
Newly created diploids were confirmed again on selective plates and then propagated on non-
selective plates allowing plasmid loss.  
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Plasmids were purified from competent DH5α bacteria using QiaPrep Spin Miniprep Kit 
(Qiagen) according to the manufacturer’s instructions. 
 
4.2.5 Co-immunoprecipitation 
Cell pellets from 100 mL exponential cultures were harvested by centrifugation at 3000 rpm 
for 5 minutes (all steps were performed at 4°C), resuspended in 200 µL IP buffer and transferred 
to Lysing Matrix C tubes containing 1 mm silica spheres (MP Biomedicals). Cells were lysed 
using two 30 seconds cycles at full power (setting 6.5) with a one minute break on ice between 
runs using a FastPrep (MP Biomedicals). After addition of 800 µL IP buffer supplemented with 
0.2 % NP40, samples were vortexed briefly at high speed and transferred to reaction tubes for 
clearance by centrifugation at 13 000 rpm for 5 minutes. Cell lysates were transferred to a new 
reaction tube and cleared in a second centrifugation step. Subsequently, protein content was 
measured with a Bradford assay. In brief, 1 µL sample was diluted in 99 µL water and 1 mL 
filtered Bradford solution was added. Using a standard curve, protein content was estimated 
after measuring the absorption at OD595nm. For immunoprecipitation, 2 mg protein were 
incubated in 1 mL final volume with 25 µL agarose beads coupled to GFP antibody fragments 
(ChromoTek) at 4°C for 2 hours in the presence of 4 µL DNase I (2000 U/ mL, NEB). An input 
sample (50 µg, equals 1/40) was taken from the remaining lysate as a control and diluted in 25 
µL urea buffer. Immunoprecipitated samples were washed four times in 1 mL IP buffer 
supplemented with 0.2 % NP40 while rotating on a wheel at 4°C followed by centrifugation at 
3000 rpm for 1 minute. After the last washing step, wash buffer was removed completely and 
immunoprecipitates were resuspended in 50 µL urea buffer, boiled at 75°C for 5 minutes and 
15 µL were subjected to SDS-PAGE followed by detection of (co-)immunoprecipitated proteins 
using chemiluminescence (see section 4.1.4).  
 
4.2.6 X-ray irradiation 
Cells were irradiated with the indicated doses after plating on YPD agar plates as described 
using a 0.5 mm aluminium filter to remove low-energy X-rays. The dose rate was kept constant 
and was set to approximately 0.9 Gy/ min at 130 kV and 5 mA.  
 
4.2.7 Plating assay and statistical analysis of cell survival 
Cells were taken from 5 mL overnight cultures in YPD at 30°C and cell numbers per mL were 
assessed by counting in 1:100 or 1:50 dilutions in a Neubauer counting chamber. Unless 
indicated otherwise, 300 cells were plated in 2 technical replicates on YPD plates as control, 
on drug-containing plates or on plates that were subjected to X-ray or UV irradiation afterwards. 
Plates were incubated at 30°C for the indicated times. Colonies were counted manually taking 
all colonies visible by eye into account and the average of the 2 technical replicates was used 
for further quantification. Plates with rad52 cells were incubated for 3 to 4 days after X-ray 
treatment and 7 to 8 days in the case of CPT treatment. Plates with wild type strains were usually 
counted after 2 or 3 days (in the presence of rapamycin). Colony numbers on plates with 
genotoxic treatment were normalized to number of colonies formed on control YPD plates and 
expressed as % survival. If not indicated otherwise, every quantification represents three 
biological replicates. Statistical analysis was performed using One-way ANOVA after 
estimating normal data distribution (Shapiro-Wilk test, alpha = 0.05) and testing the 
heterogeneity of variances (Brown-Forsythe test, P < 0.05) as built-in analyses in the Prism 
7.02 software package (GraphPad). In the case of plating assays where genotype and treatment 
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represented two different factors, normal data distribution and variance heterogeneity were 
tested as before. Subsequently, a Two-way ANOVA was used to confirm statistically 
significant interaction between the two factors. Finally, One-Way ANOVA was performed on 
data sub-groups taking into consideration either the genotype or the treatment. For Figure 17 
C, Two-way ANOVA revealed no significant interaction between genotype and treatment. 
Therefore, data were pooled either depending on genotype (regardless of treatment) or 
depending on treatment (regardless of genotype) and analysed using an unpaired two-tailed t-
test.   
 
4.2.8 Microcolony assay 
Cells were grown to saturation overnight in YPD medium at 30°C. Unbudded or small budded 
cells were manipulated onto YPD agar plates that contained 10 nM rapamycin (supplier switch 
required an adjustment of the concentration), 2 µM CPT or the combination of both. Based on 
a similar experiment performed in (Toczyski et al., 1997), microcolony formation was assessed 
by quantifying cell bodies, i.e. a cell arrest in G2/M evident as a dumbbell shape was counted 
as 2 cell bodies. Microcolonies that contained only one cell body at the 4 hour time point were 
excluded from further analysis. After 24 hours, cell bodies present in every microcolony were 
counted. Cells were counted as adapted if the microcolony contained 3, 5 or more than 5 cell 
bodies. Four cell bodies were still considered arrested since a fraction of cells did not arrest 
with only 2 but 4 cell bodies at 4 hours. This is due to a CPT-induced arrest in the next cell 
cycle if cells had already transitioned through S phase at the start of the experiment. For every 
condition, more than 90 individual cells have been analysed and mean values with the SEM are 
depicted. Normal data distribution was assessed using the Shapiro-Wilk test (alpha = 0.05) and 
homogeneity of variances was confirmed using the Brown-Forsythe test (P < 0.05) as a built-
in tool in the Prism software. Subsequently, a One-way ANOVA was performed.  
 
4.2.9 Live-cell microscopy  
Cells were grown overnight at 23°C in SC-Trp medium and then diluted to OD600nm 0.2 in 10 
mL fresh SC-Trp followed by a temperature shift to 37°C for 6 hrs to arrest cdc13-1 mutants.  
Subsequently, 0.1 OD600nm units were harvested, resuspended in 200 µL pre-warmed SC-Trp 
supplemented either with 5 nM rapamycin or the appropriate volume of DMSO. Cells were 
placed in 8-well microscopy chambers (Lab-Tek) that had been coated with 200 µL 2 mg/mL 
Concanavalin A for 15 minutes. Afterwards, images were acquired on a TCS STED CW super 
resolution microscope (Leica) every 30 minutes for 13 hours (total time at the non-permissive 
temperature 19 hours) in a 37°C humidified chamber using a 63x oil objective. At every time 
point, 3 regions of interest were imaged per well and with 8 z-stacks (2.9 µm step size). In total, 
< than 90 cells per condition were followed over the whole time course and quantified manually 
for re-budding events using Fiji image analysis software (Fiji 1.51d) and displayed in Prism 
7.02 (GraphPad). 
 
4.2.10 Genomic DNA extraction 
Cells were harvested from 20 mL exponential culture (OD600nm 0.7) by centrifugation at 3000 
rom for 3 minutes. Subsequently, cells were resuspended in 1 mL gDNA buffer 1, transferred 
to a reaction tube and centrifuged at 13 000 rpm for 1 minute. After resuspension in 400 µL of 
gDNA buffer 1 supplemented with 14 mM β-Mercaptoethanol, cell walls were digested by 
adding 20 µL of lyticase (2.5 mg/mL) for 45 minutes at 37°C. Successful creation of 
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spheroblasts was monitored with a light microscope. Subsequently, spheroblasted cells were 
centrifuged at 13 000 rpm for 1 minute and resuspended in 400 µL 1x TE buffer. After addition 
of 90 µL gDNA buffer 2, samples were vortexed briefly and incubated at 65°C for 30 minutes. 
Subsequently, 80 µL of 5 M potassium acetate were added and samples were incubated at 4°C 
for at least 1 hour. Cell residues were then eliminated by centrifugation at 14 000 rpm for 15 
minutes at 4°C. Afterwards, DNA contained in the supernatant was precipitated by addition of 
750 µL cold 100 % ethanol. To facilitate precipitation, samples were incubated at -20°C for 30 
minutes and subsequently centrifuged at 14 000 rpm for 5 minutes at 4°C. After discarding the 
supernatant, DNA contained in the pellet was washed with 1 mL cold 70% ethanol followed by 
air-drying the pellet at room temperature. DNA was resuspended gently in 500 µL 1x TE and 
incubated at 37°C for 60 minutes in the presence of 2.5 µL RNase A (10 mg/mL). Subsequently, 
500 µL isopropanol were added, the sample was mixed and centrifuged at 14 000 rpm for 15 
minutes at 4°C. After washing the pellet with 1 mL 70% ethanol, DNA was air-dried at room 
temperature and resuspended gently in 50 µL 1xTE. Insoluble material was precipitated and 
removed following centrifugation at 14 000 rpm for 10 minutes at 4°C. 
 
4.2.11 DNA copy number analysis by whole genome sequencing (WGS) 
4.2.11.1 Library preparation and sequencing 
1 µg of genomic DNA was brought to a final volume of 50 µL and sheared using a Covaris S2 
ultrasonicator system in a microTUBE AFA Fiber 6x16mm, applying the following shearing 
parameters: duty factor 10%, intensity 5, 200 cycles per curst, 45 seconds, 7C water bath 
temperature. After DNA shearing, a double-size selection was performed using Ampure XP 
beads with ratios of 0.6:1 (beads:DNA) to exclude larger fragments and 1:1 (beads:DNA) to 
remove smaller fragments. This procedure enriched the DNA for the 100-500 bp fragments. 
Purified DNA was quantified using the Qubit dsDNA HS Assay Kit in a Qubit 2.0 fluorometer 
(Life Technologies) and the DNA size distribution was profiled in a High Sensitivity DNA chip 
on a 2100 Bioanalyzer (Agilent Technologies). 
DNA sequencing library preparation was performed using NuGEN´s Ovation Ultralow System 
V2 (2014-2017), following the manufacturer’s recommendations. Libraries were prepared with 
a starting amount of 80 ng of sheared DNA (100-500 bp in size) and were amplified in 8 PCR 
cycles. Libraries were profiled on a DNA 1000 chip on a 2100 Bioanalyzer (Agilent 
Technologies) and quantified using the Qubit dsDNA HS Assay Kit in a Qubit 2.0 fluorometer 
(Life Technologies). All samples were pooled in equimolar ratio and sequenced on one NextSeq 
500 Midoutput FC (Illumina), PE for 2x 79 cycles plus 8 cycles for the index read. 
DNA sequencing (DNA-seq) libraries were sequenced on Illumina NextSeq 500 (75-nt paired-
end, with an effective read length of 79 nt), yielding 10-13 million read pairs per sample.  
 
4.2.11.2 DNA sequencing analysis 
Sequencing qualities were checked using FastQC (version 0.11.5) 
(https://www.bioinformatics.babraham.ac.uk/projects/fastqc/). All reads were mapped to the 
yeast genome (Ensembl genome assembly version R64) with the Burrows-Wheeler Aligner 
BWA (version 0.7.15) (Li and Durbin, 2010). Reads not mapped in a proper pair as well as 
secondary alignments were removed using Samtools (version 1.3.1) (Li et al., 2009). 
Furthermore, duplicate reads were removed using MarkDuplicates of the Picard tool package 
(version 2.6.0) (http://broadinstitute.github.io/picard/). Genome coverage depth and breadth 
were determined using Samtools as well as a custom made bash script. Due to very high and 
unequal coverage, the mitochondrial chromosome was removed from all subsequent analyses. 
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Reads were counted and summarized in 1000bp bins using readCounter of the HMMcopy 
package (version 0.1.1) ((Ha et al., 2012) and (https://github.com/shahcompbio/ 
hmmcopy_utils)). Resulting wig files were transformed to bedgraph files using 
wigToBedGraph of the kentUtils package (version v302) without collapsing adjacent windows 
(https://github.com/ENCODE-DCC/kentUtils) and normalized to reads per million (PRM). 
Using a custom made R script, RPMs of each bin were then normalized to the sample-wide 
median RPM and chromosome copy numbers were estimated for each sample based on the 
chromosome median of this bin-wise RPM ratio (log2). A cutoff of 0.6 or -0.6 was chosen to 
determine a higher or lower chromosome copy number than the other chromosomes in the same 
sample. 
 
4.2.12 Total RNA extraction 
Cell pellets corresponding to 8 OD600nm units from exponential cultures with an OD600nm of 0.7 
were harvested by centrifugation at 3000 rpm for 5 minutes. Pellets were then resuspended in 
400 µL AE buffer, 20 µL 20% SDS were added and the samples were vortexed. Subsequently, 
500 µL phenol (pre-equilibrated in AE buffer) were added, the sample was vortexed again and 
incubated at 65°C for 5 minutes. After cooling the samples on ice for 5 minutes, they were 
centrifuged at 13 000 rpm for 3 minutes at 4°C and the upper aqueous phase was transferred to 
a new reaction tube. 500µL phenol:chloroform:isoamylalcohol (25:24:1) were added and 
samples were incubated at room temperature for 5 minutes. After centrifugation at 13 000 rpm 
for 3 minutes, the upper aqueous phase was transferred to a new reaction tube and 40 µL of 3M 
sodium acetate were added. After mixing, 1 mL cold 100% ethanol were added and samples 
were inverted several times. After centrifugation at 13 000 rpm for 3 minutes, the supernatant 
was discarded and nucleic acids contained in the pellet were washed with 1 mL 80% ethanol. 
Pellets were then air-dried at room temperature and residual ethanol was removed using a 
vacuum pump. To digest DNA, every pellet was resuspended in 100 µL DNase I mix containing 
87 µL RNase-free water, 10 µL DNase I buffer RDD and 3 µL DNase I in the presence of 1 µL 
recombinant RNase inhibitor RNaseOut. After incubation at 37°C for 45 minutes, samples were 
purified using the RNeasy MinElute kit (Qiagen) according to the manufacturer’s instructions 
and eluted in 38 µL RNase-free water. Subsequently, cells were subjected to a second DNase I 
treatment by adding 63 µL DNase I mix containing 50 µL RNase-free water, 10 µL DNase I 
buffer RDD, 3 µL DNase I and 1 µL RNaseOut. Combining the DNase I mix with the eluted 
RNA again yielded a 100 µL sample that was incubated at 37°C for 45 minutes. As before, 
sample was purified using the RNeasy MinElute kit but RNA was eluted in 20 µL RNase-free 
water and stored at -80°C until further processing.  
 
4.2.13 RNA sequencing 
4.2.13.1 Library preparation and sequencing 
Ribosomal RNA was depleted from 1 µg of total RNA using Illumina’s Ribo-Zero rRNA 
Removal Kit (Yeast), following the manufacturer’s instructions. After purification of rRNA-
depleted RNA, library preparation was continued by adding the Elute-Prime-Fragment buffer 
from the TruSeq stranded Total RNA LT Sample Prep Kit, and the standard protocol was 
followed until the end of library prep (Part # 15031048 Rev. E). For library amplification, 10 
PCR cycles were used. 
The RNA sequencing libraries were profiled in a DNA 1000 chip on a 2100 Bioanalyzer 
(Agilent Technologies) and quantified using the Qubit dsDNA HS Assay Kit in a Qubit 2.0 
fluorometer (Life Technologies). 
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The resulting RNA sequencing libraries were pooled in equimolar ratios in 2 pools (one pool 
containing 13 libraries and the second pool 14 libraries) and each pool was sequenced on one 
lane of a HiSeq 2500 rapid flow cell, single read for 68 cycles plus 7 cycles for the index read. 
RNA sequencing (RNA-seq) libraries were sequenced on Illumina HiSeq 2500 (50-nt single-
end, with an effective read length of 68 nt), yielding 10-12 million reads per sample. 
 
4.2.13.2 RNA sequencing and GO term enrichment analysis  
Sequencing qualities were checked using FastQC (version 0.11.3) 
(https://www.bioinformatics.babraham.ac.uk/projects/fastqc/). All reads were mapped to the 
yeast genome (Ensembl genome assembly version R64, gene annotation version 86) with the 
splice-aware aligner STAR (version 2.5.2b) (Dobin et al., 2013) with two allowed mismatches 
and an overhang of at most 67 base pairs at each splice junction. Uniquely mapped reads were 
summarized per gene using featureCounts from the subread package (version 1.5.0) (Liao et 
al., 2014). Read counts per gene were corrected based on the chromosome copy number 
estimated based on the DNA sequencing (see 4.2.10.2). Differential gene expression analysis 
was done on corrected read counts using DESeq2 (Love et al., 2014). All genes with a p-value 
corrected for multiple testing of < 0.01 were considered significantly differentially expressed. 
A gene ontology (GO) term analysis was performed on significantly up- and down-regulated 
genes, respectively, using clusterProfiler (Yu et al., 2012). Here, up- and down-regulated genes 
were compare to the background of all expressed genes and the minimal number of genes 
annotated by an ontology term for testing was set to 5. A GO term was considered significantly 
enriched, if its adjusted p-value was < 0.01. Similar GO terms were combined using the simplify 
function of the clusterProfiler package 
 
4.2.14 C-terminal tagging of Cdc5-3xHA 
To tag Cdc5 under its endogenous promoter C-terminally with a 3xHA-hphNT1 cassette, the 
tagging cassette was amplified from a plasmid (pBL328) in a PCR using oKB19 as a forward 
and oKB20 as a reverse primer at a concentration of 60 nM each and using 2x Phusion HF 
master mix in a 50 µL PCR reaction. Cycling parameters were as follows: denaturation at 98°C 
for 30 seconds, 98°C for 10 seconds, 72°C for 30 seconds, 72°C for 1 minute, repeat step 2-4 
34 times, final elongation at 72°C for 10 minutes followed by incubation at 12°C until further 
processing. Correct amplification of the tagging cassette was verified by electrophoresis on a 
1.2% agarose gel run in 1x TBE buffer and subsequent staining and detection using RedSafe 
nucleic acid stain. The tagging cassette was subsequently transformed into wild type cells 
(YBL7) and positive clones selected on YPD plates containing 300 µg/mL hygromycin were 
used in a second PCR to verify the tagging. For the confirmation PCR, 2x Taq master mix was 
used and oKB21 and oBL29 served as forward or reverse primer, respectively, at a 
concentration of 10 µM. Cycling parameters were as follows: denaturation at 95°C for 30 
seconds, 95°C for 30 seconds, 50°C for 1 minute, 68°C for 1 minute, repeat steps 2-4 34 times, 
final elongation at 72°C for 5 minutes followed by incubation at 12°C until further processing. 
Correct amplification of the tagging cassette was visualized on 1.4% agarose gel and 
successfully tagged clones were send for sequencing and tested by Western Blot for expression 
of the HA peptide for final confirmation.  
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